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Hepatitis C virus (HCV) infection has become a global public health concern with over 130 
million people chronically infected and over 350,000 deaths every year from HCV-related liver 
diseases. GB virus-B (GBV-B) infection in tamarins is a surrogate model for acute HCV 
infection. Whilst HCV infection commonly leads to chronicity, GBV-B is naturally cleared. To 
better understand this natural clearance, this project aimed to study the associated humoral 
immune response to GBV-B. Additionally, GBV-B-specific antibodies were produced with the 
aim of characterising the pathology of the virus.  
Previously, there was no available GBV-B neutralisation assay to identify antibodies in this 
animal model. Therefore, a GBV-B neutralisation assay, based on a method that is known to 
be successful for the closely-related HCV, was developed. This method involved producing 
pseudotyped retroviral particles (PV) expressing the GBV-B envelope that could infect a 
human hepatocarcinoma cell line. GBV-B PV production was confirmed by western blotting. 
Future studies can now test archived tamarin sera in this assay for the presence of 
neutralising antibodies. Neutralising antibodies found through this model could be epitope 
mapped, and incorporated into HCV vaccine design strategies.  
To study the pathology of GBV-B infection, GBV-B-specific antibodies were also produced 
using two techniques in parallel- classical hybridoma technology and ribosome display. 
Antibodies targeting the nucleocapsid core protein of GBV-B have been previously detected 
in tamarins and served as the target for production of GBV-B antibodies using both 
aforementioned technologies. GBV-B core-specific antibodies were successfully isolated using 
both technologies and can now be used in downstream techniques, such as 
immunohistochemistry, to characterise the pathology of GBV-B infection thereby further 
validating the use of the animal model. 
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CHAPTER 1 : INTRODUCTION 
 
 
1.1  HEPATITIS C VIRUS (HCV) 
 
 
1.1.1 HEPATITIS VIRUSES 
 
The most common aetiological agents of hepatitis in humans, an inflammation of the liver, is 
a group of hepatotropic viruses named hepatitis A, B, C, D, E, F and G (Shafran and Conly, 
1996). Although these viruses have a common tropism for the liver and viral pathology, there 
are several differences between the viruses including the structure of each virus and the 
typical course, and subsequent outcome, of infection (Table 1-1). Whilst some of the hepatitis 
viruses, such as types A and E, typically cause acute, self-limiting infections, other hepatitis 
virus infections, such as types B and C, regularly progress to chronic infections. These chronic 
hepatitis B and C infections can lead to the development of liver cirrhosis and hepatocellular 
carcinoma. Globally, an estimated 399,000 people die every year as a result of these hepatitis 











Typical course of 
infection 
Structure of virus Family of virus Reference 
A Acute Single-stranded RNA Picornaviridae (Koff, 1998) 
B Chronic  Partially double-
stranded DNA 
Hepadnaviridae (Gitlin, 1997) 
C Chronic Single-stranded RNA Flaviviridae (Simmonds, 2013) 
D Chronic Single-stranded RNA Unassigned (Alvarado-Mora, 
2013) 
E Acute Single-stranded RNA Hepeviridae (Kamar, 2014) 
F Acute Double-stranded DNA Togavirus-like (Deka et al., 1994; 
Fagan and 
Harrison, 1994) 
G Chronic, no 
associated disease 
Single-stranded RNA Flaviviridae (Stapleton, 2003; 
Stapleton et al., 
2011) 
 
TABLE 1-1: SUMMARY OF DIFFERENT HEPATITIS VIRUSES IN HUMANS 
 
 
1.1.2 DISCOVERY OF HEPATITIS C VIRUS 
HCV is an enveloped RNA virus that can cause both acute and chronic hepatitis (Lindenbach 
and Rice, 2013). With an estimated 71 million people worldwide chronically infected, and at 
risk for developing liver cirrhosis or hepatocellular carcinoma, HCV has become a major public 
health concern.  Prior to the discovery of the virus in 1989, blood and blood products 
unknowingly contaminated with HCV aided its spread (Alter, 1991; Donahue, 1992). 
Although hepatitis A and hepatitis B were classified in the 1970s, there remained hepatitis of 
an unknown aetiologic agent termed non-A, non-B (NANB) hepatitis. Bradley and colleagues 
demonstrated that an infectious, transmissible agent was the cause of NANB hepatitis 
(Bradley et al., 1979) and that sera from affected patients resulted in acute and chronic 
hepatitis in chimpanzees  (Alter et al., 1978; Hollinger et al., 1978; Tabor et al., 1978). In 
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1989, Choo and colleagues isolated an RNA virus from both the sera and tissues of a 
chimpanzee that had been inoculated with NANB serum and this was named Hepatitis C virus 
(HCV)(Choo et al., 1989). 
 
1.1.3 CLASSIFICATION AND HETEROGENEITY  
 
 
HCV belongs to the hepacivirus genus of the Flaviviridae family, a family of positive sense, 
single-stranded, enveloped RNA viruses. HCV is a highly genetically diverse virus. There are 7 
identified genotypes, which can be further separated into 67 different subtypes (Smith et al., 
2014). Approximately 1012 new virions can be produced daily, which in combination with  
highly error-prone viral RNA-dependent RNA polymerase (Powdrill et al., 2011), allows HCV 
to establish quasispecies in a single host.    
HCV heterogeneity underpins its ability to successfully evade the immune system of its host 
permitting its persistence in the majority of cases (Forns, Purcell and Bukh, 1999). The highest 
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FIGURE 1-1: TYPICAL STRUCTURE OF AN HCV PARTICLE (ADAPTED FROM LINDENBACH, 2013). 
HCV VIRIONS ASSOCIATE WITH SERUM LIPOPROTEINS, SUCH AS LDL (AS SEEN IN THIS DIAGRAM) OR HDL (HIGH DENSITY LIPOPROTEINS). 
THESE LIPOPROTEIN PARTICLES CONSIST OF TRIGLYCERIDES, CHOLESTEROL AND CHOLESTEROL ESTERS SURROUNDED BY A PHOSPHOLIPID 
MEMBRANE. THESE PARTICLES ALSO CONTAIN VARIOUS APOLIPOPROTEINS ON THEIR SURFACE, SUCH AS APOB. OTHER APOLIPOPROTEINS ARE 
THOUGHT TO ASSOCIATE WITH THE PARTICLE DIRECTLY, SUCH AS APOE. HCV USES THESE LIPOPROTEIN PARTICLES TO AID VIRUS ENTRY AND TO 
PROVIDE SOME PROTECTION AGAINST ANTIBODY NEUTRALIZATION (LINDENBACH, 2013). THE STRUCTURAL ORGANISATION OF THE 
HCV/LIPOPROTEIN PARTICLE IS CURRENTLY UNKNOWN; THE MODEL ABOVE IS A REPRESENTATION OF THE TWO PARTICLE MODEL WHICH 
SUGGESTS THAT HCV AND SERUM LIPOPROTEINS INTERACT TRANSIENTLY. IN CONTRAST, THE SINGLE PARTICLE MODEL SUGGESTS THAT THE 
TWO SHARE AN ENVELOPE.  
 
E2 has 3 hypervariable regions that exhibit high numbers of amino acid substitutions (Kato et 
al., 1992; Troesch et al., 2006; Weiner et al., 1992). These regions are thought to be involved 
in viral persistence as they are typically targets of the immune system, in particular antibody 
targets (Torres-Puente et al., 2008; Troesch et al., 2006).  
The heterogeneous nature of HCV also impacts the outcome of therapy as drug resistance 
can develop from viral mutations. Historically, it was thought that certain genotypes were 
more closely linked to a more severe outcome, such as hepatocellular carcinoma, although 
more recent studies dispute this (Hnatyszyn, 2005; Pawlotsky, 2003). A link between different 
genotypes and treatment outcome has also been investigated where genotype 1, the most 
prevalent genotype worldwide, and genotype 4 typically responded poorly to first generation 
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Although the origins of HCV are unknown, there are two possible scenarios. The first is a 
zoonotic origin. It was originally thought that HCV might have crossed the species barrier 
from chimpanzees. This could explain why the different genotypes of HCV are 
phylogenetically and geographically distinct. However, currently, there is no evidence of HCV, 
or HCV homologues, in wild chimpanzees (Makuwa et al., 2006).  
More recently, several hepaciviruses that are closely related to HCV have been identified in a 
range of animals including horses, bats, rats and dogs, cows and monkeys. Figure 1-2 shows 
phylogenetic analysis of these closely related hepaciviruses from various species and Table 1-
2 shows a summary of HCV related viruses and the pathogenesis in their host.  
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FIGURE 1-2: PHYLOGENETIC ANALYSIS OF HCV AND SEVERAL CLOSELY-RELATED HEPACIVIRUSES 
THIS TREE WAS ROOTED TO GBV-A.  FOR EACH SEQUENCE, THE GENBANK ACCESSION NUMBER IS INCLUDED. THIS FIGURE HAS BEEN TAKEN 





21 | P a g e  
 
Host Name Pathogenesis Reference 
Human Hepatitis C virus Viral hepatitis (Choo et al., 1989) 




(Kapoor et al., 2011) 
Bovine Bovine hepacivirus, 
BHV 
None (Baechlein et al., 2015; 
Corman et al., 2015) 
Equine Equine hepacivirus, 
EHV 
Viral hepatitis (Burbelo et al., 2012; Lyons 
et al., 2012) 
Rodent Rodent hepacivirus, 
RHV 
Evidence of liver 
inflammation 
(Drexler et al., 2013; Kapoor 
et al., 2013) 
Bat Bat hepacivirus None (Quan et al., 2013) 
New World monkey GB virus B (GBV-B) Viral hepatitis (Simons et al., 1995b) 
Old World monkey Guereza hepacivirus 
(GHV) 
None (Lauck et al., 2013) 
 
TABLE 1-2: SUMMARY OF HEPACIVIRUSES RELATED TO HCV AND THE PATHOGENESIS SEEN WITH THESE VIRUSES (ADAPTED FROM 
PFAENDER ET AL., 2014). 
 
 
The broad range of animals that have been infected with these related viruses further 
support the potential for HCV jumping the species barrier. The hepaciviruses isolated from 
dogs and horses, commonly referred to as non-primate hepaciviruses, are highly genetically 
similar, with some equine hepacivirus (EHV) genomes being over 99% identical to canine 
hepacivirus (CHV) genomes. Cross-species transmission between these hosts has been 
previously suggested based on the episode of a dog which became seropositive to 
hepacivirus after being in close contact with an EHV-infected horse (Pfaender et al., 2014). 
For these viruses, cross-species transmission is likely due to the number of opportunities for 
routes of transmission, for example, the use of horse sera in canine vaccine manufacturing, 
the co-housing of these species or the consumption of horse meat by dogs (Scheel et al., 
2015).  Despite the possibility of cross-species transmission of EHV and CHV, a recent study 
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showed that EHV RNA was not detected in 172 people that are regularly exposed to horses 
(Pfaender et al., 2015). However, HCV transmission by either a single or multiple zoonosis 
events still remains a possibility and, with the continued discoveries of new hepaciviruses, 
these origins could soon be determined.  
The second possibility is that HCV emerged as a human virus and co-evolved with its human 
host. If this is the case, HCV has always infected humans, similar to herpesviruses (Wertheim 
et al., 2014). Evidence supporting this is based on the fact that HCV can persist in humans for 
decades successfully. Further supporting this argument is HCV’s requirement for human liver-
specific microRNA-122 for replication (Jopling et al., 2005). As such, an increase in detection 
of HCV infections could be due to increased surveillance, increased opportunities for 




HCV virions consist of a single stranded RNA genome encapsulated by the nucleocapsid 
formed from the core protein (Figure 1-1). This nucleocapsid is then enveloped by a lipid 
bilayer containing the E1 and E2 glycoproteins (Gastaminza et al., 2010). The virions are 
associated with low-density and very-low-density lipoproteins (LDL and vLDL) and therefore 
vary in size and density (approximate density 1.1g/mL, Lindenbach, 2013, André et al., 2002).  
 
HCV has a genome of around 9500 kilobases that encodes a single polyprotein that is then 
cleaved by both host peptidases and viral proteases into individual viral proteins (Forns et al., 
1999). These viral proteins are either classed as structural proteins (this includes the core 
protein and both envelope proteins, E1 and E2) or non-structural proteins (p7, NS2, NS3, 
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NS4A, NS5A and NS5B). Individual roles for each of these proteins can be seen in Table 1-3. 
The open reading frame encoding these proteins has at either end an untranslated region 
(UTR) which is necessary for viral replication. The highly structured 5’UTR contains an internal 
ribosome entry site (IRES) allowing ribosomes to bind, beginning the translation of the viral 
polyprotein. The 3’UTR contains a polyuridine tract and is thought to interact with ribosomes 
to regulate the translation of the viral genome (Penin et al., 2004, Bai et al., 2013).  
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Viral protein Role 
Core Forms the nucleocapsid which encapsulates the viral RNA. The N-
terminal RNA binding domain allows the formation of the 
nucleocapsid through interaction with RNA. The membrane-binding 
domain allows mature core to locate to lipid droplets promoting 
viral assembly (Hope and McLauchlan, 2000; McLauchlan, 2000) 
E1/E2 Envelope glycoproteins. The transmembrane domains for both 
function to retain the glycoproteins at the endoplasmic reticulum 
and help form the noncovalent E1E2 heterodimer (Cocquerel et al., 
1998a). This heterodimer is held together by disulphide bonds in the 
ectodomains. They are critical for viral entry by binding to entry 
receptors (Pileri et al. 1998;  Bartosch et al. 2003). 
P7 P7 is a viroporin (Griffin et al., 2003). It protects nascent particles 
from low pH and is also involved in Envelopment and capsid 
assembly (Gentzsch et al., 2013; Wozniak et al., 2010). 
NS2 A protease with a role in assembly by bringing together E1, E2, p7, 
NS3/4A (Jones et al., 2007; Popescu et al., 2011). 
NS3 Serine protease that cleaves nonstructural proteins and some 
cellular proteins such as cellular antiviral signalling proteins involved 
in the innate immune response, RNA helicase and NTPase activities 
(Morikawa et al., 2011). 
NS4A NS3 cofactor by localizing NS3 and controlling its activities (Failla et 
al., 1994). 
NS4B Integral membrane protein and known as the ‘master organizer of 
replication complex formation’. It’s required to assemble the 
membranous web for RNA replication (Moradpour and Penin, 2013). 
NS5A Zinc containing phosphoprotein involved in regulating replication 
and particle production. It delivers HCV RNA to core protein 
(Macdonald and Harris, 2004). 
NS5B RNA-dependent RNA polymerase (Behrens et al., 1996).  
 
TABLE 1-3: PROPERTIES AND FUNCTIONS OF HCV PROTEINS 
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1.1.6 LIFE CYCLE 
 
Through the use of the various in vitro and in vivo models of HCV infection, the viral lifecycle 
has now been mostly characterised. Virions are blood borne and are transmitted most 
commonly intravenously, including through contaminated needles of drug users or blood 
products and transfusions. Transmission also occurs vertically (from an HCV positive mother) 
and, rarely, sexually (Dienstag, 1997; Yeung, 2001). 
 
1.1.6.1 VIRUS ENTRY 
 
The first stage in the viral life cycle, viral entry, has been of significant interest due to the 
inability to propagate almost all strains of the virus in cell culture. In vitro models of HCV, 
such as retroviral pseudotyped viruses bearing HCV envelope proteins or the only known 
isolate of HCV that can replicate and establish infection in cell culture, JFH-1 (Wakita, 2009), 
have been invaluable in understanding the viral life cycle. 
Once the virus enters the body, it can infect a small range of cells that are most commonly 
hepatocytes. HCV entry into its host cell is an extremely complex, multi-component process 
focused on the interaction of HCV envelope proteins, associated lipoproteins and a range of 
host cell receptors, factors and regulators. This complexity surrounding HCV entry is most 
likely the contributing factor to the virus’ limited tropism (Ding et al., 2014).  
The initiation of HCV entry begins with a primary attachment of HCV particles to 
glycosaminoglycans (GAGs) present on the surface of hepatocytes as seen in Figure 1-3 
(Popescu et al., 2014). HCV virions have been shown to bind to at least 2 types of heparin 
sulphate proteoglycans, syndecan-1 and syndecan-4 (Lefèvre et al., 2014; Shi et al., 2013), 
using both the viral glycoproteins (Barth et al., 2003) and the virion-associated apolipoprotein 
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apoE (Jiang et al., 2012). This interaction is thought to anchor the virion at the surface of the 
hepatocyte allowing further interactions between the virion and specific entry receptors.  
As the HCV virion is associated with low-density lipoproteins (LDL) (Nielsen et al., 2006), 
virions can interact with lipoprotein receptors. Initially, the LDL receptor (LDLr) was thought 
to be involved in HCV entry (Agnello et al., 1999; Molina et al., 2007; Owen et al., 2009) 
however a recent study has suggested that interaction with this receptor would lead to a 
non-productive pathway and virion degradation (Albecka et al., 2012). Instead, virion 
glycoprotein E2 interaction with the lipoprotein receptor scavenger receptor 1 (SRB1), a 
receptor that typically binds a range of host lipoproteins (Shen et al., 2014), leads to a 
productive HCV entry pathway (Scarselli et al., 2002). Moreover, SRB1 appears to have a 
multifunctional role in HCV entry as it also is involved in virion attachment through virion-
associated lipoproteins and a post-binding event (Dao Thi et al., 2012, 2011; Maillard et al., 
2006; Zahid et al., 2013). From these studies, it is clear that the exact role of SRB1 in viral 
entry may not be completely understood. Current opinion is that SRB1 initially interacts with 
viral lipoproteins allowing a subsequent interaction between SRB1 and HCV E2. SRB1 could 
then modify the lipid composition of the virion or the plasma membrane of the hepatocyte to 
allow further interactions between the virion and other entry receptors (Popescu et al., 
2014).   
After the interaction between the hypervariable region 1 (HVR1) of HCV E2 and SRB1, the 
CD81 binding site of E2 is revealed (Bankwitz et al., 2010). This allows HCV to bind to the 
extracellular loop of CD81, a tetraspanin found on the plasma membrane of a variety of cells 
including hepatocytes and lymphocytes (Pileri et al., 1998). The binding of HCV E2 to CD81 
induces signaling pathways involving epidermal growth factor receptor (EGFR) and the 
GTPase HRas that leads to the assembly of CD81-viral particle and tight-junction protein 
Claudin-1 (CLDN1) complexes (Diao et al., 2012; Douam et al., 2014; Harris et al., 2010; 
27 | P a g e  
 
Hopcraft and Evans, 2015; Lupberger et al., 2011; Zona et al., 2013). This interaction with 
CLDN1 has been shown to be essential for viral entry, along with another tight-junction 
protein Occludin (OCLN), although the exact role of OCLN is unknown (Evans et al., 2007; 
Ploss et al., 2009). The clustering of CD81-virions and CLDN1 is then thought to lead to 
internalisation of the virion via clathrin-dependent endocytosis (Blanchard et al., 2006; 
Farquhar et al., 2012). Numerous other additional factors have also been identified as to be 
involved in viral entry including the Niemann-Pick C1-like 1 receptor (NPC1L1), the 
transferrin-1 receptor and the serum response factor-binding protein 1 (SRFBP1) (Gerold et 
al., 2015; Martin and Uprichard, 2013; Sainz et al., 2012). 
Following receptor-mediated binding to the cell surface, the virions are internalised into 
endosomes causing the viral envelope proteins to undergo the conformational changes 
required to promote fusion to the endosome membrane and the release of the viral genome 
(Blanchard et al., 2006; Tscherne et al., 2006). This process is briefly summarised in Figure 1-
3, below. 
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FIGURE 1-3: SUMMARY OF HCV ENTRY (ADAPTED FROM LINDENBACH AND RICE, 2013). 
 
BRIEFLY, THE LIPOPROTEIN COMPONENT OF HCV LIPOVIRAL PARTICLES PROMOTES THE INITIAL INTERACTION BETWEEN THE HCV AND HCV 
ENTRY RECEPTORS GAG, LDLR AND SRB1 (1). THIS INTERACTION WITH SRB1 INDUCES A CONFORMATIONAL CHANGE IN HCV E2 
ALLOWING THE SUBSEQUENT BINDING OF HCV E2 WITH CD81 (2). THIS IN TURN ACTIVATES A SIGNALLING CASCADE RESULTING IN THE 
REMODELLING OF ACTIN AND THE INTERNALISATION OF THE HCV PARTICLE (3). THE INTERACTION BETWEEN HCV-CD81 AND CLDN1 LEADS 
TO CLATHRIN-MEDIATED ENDOCYTOSIS. ONCE ENDOCYTOSED, H+ IONS FLOW INTO THE VESICLE LEADING TO HCV ENVELOPE FUSION WITH 




1.1.6.2 HCV REPLICATION  
 
Once released in to the cytoplasm of the host cell, the positive-sense viral genome acts as 
messenger RNA allowing the translation of the viral genome. Translation of the viral genome 
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into a large polyprotein of around 3000 amino acids occurs at the rough ER and is initiated by 
the IRES within the 5’UTR of the viral genome (Dubuisson and Cosset, 2014). The HCV 
polyprotein is targeted to the ER membrane by internal ER signal peptides (Wu, 2001). Once 
translated, the polyprotein is processed. Host proteases, such as host-cell signal peptidases, 
work to cleave the structural proteins, core, E1 and E2, along with the non-structural p7. 
Cleaved E1 and E2 can then undergo glycosylation and conformational changes before 
mature E1E2 heterodimers are assembled (Penin et al., 2004).   When separated from p7, the 
autoprotease NS2 is then able to cleave itself from NS3 (Grakoui et al., 1993). This cleavage 
allows NS3 to cleave the downstream NS4A/B junction leading to the association of NS3 and 
NS4A. This NS3/4A protease is then responsible for cleavage of the remaining HCV proteins 
(Penin et al., 2004). All HCV proteins are anchored at the ER via transmembrane regions, 
amphipathic α-helices or, in the case of NS3, by association with another membrane-bound 
protein (Bartenschlager et al., 2013).  
After polyprotein processing, some of the non-structural HCV proteins NS3, NS4A, NS4B, 
NS5A and NS5B form a replication unit that, along with host factors, induces complex 
structural changes in the ER membrane forming what is known as the membranous web 
(Dubuisson and Cosset, 2014; Gosert et al., 2003; Lohmann et al., 1999). The membranous 
web, consisting of clusters of predominately double-membraned vesicles along with lipid 
droplets, is the site of HCV replication (Gosert et al., 2003). Host cell membrane 
rearrangements, such as the membranous web produced by HCV, is a common feature of the 
replication of positive-sense viruses (Miller and Krijnse-Locker, 2008). For example, both 
poliovirus and severe acute respiratory syndrome virus produce similar double-membraned 
vesicles.   
HCV RNA synthesis, through the use of the RNA-dependent RNA polymerase NS5B and host 
factors such as miR-122, leads to the production of negative-sense HCV RNA from which 
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several positive-sense HCV RNA genomes can be produced. A summary of this process is seen 
in Figure 1-4 below. The RNA genomes formed are then either translated to more viral 
proteins, more RNA genomes or packaged in new virions (Bartenschlager et al., 2013).  
 
 
FIGURE 1-4: SUMMARY OF HCV RNA REPLICATION (ADAPTED FROM LINDENBACH AND RICE, 2013). 
 
AFTER HCV RNA IS RELEASED FROM THE HCV PARTICLE IN THE CYTOSOL, THE RNA GENOME IS TRANSLATED ON RIBOSOMES LOCATED ON 
THE ROUGH ER (1) THAT RESULTS IN A LARGE POLYPROTEIN (2). THIS POLYPROTEIN IS THEN PROCESSED BY HOST AND VIRAL PROTEASES TO 
PRODUCE EACH INDIVIDUAL HCV PROTEIN, WHICH REMAIN LOCATED AT THE ER (3). ONCE PROCESSED, THE MEMBRANOUS WEB IS FORMED 
(4). NON-STRUCTURAL PROTEINS MIGRATE TO THIS AREA TO ALLOW THE REPLICATION OF THE HCV RNA GENOME. FOR EACH NEGATIVE-
STRAND RNA GENOME PRODUCED, SEVERAL POSITIVE-SENSE RNA GENOMES ARE PRODUCED. SEE TABLE 1-3 FOR THE FUNCTION OF EACH 
HCV PROTEIN. 
 
1.1.6.3 HCV ASSEMBLY 
 
The assembly of HCV particles is a complicated process that is dependent on the interaction 
of both host and viral proteins (Figure 1-4, Lindenbach and Rice, 2013). The main structural 
components of HCV virions are the nucleocapsid core protein and the envelope proteins, E1 
and E2. Core proteins are produced in the ER and transferred to lipid droplets, intracellular 
stores of neutral lipids in cells (Barba et al., 1997). These lipid droplets are thought to be the 
site of virion assembly as core is able to recruit the relevant HCV non-structural proteins and 
RNA genomes to nearby lipid droplet-associated membranes (Miyanari et al., 2007). Once 
core interacts with the RNA genome of HCV, core is able to oligomerise to produce the 
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nucleocapsid (Boulant et al., 2006). NS5A can also bind RNA and deliver it to core further 
promoting virion assembly (Huang et al., 2005). Additionally, viral particles are often found 
nearby lipid droplets further implying that the lipid droplets are the site of HCV assembly 
(Miyanari et al., 2007).  
The other major structural elements of HCV particles are the envelope proteins, E1 and E2. 
These proteins are also produced in the ER where they form heterodimers that are retained 
via an ER-retention signal, as described earlier. These heterodimers migrate to the site of viral 
assembly through the interaction with NS2 and P7 (Atoom et al., 2013; Stapleford and 
Lindenbach, 2011). As such, the envelope is acquired through the budding of the HCV particle 
through the ER membrane. In contrast to other viruses, HCV virions at this point are mature 
and infectious due to the budding from the ER rather than the cellular plasma membrane 
(Gastaminza et al., 2006). 
This budding through the ER is linked to lipoprotein synthesis and assembly thereby allowing 
the association of lipoproteins with the new HCV particles (Catanese et al., 2013).  This link 
between lipoprotein synthesis, lipoprotein assembly and HCV particle production was 
confirmed as inhibition of microsomal triglyceride transfer protein or ApoB prevented the 
generation of infectious HCV particles (Gastaminza et al., 2008; Huang et al., 2007).  
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FIGURE 1-5: SUMMARY OF HCV ASSEMBLY (ADAPTED FROM LINDENBACH AND RICE, 2013). 
 
AFTER REPLICATION OF HCV RNA GENOMES AT THE MEMBRANOUS WEB (1), THE RNA IS EITHER USED TO PRODUCE MORE RNA GENOMES, 
MORE HCV PROTEINS OR FOR PACKAGING IN NEW VIRIONS. CORE PROTEINS ARE TRANSFERRED TO LIPID DROPLETS ALLOWING THE 
RECRUITMENT OF NS5A AND HCV RNA (2). THE LIPID DROPLETS ARE THOUGHT TO BE THE SITE OF HCV ASSEMBLY AS CORE THEN 
OLIGOMERISES AROUND THE HCV RNA PRODUCING THE NUCLEOCAPSID. E1E2 COMPLEXES MIGRATE TO NEARBY LIPID DROPLETS, THROUGH 
INTERACTION WITH P7/NS2 COMPLEXES, ALLOWING THE BUDDING OF THE NUCLEOCAPSID FROM THE E1E2-STUDDED PHOSPHOLIPID ER 
MEMBRANE.  
 
1.1.6.4 HCV PARTICLE EGRESS 
 
As seen with other flaviviruses, HCV particle release is then thought to occur via the secretory 
pathway (Coller et al., 2012; Lindenbach and Rice, 2013b; Mackenzie and Westaway, 2001). 
This pathway is used to transport, among other proteins, lipoproteins including very LDL 
(VLDL, an LDL precursor) and HDL. As such, both very low density lipoprotein (vLDL) and HCV 
virion secretion can be blocked using the same reagents (Huang et al., 2007; Nahmias et al., 
2008). Both vLDL and HCV particles are transported in VLDL transport vehicles (VTVs) through 
the Golgi apparatus and through the plasma membrane (Siddiqi, 2008). It has been previously 
suggested that the p7 viroporin protects the HCV particle from acidic conditions in these 
compartments (Wozniak et al., 2010). Whilst the particles progress through the Golgi, the 
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HCV envelope proteins on these particles are post-translationally modified (Vieyres et al., 
2010). 
 
1.1.7 REGULATION OF HCV REPLICATION AND ASSEMBLY 
 
Several microRNAs interact either directly or indirectly with HCV and have been shown to 
affect HCV replication. One particular microRNA, the liver-specific miR-122, is required for 
HCV replication (Jopling et al., 2005). This microRNA has been shown to have two separate 
functions by binding to two separate binding sites within the 5’ untranslated region of the 
HCV viral genome. These two effects work to stabilise the viral RNA against degradation by 
host endonucleases and stimulating HCV RNA translation. By comparison, other microRNAs 
that are generally expressed in non-hepatic cells have the opposite effect of inhibiting viral 
replication (Conrad and Niepmann, 2014).  
Another key regulator of HCV replication is lipid peroxidation, the process of oxidative 
degradation of lipids by reactive oxygen species (ROS). Viral infections typically induce the 
production of ROS (Peterhans, 1997); HCV is known to induce oxidative stress in the liver 
thereby promoting liver damage (Paracha et al., 2013). There is now evidence that HCV can 
sense lipid peroxides induced by infection and restrict viral replication with the aim to 
potentially facilitate virus persistence (Yamane et al., 2014). 
 
1.1.8 INFECTION OUTCOMES 
 
 
HCV infection has two potential outcomes within its host. Of those infected, an estimated 
30% will successfully clear the virus without any intervention or treatment (Miller and Dillon, 
2015). Most of these cases are asymptomatic and therefore subclinical resulting in an 
estimated diagnosis rate of acute infections of around 35% in England. In the remaining 
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cases, HCV persists resulting in chronic infection that can last several decades. In addition, in 
some patients that have successfully cleared HCV (defined as having no detectable HCV RNA 
in sera and normal liver function tests), HCV RNA has been documented to persist at low 
levels in the liver and peripheral blood mononuclear cells. This type of infection is now known 
as occult HCV infection. Patients are still at risk of developing the same liver diseases seen in 
chronic HCV infection but at a slower rate (Carreño et al., 2012; Pham et al., 2004). Defining 
what immune response is needed to effectively clear the virus is therefore of particular 
interest to researchers in this field. 
It is now thought that immunological events early in infection determine the outcome of 
infection. Distinct profiles defined by clinical and immunological parameters, including viral 
load, alanine transaminase (ALT) levels, HCV-specific CD4+ and CD8+ T cell responses, are seen 
for both acute and chronic infections thereby potentially predicting infection outcome (Lauer, 
2013). However, these early immunological events affecting infection outcome are poorly 
understood and the subclinical nature of acute HCV infections has made their study difficult; 
understanding these events is, however, critical for vaccine development.  
 
1.1.9 THERAPIES AND VACCINES  
 
In the absence of a licensed vaccine, historical standard treatment was based on combination 
therapy with pegylated interferon- and ribavirin (Shiffman, 2014). However, these drugs 
required a 24-48 week course of treatment, were only effective in 50% of patients and had 
severe side effects due to their non-specificity. Side effects included autoimmune diseases 
and haemolytic anaemia, and for this reason, many patients could not continue with 
treatment (Manns et al., 2006). 
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The next generation of HCV therapies, Telaprevir and Boceprevir, were first approved in 2011 
for use with difficult to treat genotypes, such as genotype 1. These direct-acting antiviral 
agents (DAA) specifically targeted one of the viral proteins, the NS3-NS4A protease, and were 
effective in around 70% of patients. However, the treatments were compromised by side 
effects, resistance and drug-drug interactions (Au and Pockros, 2014).    
More recently, new DAAs have been approved targeting not only the NS3-NS4B protease 
(Simeprevir) but also NS5A inhibitors (Daclatasvir, Ledipasvir) and NS5B inhibitors 
(Sofosbuvir). These new drugs have a high potency and can be combined to achieve over 90% 
effectiveness in around 12 weeks, even in patients who had previously not responded to 
treatment (Popescu et al., 2011; Younossi et al., 2014).  
 
Despite these advancements in drug therapies, these are expensive and therefore not widely 
available to most people (Gornall et al., 2016). As the therapies can’t protect against 
reinfection, resistance mutations could appear with repeated use of these drugs allowing 
HCV infections to persist. A vaccine would not have these problems and would therefore be a 
more tractable solution, especially in developing countries.   
Vaccines based on recombinant proteins, peptides, DNA of HCV proteins or epitopes, viral 
vectors delivering HCV RNA, or dendritic cells expressing foreign proteins such as HCV 
epitopes have all been investigated and each has at least one vaccine candidate in either 
Phase I or II clinical trials (Table 1-4) (as reviewed in Ghasemi et al., 2015; Xue et al., 2014). 
These approaches all have technical issues such as weak immune responses, pre-existing 
immunity or the limited availability of dendritic cells from patients. Additionally, limited data 
is available for these vaccines and none have progressed to Phase 3 clinical trials yet.   
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Recombinant protein E1 Ceased in 
2007 
(Leroux-Roels et al., 2004) 
 E1 or E2 I (Frey et al., 2010) 
 Core I (Drane et al., 2009) 
 NS3-core fusion 
protein 
II NCT00606086* 
Peptide Core II (Yutani et al., 2015, 2009) 
 NS3 I NCT00445419* 
 E1, E2, NS3, NS5A I (Yutani et al., 2007) 
 Core, NS3, NS4 II (Klade et al., 2008; 
Wedemeyer et al., 2009) 
 T cell epitopes II (Firbas et al., 2010, 2006) 
DNA Core, E1, E2+ 
recombinant core 
protein 
II (Alvarez-Lajonchere et al., 
2009; Amador-Cañizares et 
al., 2014) 
 NS3, NS4A II NCT01335711* 
Viral vector Ad6/ChAd3 
expressing NS3-NS5B 
I (Barnes et al., 2012) 




Dendritic cell Core, NS3, NS4B, 
universal Th epitopes 
I (Gowans et al., 2010) 
 
 
TABLE 1-4: LIST OF HCV VACCINES IN CLINICAL TRIALS (ADAPTED FROM GHASEMI ET AL., 2015; XUE ET AL., 2014).  
*: CLINICALTRIALS.GOV IDENTIFIER. 
 
HCV vaccine development is complicated due to the virus’ high genetic variability, its 
association with lipoproteins and the glycosylation of the envelope proteins helping to shield 
the virus from neutralising antibodies (Maillard et al., 2006). The virus can also spread 
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directly by cell-to-cell transfer aiding its evasion of the immune response (Timpe et al., 2008). 
Despite this, at least partial protection against reinfection is documented in many cases in 
both humans and chimpanzees (Bassett et al., 2001; Mehta et al., 2002; Nascimbeni et al., 
2003; Osburn et al., 2010). To develop a vaccine, the immune response behind viral clearance 
must be completely understood so that a vaccine can be designed that directly elicits this 
type of response. Currently, it is accepted that a vaccine could be used to prevent infections 
progressing to chronicity, the type of infection associated with liver cirrhosis and cancer, 
rather than inducing sterilising immunity. 
 
1.1.10 HCV MODEL SYSTEMS 
 
 
1.1.10.1 IN VITRO MODELS 
 
One of the biggest hindrances to the study of HCV is its restricted host range and the inability 
to culture the virus in vitro. To address this issue, in vitro and in vivo model systems were 
developed. HCV replicons were the first established in vitro model of HCV. These viral RNA 
units of reduced length commonly contained the NS3-NS5B replication complex of HCV and a 
drug resistance gene replacing the rest of the genome (Lohmann et al., 1999). Unfortunately, 
it acquired several adaptive mutations in NS3 or NS5A which made the replicon ineffective in 
vivo and unable to produce infectious HCV particles (Blight et al., 2000; Bukh et al., 2002). 
These HCV replicons were later replaced with a genotype 2a strain of HCV, named JFH-1, that 
can replicate efficiently in cell culture without acquiring adaptive mutations (Kato et al., 
2003). Moreover, infectious virions could be produced that successfully infected chimpanzees 
(Lindenbach et al., 2005; Wakita et al., 2005; Zhong et al., 2005). The infectivity titre 
remained low for this system until chimeric viruses were created containing the replication 
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complex of JFH-1 (NS3-NS5B) but the rest of the genome of a different HCV isolate allowing 
the study of different HCV genotypes. This cell cultured HCV (HCVcc) has been invaluable in 
studying the entire HCV lifecycle and testing of novel antivirals and candidate vaccines 
(Gottwein et al., 2009; Imhof and Simmonds, 2010; Pietschmann et al., 2006; Scheel et al., 
2011). In combination with these developments, improved cell lines such as the human 
hepatocarcinoma 7-Lunet cells, which have low CD81 expression (an essential HCV entry 
receptor) but could be transduced to overexpress CD81 to support robust HCV replication, 
significantly aided the study of HCV’s lifecycle (Koutsoudakis et al., 2007; Saeed et al., 2015). 
The main other method to study HCV entry is using pseudotyped HCV (HCVpp). These consist 
of either a retroviral or lentiviral backbone encoding a reporter gene instead of its own 
genome and bearing functional HCV envelope proteins (Bartosch et al., 2003). This system 
has been crucial for studying viral entry and response of virus to neutralising antibodies. In 
particular, it has been used to discover entry receptors such as Claudin-1 (Evans et al., 2007). 
As the HCVpp is non-replicative, it can be used in lower containment level laboratories than 
the original wildtype virus. The obvious disadvantage with this system is that only viral entry 
can be studied as the envelope proteins of HCV are the only parts of the virus that are 
incorporated. 
 
1.1.10.2 IN VIVO MODELS 
 
Although in vitro models have provided methods for studying the life cycle of HCV and the 
testing of novel antiviral compounds and vaccines, an in vivo model is vital for studying host-
virus interactions and novel vaccines and treatments. In vivo models also permit the study of 
the whole duration of infection in comparison to HCV infections in patients where important 
tissue samples and time points are difficult to access (Bukh, 2012). 
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Chimpanzees are the only animal model that can support HCV replication and produce a 
similar infection profile to that seen in humans. This model had several advantages: both 
acute and chronic infections are produced, liver tissue can be taken for biopsy, and the entire 
duration of infection can be observed (Lanford et al., 2001; Prince and Brotman, 1994; 
Walker, 1997). There are differences between HCV infection of humans and chimpanzees, 
such as a reduced rate of chronicity in chimpanzees, but they remain the best animal model 
of HCV infection (Lanford et al., 2001). The use of chimpanzees is now banned within the 
European Union due to ethical reasons so this model has not been viable for a number of 
years (Altevogt et al., 2011; Harrington, 2012). 
Tree shrews (Tupaia belangeri chinesis) have also been used as an in vivo model for HCV 
infection. Of the animals infected, 20-35% tested positive for HCV by PCR (Xie et al., 1998). 
This model has not been widely accepted because studies showed that only certain isolates of 
HCV could cause infection in these animals (Xu et al., 2007; Zhao et al., 2002).  
Other in vivo models are based on the use of mice. Both transgenic mice and mice with 
humanised livers have been created to study the HCV lifecycle. Although HCV replication at 
low levels in murine cells has been previously reported (Uprichard et al., 2006), murine cells 
are not naturally permissive for HCV entry. The reason for this was discovered in 2009 when 
it was identified that only murine hepatocytes expressing the human occludin and CD81 
receptors could support HCV entry (Ploss et al., 2009). This was an important step forward for 
developing a small animal model of HCV infection in which to test new antiviral therapies or 
vaccines. The mouse model is still not ideal as HCV replication in mice is inefficient.  
Transgenic mice were also produced stably expressing the four central HCV entry receptors: 
CD81, OCLN, SCARB1 and CLDN1, or combinations of these. These mice proved useful for 
studying viral entry, potential inhibitors of viral entry and vaccine candidates (Dorner et al., 
2011). In addition to this, mice that express different parts of the HCV genome, for example 
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HCV core protein, have also been produced to study host-virus interactions  (Lerat et al., 
2011).  These mice can develop liver co-morbidities similar to that seen in HCV infection in 
humans, but without inflammation in the liver or HCV replication (as reviewed in Mailly et al. 
2013).  
To further improve the mouse model, researchers developed urokinase-type plasminogen 
activator-severe combined immunodeficiency (uPA-SCID) mice (Mercer et al., 2001). These 
immunodeficient mice have a transgene that caused liver damage. Liver of the mice can then 
be repopulated with human hepatocytes. These mice provide a useful model for studying the 
whole of the HCV lifecycle. Typical viral titres as seen in humans can be achieved, as well as 
chronic infections (Mercer et al., 2001). These mice have been an invaluable asset for 
studying the effect of neutralising antibodies on viral entry and assessing novel directly acting 
antivirals (Akazawa et al., 2013; Vanwolleghem et al., 2007). Despite the usefulness of this 
model, the mice are immunodeficient meaning that the immune response to HCV cannot be 
studied. Other murine model variations also exist, but all have significant limitations of either 
immunodeficiency, no viraemia or inefficient replication of HCV (Mailly et al., 2013). 
Surrogate models of HCV infection have also been established to allow the study of the 
immune response. One such model is GBV-B infection in tamarins. HCV and GBV-B cluster 
together on their phylogenetic tree (see Figure 1-2) and therefore share many similarities 
including the same genome structure, organisation, tropism and functions (Beames et al., 
2001). Although novel hepaciviruses have now been discovered that cluster closer to HCV, 
most of these viruses are not known to be hepatotropic or have other disadvantages. GBV-B 
infection in tamarins is therefore used as a surrogate animal model to study acute HCV 
infection which permits the study of the immune response, unlike most other HCV models. 




1.2.1 IDENTIFICATION  
 
Prior to the identification of HCV, Deinhardt and colleagues were aiming to discover a 
nonhuman primate that could be infected with the agent of NANB hepatitis for use as an 
animal model (Deinhardt et al., 1967). To achieve this, sera from a surgeon, who had the 
initials GB, with viral hepatitis was inoculated into tamarins, a type of New World monkey, 
which subsequently developed hepatitis. Passage of serum from the infected tamarins to 
naïve tamarins resulted in hepatitis in the recipients, thus initially the infectious agent in the 
serum was proposed as the cause of NANB hepatitis (Deinhardt et al., 1967). However, 
subsequently, Simons and colleagues (Simons et al., 1995a, 1995b) identified two flaviviruses 
in the sera and livers of the infected tamarins, termed GBV-A and GBV-B, the latter of which 
was later determined to be the aetiologic agent of hepatitis in these animals (Schaluder et al., 
1995). By contrast, GBV-A has not been associated with any disease (Stapleton et al., 2011). 
 
1.2.2 ORIGINS  
 
The origin of GBV-B is unknown. The virus has never been isolated from wild tamarins, only 
from tamarins infected with passages of the original Deinhardt GB serum (Deinhardt et al., 
1967; Simmonds, 2013). However, neither humans nor chimpanzees can support GBV-B 
infection suggesting that the GB serum cannot have been the source of GBV-B (Tabor et al., 
1980).  GBV-B has been shown to be able to infect a number of New World monkey species 
including several species of tamarins (Beames et al., 2001, 2000; Bukh et al., 1999; Deinhardt 
et al., 1967; Schaluder et al., 1995), owl monkeys (Bukh et al., 2001) and marmosets (Lanford 
et al., 2003). Infection profiles differ between each of these hosts leading to the hypothesis 
that GBV-B is most likely a tamarin virus as GBV-B replicates most efficiently in this host 
species (Bright et al., 2004; Bukh et al., 2001; Lanford et al., 2003). Further supporting this 
42 | P a g e  
 
hypothesis, the closely-related GBV-A has been determined to be an indigenous tamarin virus 
(Bukh and Apgar, 1997). 
 
1.2.3 CLASSIFICATION AND HETEROGENEITY 
 
 
Initially, GBV-B was considered a conserved virus that exhibited little genetic variation. The 
virus has only one genotype and nucleotide sequence identities of 99.6-99.9% have been 
documented by sequencing the whole genome of either the virus or infectious molecular 
clones (Bukh et al., 1999; Martin et al., 2003; Nam et al., 2004).  In addition, the N-terminal 
end of E2 does not have the same hypervariability that is seen with HCV (Weiner et al., 1991). 
Mutations do occur within the GBV-B proteins and have been shown to accumulate more 
frequently within the non-structural proteins, in particular NS5A, and very rarely in the 
structural proteins (Kyuregyan et al., 2005; Martin et al., 2003; Nam et al., 2004; Rijnbrand et 
al., 2005). These are most likely adaptive mutations that could help the virus evade the 
immune system (Kyuregyan et al., 2005). 
More recent studies have shown that GBV-B has a higher genetic variability than previously 
thought. Preliminary deep sequencing data has showed that mutations accumulate over the 
course of infection and are positively selected; these mutations also accumulate at a higher 
rate as the infection progresses (Bowen et al., manuscript in preparation). The molecular 
evolution of GBV-B and HCV is now thought to be similar (Fernandez et al., 2004; Takikawa et 
al., 2010).  As GBV-B has only been identified from one source, it is entirely possible that 
different genotypes could also exist within other sources. However, all animal experiments 
have been undertaken with virus isolated from one source which significantly impacts on any 
estimation of genetic heterogeneity (Beames et al., 2001). 
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1.2.4 STRUCTURE AND LIFE CYCLE 
 
 
Although the life cycle of GBV-B has not been directly studied, its genome encodes 
homologous proteins to HCV with corresponding functions. Despite the overall amino acid 
homology being only around 28%, some regions are more conserved than others, with the 
NS3 serine protease, the NS3 RNA helicase and NS5B having a much higher homology with 
their HCV counterparts (Muerhoff et al., 1995; Zhong et al., 2000, 1999). Functional 
homology also exists between the NS3 proteases of both viruses enabling the cleavage of 
both HCV and GBV-B polyproteins by either viral NS3 (Scarselli et al., 1997).  
The natural host of GBV-B remains uncertain resulting in a lack of knowledge about both its 
origin and its life cycle as a virus. In addition, the lack of a robust cell culture system for GBV-
B provides another barrier for determining its viral life cycle. However, the core protein of 
GBV-B is directed to lipid droplets, as is seen in HCV’s life cycle, suggesting that GBV-B and 
HCV virions share a similar structure, function and life cycle (Hope et al., 2002). 
 
1.2.5 GBV-B INFECTION AND PATHOLOGY 
 
 
Typically, GBV-B causes an acute infection in its New World monkey host. Commonly, the 
infection profile consists of a high viraemia that appears within 2 weeks after inoculation, 
quickly peaking and then declining to an undetectable level at around weeks 16-18. These 
timings are dependent on the initial GBV-B inoculation dose used and the route of infection 
(Lanford et al., 2003). Alanine aminotransferase (ALT) levels, a measure of liver damage, have 
showed to peak immediately prior to clearance. Occasionally, viral recrudescence is seen in 
the last weeks of infection but is quickly cleared. Chronic infections are rarely seen in this 
animal model with most only occurring under immunosuppression or if infected 
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intrahepatically (Lanford et al., 2003; Martin et al., 2003). The rare natural chronic infections 
that have been documented do not appear to have a consistent infection profile (Iwasaki et 
al., 2011). 
Therefore, whilst GBV-B infection in tamarins, or other New World monkeys, is not ideal to 
model chronic HCV infection, it remains a valuable animal model of acute HCV infection. This 
model could be used to investigate novel drugs, vaccines or other treatments that are 
developed over the coming years. 
 
1.3 THE IMMUNE SYSTEM 
 
The human immune system is a complex defense system that functions to recognise non-self 
molecules within the body to control infection and disease. It has two components: innate 
and adaptive immunity. Innate immunity is the initial non-specific response to infection with 
a foreign body, such as a pathogen. Adaptive immunity is the second branch of the immune 
system and is highly specialised. If the innate immune response cannot destroy the pathogen 
alone, the adaptive immune response is apparent several days post infection (Murphy and 
Weaver, 2016a). This lymphocyte-driven response is highly effective and also has the capacity 
for the development of immunological memory. If the pathogen is encountered for a second 
time, this memory response is much quicker and stronger, protecting the host from a second 
infection. Despite the separate branches, the innate and adaptive immune responses overlap 
throughout infection (Clark and Kupper, 2005).  
 
1.3.1 INNATE IMMUNITY 
 
45 | P a g e  
 
Alongside the physical and chemical barriers, for example the ciliated respiratory epithelium 
and various molecules capable of degrading microbes (Gallo and Hooper, 2012), the innate 
immune system also involves several types of cells including antigen-presenting dendritic 
cells, phagocytic macrophages that can engulf and degrade microbes, cytotoxic natural killer 
cells (NK) and a specific subset of T cells called γδ (Banchereau and Steinman, 1998; Born et 
al., 2006; Iwasaki and Medzhitov, 2010; Topham and Hewitt, 2009). These components work 
together to limit the spread of infection and, if possible, to ultimately destroy the invading 
pathogen.  
The first phase of the innate immune response to a pathogen includes enzymes such as 
lysozyme which digests bacterial cell walls, peptides, such as defensins, which are thought to 
disrupt the membrane integrity of pathogens, and complement proteins that directly lyse 
pathogens or recruit innate immune cells, such as phagocytes, to engulf and destroy the 
pathogen (Ganz, 2003; Nagl et al., 2002; Noris and Remuzzi, 2013; Sukhithasri et al., 2013). If 
this fails to control infection, the second phase of the innate immune response is activated.  
This second phase response is reliant on the recognition of conserved features between 
pathogens, hence the non-specific element of this response. In general, pathogens contain 
conserved sequences called pathogen-associated molecular patterns (PAMPs) that are 
recognised by pattern-recognition receptors (PRRs, Takeda and Akira, 2005). Several families 
of PRRs exist to recognise the huge diversity of PAMPs, which can be derived from 
polysaccharides, glycolipids, lipoproteins, nucleotides and nucleic acids from a wide variety of 
pathogens (Mogensen, 2009). These families of PRRs are expressed not only intracellularly 
such as cytosolic sensors of viral RNA or DNA, but also extracellularly such as Toll-like 
receptors (TLRs) expressed on the plasma membranes of macrophages and dendritic cells. 
Indeed, most PAMPs can be recognised by both extracellular and intracellular PRRs (Iwasaki 
and Medzhitov, 2015).  
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Alongside the recognition of PAMPs, the innate immune system is also able to recognise 
functional effects of infection, such as the common effects of virulence factors (Chovatiya 
and Medzhitov, 2014). For example, influenza virus activates NLRP3 inflammasomes via its 
M2 ion channel resulting in the induction of an inflammatory response (Ichinohe et al., 2010). 
This detection of common functional effects reduces the number of specific receptors 
needed and also confirms that the invading microbe is a pathogen.  
Once a pathogen has been detected through a PRR, a signaling cascade is triggered that 
involves the activation of a range of adapter molecules, kinases and transcription factors 
(Takeda and Akira, 2005). These pathways lead to the activation of gene expression and the 
production of cytokines, chemokines, cell adhesion molecules and immunoreceptors which in 
turn leads to a rapid and potent inflammatory response (Akira et al., 2006). Important 
proinflammatory cytokines include tumor necrosis factor (TNF), interleukin (IL)-1 and IL-6. 
Proinflammatory molecules have a range of roles. These include the modification of vascular 
endothelial permeability, cell death, recruitment of leukocytes at the site of infection, the 
appearance of selectin proteins allowing leukocyte adherence to inflamed tissue and the 
induction of acute phase proteins leading to the well-defined symptoms of inflammation 
(redness, swelling, heat, pain and loss of tissue function) (Takeuchi and Akira, 2010). Non-
specific phagocytes (including dendritic cells) that have now migrated to the site of infection 
can then go on to engulf pathogens, degrade it into peptides and present the remaining 
peptides on protein complexes called major histocompatibility complexes (MHC) class II 
(Roche and Furuta, 2015). These activated antigen-presenting cells (APC) then migrate to 
lymphoid tissue to present these peptides, or antigens, to lymphocytes. This antigen 
presentation leads to the initiation of the adaptive immune response (Medzhitov, 2007).   
 
1.3.2 ADAPTIVE IMMUNITY 
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Once activated, APC engulf the pathogen, degrade it into peptides and present these 
peptides on their surface. Antigen presentation occurs via one of two types of highly 
polymorphic MHC molecules: class I molecules activate the cytotoxic CD8 subset of T cells 
whereas class II molecules activate the helper CD4 subset of T cells (Doyle and Strominger, 
1987; Norment et al., 1988). As such, the MHC molecules present different types of peptides. 
To combat intracellular infections, MHC class I molecules are produced in the ER where they 
are able to bind to intracellular microbial peptides. These peptides are produced from 
microbial proteins that have been degraded via the proteasome. In contrast, MHC class II 
molecules obtain their peptides from within intracellular endocytic vesicles containing 
digested pathogens in APC (Neefjes et al., 2011; Vyas et al., 2008). Once peptides are bound 
to MHC molecules, they are transported to the cell surface where T cells are able to recognise 
the complexes.  
In the case of an extracellular pathogen, this initial antigen presentation on APC activates the 
cell which in turn results in the upregulation of MHC class II molecules on the APC allowing 
the efficient presentation of antigens (Roche and Furuta, 2015). This activation also leads to 
the expression of co-stimulatory molecules, such as CD80 and CD86, on the cell’s surface 
(Zhang et al., 2004). These activated APC migrate to the lymphoid tissue, due to chemokines, 
whereby they encounter naïve antigen-specific CD4 T helper cells (CD4 T cells, Sprent, 1995).   
APCs are responsible for delivering up to three types of signals required for the efficient 
activation, expansion and differentiation of CD4 T cells (Goral, 2011). The first activation 
signal comes from CD4 co-receptor after the binding of the MHC: peptide complex to the TCR 
and CD4. A second, co-stimulatory signal is delivered to ensure the survival and proliferation 
of T cells that have received the first signal. The last signal determines the pathway of 
differentiation of the now activated CD4 T cell. Typically, the final signal is a cytokine.  Once 
activated, the CD4 T cells proliferate and differentiate into one of several types of effector 
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CD4 T cells. Each subset is specialised for the control and destruction of different types of 
pathogens. The type of effector CD4 T cells produced during infection depends on the type of 
antigen presented on the initial APC (Goral, 2011; MacLeod et al., 2010; Smith-Garvin et al., 
2009; Zhu and Paul, 2008).  
Another important subset of T cells, CD8 T cells, are also involved in the adaptive immune 
response and require activation (Wiesel et al., 2009). These cells are specialised to destroy 
host cells infected with intracellular pathogens through apoptosis, otherwise known as 
programmed cell death (Elmore, 2007). As such, these cells recognise peptides bound to MHC 
class I molecules on infected cells (Norment et al., 1988). CD8 T cells also require co-
stimulatory activation which they can receive in two possible ways: direct activation by an 
activated dendritic cell or through CD4 T cell help (Ruedl et al., 1999; Zhang et al., 2009). This 
CD4 T cell help occurs if a CD4 and CD8 T cell recognise antigens presented on the same APC. 
The CD4 T cell can deliver additional co-stimulatory signals to promote CD8 T cell 
proliferation and differentiation (Zhang et al., 2009).  
Once both CD4 and CD8 cells have become activated effector T cells, these cells can migrate 
from the lymphoid tissues to perform specific effector functions (Berstein and Abraham, 
2008). Effector CD8 T cells are able to destroy infected cells that display peptides from an 
intracellular pathogen on an MHC class I molecule. These effector functions are due to the 
release of two types of effector molecules into an infected cell: perforin to form pores in the 
cellular membrane and granzymes to activate apoptosis (Trapani and Smyth, 2002). Other 
effector molecules that are produced by this cell type include interferon (IFN)-γ which can 
block viral replication and activate macrophages along with Fas ligand which can trigger 
apoptosis in a cell bearing Fas on its surface (Refaeli et al., 2002; Schroder et al., 2003). 
In contrast, CD4 T cells will recognise peptides bound to MHC class II molecules (Doyle and 
Strominger, 1987). Effector CD4 T cells can activate macrophages to allow the destruction of 
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infected cells and activate B cells to produce antibodies to label pathogens (Murphy and 
Weaver, 2016a). Macrophages act to clean up cellular debris from destroyed cells but also 
can destroy pathogens by a process known as phagocytosis. This involves the ingestion of a 
pathogen, fusion of this pathogen with a lysosome containing various enzymes and the 
subsequent degradation of that pathogen (Murphy and Weaver, 2016a). CD4 T cells can also 
activate B cells to proliferate, produce antibodies and effector molecules. These molecules 
include IFN-γ to activate macrophages, CD40 ligand to activate B cells and macrophages and 
the B cell activation factors IL-4 and IL-5 (Luckheeram et al., 2012).  
Another highly-specific lymphocyte type involved in the adaptive immune response is the B 
cell, also known as antibody-producing cells.  These cells are activated via a signal supplied 
from either an effector CD4 T cell that has the same antigen-specificity as the B cell (T cell-
dependent activation) or certain types of antigen that can directly provide the second 
activation signal (T cell-independent activation) (Murphy and Weaver, 2016; Parker, 1993; 
Vos et al., 2000). Once activated, the B cell begins to proliferate and differentiate into plasma 
cells that are able to secrete antibodies (Nutt et al., 2015).  
Antibodies have several important functions within the adaptive immune response, including 
neutralisation of pathogen, opsonisation of a pathogen, complement activation or antibody-
dependent cell-mediated cytotoxicity (Forthal, 2014, Huber and Trkola, 2007). Neutralisation 
occurs when antibodies bind to a pathogen, coating it and preventing it from infecting host 
cells. Binding of antibodies to pathogens also promotes the uptake of these pathogens by 
phagocytes, also known as opsonisation. Antibodies can also activate the complement 
proteins through the activation of the complement protein C1 (Melis et al., 2015). This 
activation of C1 can either lead to further opsonisation or the destruction of pathogens, such 
as bacterial cells, through the insertion of the membrane-attack complex which inserts pores 
into cellular membranes. The last effector mechanism of antibodies is antibody-dependent 
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cell-mediated cytotoxicity. This mechanism of killing infected cells relies on the coating of 
these cells with antibodies. The Fc domain of the antibodies can then be recognised by NK 
cells and the NK cells act to initiate apoptosis of the infected cells (Huber and Trkola, 2007).  
More recent studies suggest further functions of antibodies including acting as direct effector 
molecules (example: directly bactericidal or fungicidal antibodies) and modifying microbial 
signal transduction or microbial physiology (Casadevall and Pirofski, 2012). 
In the case of viral infection (relevant to this thesis), antibodies specific for viral envelope 
proteins can bind to these proteins thereby neutralising the virus, activate the complement 
system to lyse viral particles alongside infected cells, label the pathogen for destruction by 
phagocytes and interact with effector cells via the fragment crystallisable (Fc) receptors 
leading to antibody-dependent cellular cytotoxicity (ADCC) (Burton, 2002; Huber and Trkola, 
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FIGURE 1-6: SUMMARY OF ANTIBODY FUNCTIONS IN RESPONSE TO A VIRAL INFECTION (ADAPTED FROM HUBER AND TRKOLA, 2007). 
 
ANTIBODIES FUNCTION TO CLEAR VIRAL INFECTIONS THROUGH FOUR MAIN PATHWAYS. 1: NEUTRALISING ANTIBODIES TARGET VIRAL ENVELOPE 
PROTEINS TO STOP VIRUSES FROM ENTERING HOST CELLS (1A) OR BY BLOCKING VIRUS UNCOATING OR BUDDING (1B). 2: ANTIBODIES CAN 
CAUSE THE LYSIS OF EITHER FREE VIRUS OR INFECTED CELLS VIA THE C1 COMPLEMENT COMPLEX AND THE CLASSICAL COMPLEMENT PATHWAY. 
3: COMPLEMENT PROTEINS AND ANTIBODIES OPSONISE VIRUSES ENHANCING THE PHAGOCYTOSIS OF VIRAL PARTICLES USING COMPLEMENT OR 
FC RECEPTORS. 4: EFFECTOR CELLS, INCLUDING NATURAL KILLER CELLS, MACROPHAGES AND DENDRITIC CELLS, RECOGNISE INFECTED CELLS 
LABELLED WITH ANTIBODIES LEADING TO THE RELEASE OF CYTOTOXIC GRANULES OR EXPRESSION OF CELL-DEATH INDUCING MOLECULES 
(TEILLAUD ET AL., 2012).    
 
 
1.3.3 ANTIGEN SPECIFICITY OF ADAPTIVE IMMUNE CELLS 
 
Pathogen recognition capabilities of the adaptive immune system is based on the 
presentation of antigens by MHC molecules on APC and cell surface receptors on B cells and T 
cells, named T cell receptors (TCRs) and B cell receptors (BCRs) respectively (Choudhuri et al., 
2005; Edelman, 1991). Whilst TCRs and MHC molecules remain on the cell surface, BCRs can 
also be secreted as an effector molecule of the immune response (Kehry et al., 1980). These 
soluble receptors are known as antibodies. Despite their different functions, B and T cells are 
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required to recognise a huge array of foreign antigens via receptors on their cell surface; both 
sets of cells achieve this by rearranging their genes that encode the receptors for antigen 
recognition during development (Murphy and Weaver, 2016b).  
Both BCRs and TCRs are complexes of multiple proteins: the heavy and light chain of the BCR 
or α and β chains of the TCR (Pleiman et al., 1994; Wucherpfennig et al., 2010). Invariant 
accessory proteins are also associated with these complexes that primarily play a role in 
signalling during antigen recognition. In the case of the BCR, two proteins, Igα and Igβ, are 
associated with the heavy chain of the BCR (Treanor, 2012). These proteins are required for 
the BCR to be expressed at the cell surface and for signalling post antigen recognition as 
these proteins contain cytoplasmic domains that contain immunoreceptor tyrosine-based 
activation motifs (ITAMs). As the heavy and light chains do not contain cytoplasmic domains, 
these polypeptide chains alone can only recognise and bind antigen, they cannot provide any 
signal to activate transcription factors and gene expression downstream which in turn 
supports the control of the adaptive immune response. In comparison, the TCR is also 
associated with several accessory protein chains named the CD3 complex. Similarly, to Igα 
and Igβ, the CD3 complex contains ITAMs for downstream signalling after antigen recognition 
(Al-Lazikani et al., 2000; Choudhuri et al., 2005; Wucherpfennig et al., 2010).  
Both receptors also recognise a unique antigen, although B cells and T cells differ in the type 
and form of antigen presented; T cells recognise antigens that have been processed into 
peptides and presented on MHC molecules on infected cells whilst B cells recognise both 
conformational or continuous epitopes within intact antigens alone in the form of protein, 
polysaccharide or lipid.  The final major similarity between the receptors is their need to 
recognise a huge range of antigen specificities (Batista and Harwood, 2009; Carbone and 
Gleeson, 1997; Choudhuri et al., 2005).  
53 | P a g e  
 
1.3.4 BCR/TCR REARRANGEMENT IS ESSENTIAL FOR ANTIGEN RECEPTOR DIVERSITY 
 
To provide the required level of antigen receptor diversity needed to respond to all potential 
pathogen encounters, each BCR and TCR chain consists of a highly variable region and several 
constant regions (Edelman, 1991; Ely et al., 2005; Yoshikai et al., 1985).  Whilst the constant 
regions are involved in effector functions, the highly variable regions recognise and bind the 
specific antigen. The basic structure of a BCR/antibody is shown below in Figure 1-7. Each 
immunoglobulin is constructed from two heavy chains and two light chains, further increasing 
the antigen receptor diversity. These chains are encoded on three separate loci: the heavy 
chain loci, the κ light chain loci and the λ light chain loci (Matsuda et al., 1998). The only 
structural difference between the BCR and a secreted antibody is that the C-terminus of the 
constant region of the heavy chain can contain either a hydrophobic sequence (BCR) or a 
hydrophilic sequence (antibody). This is achieved through alternate splicing of the mRNA 
molecule encoding the heavy chain of the immunoglobulin (Kehry et al., 1980). 
 
FIGURE 1-7: THE BASIC STRUCTURE OF AN ANTIBODY (ADAPTED FROM MURPHY AND WEAVER, 2016A). 
 
EACH IMMUNOGLOBULIN CONSISTS OF 4 POLYPEPTIDE CHAINS- 2 IDENTICAL LIGHT CHAINS AND 2 IDENTICAL HEAVY CHAINS, BOUND TOGETHER 
BY DISULPHURIC BONDS.  THE FRAGMENT ANTIGEN BINDING DOMAIN (FAB) CONTAINS THE V REGION AND THE FIRST CONSTANT DOMAIN AND 
IT IS INVOLVED IN ANTIGEN BINDING. THE FRAGMENT CRYSTALLISABLE (FC) DOMAIN CONTAINS THE SECOND AND THIRD CONSTANT DOMAINS 
AND IT IS INVOLVED IN MEDIATING EFFECTOR FUNCTIONS.  
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As shown in Figure 1-7, the variable and constant regions of immunoglobulin chains form two 
basic units: the Fragment antigen binding (Fab) domain and the Fragment crystallisable (Fc) 
domain.  The Fab region contains the highly variable (V) region and one constant (C) region of 
both the heavy and light chain (Edelman, 1991). Consequently, there are two Fab regions in 
each complete immunoglobulin molecule. This V region confers the high variability of the 
immunoglobulin receptors. To achieve this level of variability, a V region is encoded by gene 
segments, rather than whole genes, which are combined via somatic recombination 
(Fugmann et al., 2000; Herbst et al., 1986; Lewis, 1994; Schatz and Ji, 2011; Tonegawa, 1983). 
This type of diversity is called combinatorial diversity (Boehm, 2011). 
To produce a complete immunoglobulin light chain, two segments are combined: a V 
segment of around 95-101 amino acids and a joining (J) segment of up to 13 amino acids 
(Fugmann et al., 2000; Lewis, 1994; Murphy and Weaver, 2016c). These segments encode the 
variable region of the light chain. The recombination of V region segments is required as the J 
gene segments are located close to the C region thereby bringing the V, J and C sequences 
together. Through RNA splicing to remove introns, the V region is joined to the C region to 
allow translation and downstream expression. In comparison, to produce a complete 
immunoglobulin heavy chain gene, three segments are combined: V, J and a diversity (D) 
segment. First, recombination occurs to join the D and J segment together; later, a V segment 
is combined. Again, RNA splicing removes introns in the VDJ segment to combine the V region 
sequence to the C region sequence (Fugmann et al., 2000; Murphy and Weaver, 2016c; 








FIGURE 1-8: REARRANGEMENT OF IMMUNOGLOBULIN GENE LOCI TO PRODUCE IMMUNOGLOBULINS. 
 
VARIABLE (V), JOINING (J) AND DIVERSITY (D) GENE SEGMENTS ON THE LIGHT CHAIN (A) AND HEAVY CHAIN (B) IMMUNOGLOBULIN LOCI ARE 
REARRANGED AND JOINED TO A C REGION TO PRODUCE IMMUNOGLOBULINS (adapted from Murphy and Weaver, 2016c). A LEADER 
SEQUENCE (L) IS NECESSARY FOR THE SECRETION OF IMMUNOGLOBULIN CHAINS. A HINGE (H) REGION IS ALSO INCLUDED IN THE CONSTANT 
REGION OF HEAVY CHAINS TO ALLOW FLEXIBILITY FOR BINDING TO ANTIGENS.  
A: THE PROCESS OF GENE SEGMENT REARRANGEMENT ON THE LIGHT CHAIN IMMUNOGLOBULIN LOCI, TERMED IG AND IG. (1) SEVERAL 
COPIES OF V AND J GENE SEGMENTS ARE PRESENT IN THE GENOMIC DNA WITH ONLY ONE CONSTANT REGION ENCODED ON EACH LIGHT CHAIN 
LOCI. (2) THROUGH RECOMBINATION, ONE V AND ONE J GENE SEGMENT ARE JOINED. (3) THE VJ SEGMENTS ARE JOINED TO THE C REGION 
AFTER TRANSCRIPTION OF THE PRIMARY RNA TRANSCRIPT AND SUBSEQUENT SPLICING OF RNA TO REMOVE INTRONS. (4) THIS MRNA IS 
THEN TRANSLATED INTO THE LIGHT CHAIN OF AN IMMUNOGLOBULIN MOLECULE.  
B: THE PROCESS OF GENE SEGMENT REARRANGEMENT ON THE HEAVY CHAIN IMMUNOGLOBULIN LOCUS, TERMED IGH. (1) SEVERAL COPIES OF 
V, D AND J GENE SEGMENTS ARE PRESENT IN THE GENOMIC DNA ALONG WITH SEVERAL CONSTANT REGION EXONS. A MATURE HEAVY 
CONSTANT REGION TRANSCRIPT IS GENERATED BY THE JOINING OF THREE EXONS: CH1, CH2 AND CH3 (2) THROUGH RECOMBINATION, A D 
AND J SEGMENT ARE JOINED. (3) THROUGH FURTHER RECOMBINATION, A V SEGMENT IS JOINED TO THE DJ SEGMENTS. (4) THE VDJ 
SEGMENTS ARE JOINED TO THE C REGION AFTER TRANSCRIPTION OF THE PRIMARY MRNA AND SUBSEQUENT SPLICING TO REMOVE INTRONS. 
(5) AFTER TRANSLATION OF THE MRNA MOLECULE, A HEAVY CHAIN OF AN IMMUNOGLOBULIN IS PRODUCED.  
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The combinatorial diversity that arises by immunoglobulin gene segments increases antigen 
recognition specificities as there are many copies of each segment of each immunoglobulin 
loci (Boehm, 2011). In humans, for example, the heavy chain locus consists of 65 V, 27 D and 
6 J whilst the κ light chain locus consists of 40 V, and 5J and the λ light chain locus consists of 
30V and 4J (Li et al., 2004; Matsuda et al., 1998; Murphy and Weaver, 2016c). In humans, the 
V segments are grouped in families- there are 7 families for the heavy chain and κ chain and 
11 families for the λ chain. In each family, the V segments share at least 80% sequence 
identity with each other (Matsuda et al., 1998).  
 
To ensure that gene segment recombination occurs in the correct order and location, 
rearrangement is directed by the presence of a recombination signal sequence (RSS) that 
flanks gene segments (Schatz and Ji, 2011). This sequence consists of three elements: a 
conserved non-coding heptamer sequence, a non-conserved spacer of 12 or 23 nucleotides 
and finally another conserved sequence of 9 nucleotides. The presence of a spacer brings the 
heptamer and nonamer to the same side of the DNA helix allowing the recognition of the 
sequences by a complex of enzymes called the V(D)J recombinase. The presence of two 
different length spacers also has another important role. Recombination relies on the 12/23 
rule that stipulates that a gene segment with a 12 base pair spacer can only be joined to a 
segment with a 23bp spacer. Therefore, V, D and J segments contain the relevant length of 
spacer to ensure that the order of recombination remains VDJ or VJ (Hiom and Gellert, 1998).  
The RSS also play a role in the rearrangement of the gene segments (Schatz and Ji, 2011). 
Segments are typically rearranged by the looping out of DNA and the subsequent deletion of 
the extra gene segments. To delete the extra gene segments, the VDJ recombinase complex 
causes a break in the DNA. However, the location, or junction, of where this DNA is re-joined 
is imprecise. Additionally, the enzymes involved in DNA repair remove nucleotides and also 
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randomly add nucleotides further increasing the diversity seen in the V region. This type of 
diversity is known as junctional diversity (Jeske et al., 1984).  
All of these stages of recombination occur early during B cell development. Once the loci are 
successfully rearranged to encode complete immunoglobulin genes, another form of 
combinatorial diversity is seen. The pairing of different heavy chains with light chains 
provides a further enhancement of diversity. Using these three methods alone, up to 1011 
different receptors could be produced, although this is somewhat unlikely due to instability 
of immunoglobulins with particular heavy and light chain combinations and the fact that V 
gene segments are not used at the same frequency (Jayaram et al., 2012; Murphy and 
Weaver, 2016c).  
 
1.3.5 AFFINITY MATURATION OF B CELLS 
 
A further increase of the diversity of the antibody repertoire occurs in mature B cells in the 
peripheral lymphoid tissue (Riss, 2013; Weiser et al., 2011). These processes are called 
somatic hypermutation and class switch recombination (Maul and Gearhart, 2010; Stavnezer 
et al., 2008). These mature B cells already express functional BCRs and have encountered a 
foreign antigen along with signals from activated T cells. Whilst in the peripheral lymphoid 
tissue, random point mutations occur in the V regions as this affects antigen binding (Maul 
and Gearhart, 2010). The enzyme activation induced deaminase (AID) is responsible for this 
process as it converts cytosines to uracils. A uracil in DNA is mutagenic thereby initiating 
error-prone DNA repair (Maul and Gearhart, 2010). As B cells proliferate and their BCRs are 
mutated, they are still subjected to selection and those B cells with improved antigen binding 
may be positively selected. This process of increasing antigen binding affinity is also known as 
affinity maturation (Siskind and Benacerraf, 1969). The process of somatic hypermutation is 
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in fact the predominant method of diversity for a number of other animals including birds, 
rabbits, cows, pigs, sheep and horses (Sitnikova and Su, 1998). 
  
1.3.6 CLASS SWITCH RECOMBINATION 
 
Whilst somatic hypermutation occurs in the V regions of mature B cells, class switch DNA 
recombination (CSR) occurs in the C regions (Stavnezer et al., 2008). Both mechanisms are 
crucial in the development of an effective antibody response. As the C region determines the 
class and functionality of the antibody produced, the switching of these C regions can change 
the effector functions of the antibody (Stavnezer et al., 2008). 
The process of CSR is similar to the recombination seen between gene segments in the V 
region, although all recombination events are productive (Murphy and Weaver, 2016c; Xu et 
al., 2012). In this case, the different exons, relating to the different possible isotypes of 
antibodies, are located in the immunoglobulin heavy chain locus sequentially: Cµ, Cδ, Cγ, Cε 
and Cα. The switching of Cµ (IgM) with Cγ, Cε or Cα produces the corresponding IgG, IgE or 
IgA whilst generation of IgD is through alternate splicing of the IgM transcript. Using the AID 
enzyme, double-stranded breaks in the DNA are made in Switch (S) regions, G-rich regions 
located upstream of Cµ, Cγ, Cε and Cα. Once broken, the strands are repaired resulting in the 
VDJ cassette now preceding a different C region (Xu et al., 2012).  
 
1.3.7 ANTIBODY CLASSES 
 
Different classes of antibodies have different functions (Schroeder et al., 2010; Ward and 
Ghetie, 1995). Pre-B cells begin their development by expressing IgM on their surface due to 
the proximity of the Cµ exon to the J gene segments of the VDJ cassette (Nishimoto et al., 
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1991). Directly downstream of the Cµ exon lies the Cδ exon. B cells produce one long primary 
transcript that includes both Cµ and Cδ exons, which is then spliced to produce one of two 
mRNA molecules- one encoding an IgM molecule, the other an IgD molecule. This means that 
mature B cells are able to express both IgM and IgD receptors, however, IgD receptors only 
appear at the later stages of B cell development (Geisberger et al., 2006; Yuan et al., 1996).  
 
Despite this co-expression, IgM is always the first antibody produced during infection whilst a 
limited amount of IgD is secreted and the function of these remains elusive (Chen and 
Cerutti, 2010). The secreted IgM is typically of a lower affinity as the B cells have not yet 
undergone affinity maturation (Eisen, 2014). The other classes, IgG, IgA and IgE, are produced 
after antigen recognition and the subsequent CSR. Each of the subtypes has specific functions 
and locations (Table 1-5). For example, IgG has a larger cytoplasmic domain and increased B 
cell signaling and therefore a B cell carrying an IgG responds to antigens faster (Xu et al., 
2014); IgA and IgE do not efficiently activate complement whilst particular IgG subclasses, 
such as IgG1 and IgG3, activate complement very efficiently which is important in infection 
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antigens due 












Role in allergy, 
hypersensitivity 









TABLE 1-5: THE MAIN PROPERTIES OF THE DIFFERENT IMMUNOGLOBULIN CLASSES (ADAPTED FROM MURPHY AND WEAVER, 2016C, CHEN 
AND CERUTTI, 2010).   
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1.3.8 IMMUNOLOGICAL MEMORY 
 
 One of the most important features of the adaptive immune response is the memory 
response. This response is coordinated by a subset of B and T cells, called memory cells. Once 
B and T cell activation during infection occurs, both cell types begin to proliferate and 
differentiate. B cells differentiate into plasma cells that can secrete antibodies or long-lived 
memory B cells. On the other hand, T cells, when activated, typically become short-lived 
effector T cells (Murphy and Weaver, 2016b). A small subset of these cells is able to express 
cytokine receptors, such as IL-7 and IL-15 receptors, that allows their survival for decades 
(Tan et al., 2002). Therefore, if a pathogen has been previously encountered, the memory 
response enables a faster and more efficient clearing of the same pathogen from the host as 
these cells already exist.  
In the case of antibody production, a typical primary antibody response consists of mostly 
IgM and, after class-switching, a delayed IgG response (Murphy and Weaver, 2016d). In 
contrast, the secondary response generally consists of a lower level production of IgM 
antibodies and much higher levels of IgG antibodies, alongside lower levels of IgA and IgE. 
Memory B cells formed after a primary infection are responsible for this secondary antibody 
response (Kurosaki et al., 2015). Memory B cells express higher levels of MHC class II 
molecules and co-stimulatory molecules which allows more efficient antigen presentation 
and subsequent activation of effector T cells (Murphy and Weaver, 2016d). The effector T 
cells can then aid in promoting antibody production which leads to an earlier antibody 
response in secondary infection in comparison to primary infection. Furthermore, the level of 
plasma cells produced is higher and launches much earlier in secondary infection contributing 
to the antibody response seen. Along with a higher level of antibody production in secondary 
infections, the affinity of antigen-specific antibodies also increases as memory B cells are able 
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to undergo additional somatic hypermutation and affinity maturation. This means that the 
affinity of antibodies produced increases with each subsequent infection.   
More recently, immunological memory has also been associated with IgM-positive, CD4 T 
cell-dependent memory B cells that are generated following immunization, although their 
physiological role has not yet been determined (Yates et al., 2013). Interestingly, these cells 
do not secrete antibodies ex vivo, have a differentiated profile of cell surface markers, are 
generally located in the spleen rather than the blood or lymphoid organs. Data from a recent 
study suggests that these cells are required for humoral immunity as when depleted in vivo, 
the IgG memory responses to specific antigen challenge was impaired (Yates et al., 2013). 
Memory T cell responses are equally important for immunological memory. Memory T cells 
can be activated by lower amounts of antigen, proliferate to higher levels and can exert their 
effector functions much earlier than naïve T cells (Rogers et al., 2000; Slifka and Whitton, 
2001; Veiga-Fernandes et al., 2000). This is important for promoting a fast and efficient 
secondary immune response.   
The induction of the immunological memory response is the basic concept behind vaccine 
design (Castellino et al., 2009). By eliciting an initial priming of the immune response with a 
vaccine (the primary response), if the vaccinee encounters the same pathogen again, a higher 
affinity, more effective and faster response to this pathogen will be raised.  
 
 
1.4 IMMUNE RESPONSE TO HCV AND GBV-B INFECTION 
 
1.4.1 IMMUNE RESPONSE TO HCV 
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The initial immune response to HCV infection is provided by the innate immune system. 
Detection of HCV infection leads to the activation of two distinct types of receptors thereby 
initiating the production of anti-viral and proinflammatory cytokines: Toll-like receptor-3 
(TLR-3) and RIG-1-like receptors (RIG-1 and MDA-5) (Li et al., 2012). Polymorphisms in MDA-5 
have shown to influence the clearance of HCV infection, further confirming the importance of 
this innate response in viral infection outcome (Hoffmann et al., 2015). Indeed, a human 
hepatocarcinoma cell line that has a single mutation in the RIG-1 gene supports much higher 
levels of HCV RNA replication (Blight et al., 2002). 
To overcome this innate immune response, HCV proteins are able to block signalling cascades 
that result in IFN production. For example, HCV NS3-4A serine protease is able to cleave host 
proteins, such as mitochondrial anti-viral-signalling protein (MAVS), leading to the inhibition 
of the signalling cascade resulting in the release of anti-viral IFN (Li et al., 2005). NS4B has 
also recently been implicated in blocking IFN production by interacting with the stimulator of 
interferon genes (STING) protein (Ding et al., 2013; Nitta et al., 2013).  
HCV escape from the innate response leads to the second branch of the immune response, 
the highly-specific adaptive immune response (Larrubia et al., 2014). This leads to the 
induction of both cellular and humoral immune responses. Cellular immunity involves the 
generation of HCV-specific CD8+ cytotoxic T cells and CD4+ helper T cells, whilst the humoral 
immune response leads to the production of both non-neutralising and neutralising 
antibodies. This highly-specific response is usually detectable at 6-8 weeks after initial viral 
infection (Netski et al., 2005; Thimme et al., 2002). The reason for this delay, however, is 
unknown (Rehermann, 2013; Shin et al., 2011; Su et al., 2002; Thimme et al., 2012, 2002). 
Defining the adaptive immune response that leads to viral clearance is essential for vaccine 
development, however current understanding is lacking in this area. 
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In cellular immunity, naïve CD4+ helper and CD8+ cytotoxic T cells are activated by antigen-
presenting cells and play a hugely important role in orchestrating the adaptive immune 
response through the production of cytokines and destruction of infected cells, respectively 
(Larrubia et al., 2014). A multi-specific and long-lasting T cell response is vital for controlling 
HCV infection in both patients and animal models (Dustin and Rice, 2007; Lechner et al., 
2000; Thimme et al., 2002).  
Studies investigating T cell dysfunction in patients with chronic viral infections support the 
theory that continuous antigenic stimulation and exposure to proinflammatory cytokines 
leads to the upregulation of inhibitory receptors on cytotoxic CD8+ T cells (Wherry and 
Kurachi, 2015). It is of note however that these CD8+ T cells are not inert but maintain a 
suboptimal level of effector functions allowing viral load to be controlled, but not cleared. 
Blocking of these inhibitory receptors on CD8+ T cells leads to an increase in functional 
cytotoxic T cells and improved viral control (Fuertes Marraco et al., 2015). In a clinical setting, 
blocking the signalling pathways of inhibitory receptors is known to be successful in restoring 
T cell function (Gardiner et al., 2013; Nguyen and Ohashi, 2014). This correlation between 
viral clearance and reversal of T cell exhaustion has also been seen in a patient that 
spontaneously cleared HCV infection (Raghuraman et al., 2012).  
Along with T cell exhaustion, T cell effector functions can also be impacted by the significant 
expansion of T regulatory cells seen in HCV infection. One study in chimpanzees found that 
after an initial exposure to HCV, subsequent exposure to subinfectious doses of HCV lead to 
expansion of T regulatory cell populations and suppressed T cell effector responses (Park et 
al., 2013). This study suggests that repeated exposure to HCV could increase the propensity 
for chronic HCV infection. Additional evidence confirming HCV’s ability to affect T cell effector 
functions came from a recent study that showed HCV envelope protein E2 and HCV RNA can 
inhibit T cell activation by inhibiting T cell receptor signalling (Bhattarai et al., 2015). 
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A humoral immune response, leading to the production of antibodies specific to the invading 
pathogen, is also seen in HCV infection (Cashman et al., 2014). HCV-specific antibodies are 
likely to play a role in controlling infection, in particular with regards to controlling initial viral 
load and protection against reinfection. Early studies focusing on the identification of 
neutralising antibodies (antibodies that block virus entry on a permissive cell) were largely 
performed in chimpanzees (Choo et al., 1994; Farci et al., 1996). These studies determined 
that HCV-specific neutralising antibodies are produced in infection and have some protective 
capacity to limit future infections.  A more recent study in chimpanzees showed that 
transfusion of a human monoclonal antibody against HCV E2 protected a naïve chimpanzee 
from infection and reduced HCV RNA replication in an animal acutely infected with the virus 
(Morin et al., 2012). Human studies have also confirmed that a human monoclonal anti-E2 
antibody could delay viral rebound in liver transplant HCV patients (Chung et al., 2013).  
Further confirming the role of antibodies in control of HCV infection, 
hypogammaglobulinaemic patients with dramatically reduced immunoglobulin levels have a 
severe and rapid disease progression (Bjoro et al., 1994). Additionally, patients treated with 
rituximab to deplete B cells experience an increase of HCV viral load which reduces as 
therapy is completed (Ennishi et al., 2008).  
Although antibodies are known to be produced in both acute and chronic HCV infections, it is 
important to define their role in both outcomes of infection. In 1997, a study found that 
antibodies specific to the hypervariable region 1 (HVR1) in HCV glycoprotein E2 generated in 
the first six months of infection were detected in 43% of patients who spontaneously cleared 
infection in comparison to only 13% of patients who failed to clear HCV (Zibert et al., 1997). 
Antibody profiles to other viral proteins did not differ between the two groups indicating that 
neutralising antibodies early in infection are involved in viral clearance. Similar antibody 
profiles were seen in other patients with acute HCV infections (Allander et al., 1997).  
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Recent studies indicate that neutralising antibodies may play more of an important role in 
viral clearance than originally thought if induced early in infection. In a reported case of 
spontaneously resolved chronic HCV infection, a neutralizing antibody response appeared 
before the decline in viral titre and reversal of T cell exhaustion, eventually leading to viral 
clearance (Raghuraman et al., 2012). Additionally, in two separate studies of acutely infected 
HCV patients, a neutralising antibody response early in infection was thought to correlate 
with viral clearance (Lavillette et al., 2005; Pestka et al., 2007). An early, strong and broad 
neutralising antibody response will most likely be needed for viral control and clearance, 
although successful viral clearance is almost certainly dependent on a balance of cellular and 
humoral immunity (Giang et al., 2012; Law et al., 2008; Osburn et al., 2014; Osburn et al., 
2010; Raghuraman et al., 2012).  
 
1.4.2 IMMUNE RESPONSE TO GBV-B  
 
 
Data surrounding the precise role of both the humoral and cellular immunity in GBV-B 
clearance is still relatively limited. The humoral immune response in GBV-B infection is poorly 
understood due to the limited availability of immunological assays covering this area. There 
are few data on the identification and role of neutralising antibodies during GBV-B infection 
and clearance, yet information regarding this would enhance the value of the GBV-B/tamarin 
model of HCV infection. Limited in vivo work has been carried out in tamarins. Convalescent 
sera from tamarins mixed with GBV-B at a low dose and then inoculated into naïve tamarins 
was not found to neutralise GBV-B (Bukh et al., 2008). However, no definitive answer to 
whether neutralising antibodies exist in GBV-B infection can be attained without the 
development of an in vitro neutralisation assay. 
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The presence of antibodies targeting other GBV-B proteins has been identified in previous 
studies in both marmosets and tamarins, in particular against GBV-B core, NS3 and NS5B 
(Beames et al., 2000; Bukh et al., 2008; Woollard et al., 2008). Antibodies targeting core are 
not commonly identified but have been previously detected during both acute and chronic 
infections (Bukh et al., 2008; Nam et al., 2004). In contrast, reports of antibodies targeting 
the non-structural proteins of GBV-B vary: NS3 antibodies have been found in several animals 
whilst NS5B antibodies are rare (Beames et al., 2000; De Tomassi et al., 2002; Lanford et al., 
2003; Martin et al., 2003; Sbardellati et al., 2001; Woollard et al., 2008). Although these 
antibodies are unlikely to be neutralising as they are not specific for the envelope protein 
(Bukh et al., 2008), their role has yet to be clearly defined in GBV-B infection. Similar to HCV, 
antibodies targeting non-structural proteins typically appear first and at high levels, peak 
prior to viral clearance and then decrease to undetectable levels after viral clearance 
implicating a role in elimination (Lanford et al., 2003). 
Cellular immunity also exists in GBV-B infection and may be necessary, but not sufficient, for 
viral clearance. Virus-specific T cell responses to non-structural GBV-B proteins have been 
documented in marmosets, in particular towards NS3 and NS4A, which appear around the 
period when the virus is cleared suggesting a role in control and clearance (Woollard et al., 
2008). Cellular immunity may also be involved in protection against reinfection via memory T 
cells as a rapid spike in virus-specific T cell responses targeting the non-structural proteins 
appears more quickly in secondary infection than in primary (Bukh et al., 2008). However, 
viral clearance is most likely a multifactorial process, as with HCV, involving both cellular and 
humoral immunity. Supporting this hypothesis, the percentage of all T cells increases whilst B 
cell numbers decrease during high viraemia in tamarins yet reverses immediately prior to 
viral clearance and NS3 antibody peaks (Hood et al., 2014).  
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If the immune mechanisms surrounding viral clearance in the GBV-B/tamarin model can be 
delineated, this may be translatable to acute HCV infection which could help to elucidate how 
HCV infections so readily progress to chronicity. 
 
 
1.5 MONOCLONAL ANTIBODY PRODUCTION AND RECOMBINANT DNA 
TECHNOLOGIES 
 
1.5.1 MURINE HYBRIDOMA SYSTEM  
 
Antibodies are regularly used as diagnostic tools and therapeutically. Consequently, 
production of high specificity and high affinity antibodies is of great importance. In 1975, 
monoclonal antibodies (mAb) were produced for the first time using the hybridoma system 
(Köhler & Milstein, 1975). The procedure consists of immunizing mice with a target antigen 
followed by one or more boosts (Goodall, 1999). After several weeks, B cells are harvested 
from the spleen and immortalized by fusion, using either chemical or virus induced methods, 
with a myeloma cell line that lacks the hypoxanthine-guanine-phosphoribosyl transferase 
(HGPRT) gene. These cells are grown in a selective medium containing hypoxanthine-
aminopterin-thymidine (HAT) that allows only fused cells to survive. Fused cells are able to 
grow as they are immortal due to the myeloma cell line and have the ability to synthesize 
purine nucleotides due to the HGPRT gene from the primary B cells. Fused cells are then 
isolated by single cell titration, cultured and screened for production of antibodies against the 
target antigen (Little et al., 2000). This method is summarized in Figure 1-9 below. 




FIGURE 1-9: PRODUCTION OF MONOCLONAL ANTIBODIES USING THE HYBRIDOMA SYSTEM (ADAPTED FROM ALKAN, 2004).  
 
THE PRODUCTION OF MONOCLONAL ANTIBODIES STARTS WITH THE IMMUNIZATION OF A MOUSE WITH THE ANTIGEN OF INTEREST (1). AFTER 
THIS IMMUNIZATION PERIOD, SPLEEN CELLS, INCLUDING B CELLS (SHOWN IN PURPLE), ARE COLLECTED (2) AND MIXED WITH MYELOMA CELLS 
(SHOWN IN BLUE) THAT HAVE A MUTATION IN THE HGPRT GENE (3). CELLS ARE FUSED USING POLYETHYLENE GLYCOL (YANG AND SHEN, 
2006). AS THE MYELOMA CELLS LACK THE HGPRT GENE AND PRIMARY SPLEEN CELLS CAN ONLY SURVIVE IN CULTURE FOR A WEEK OR SO, 
AFTER 10-14 DAYS ONLY SPLEEN CELL-MYELOMA CELL FUSIONS SURVIVE AND REPLICATE (4). FUSED CELLS ARE THEN TITRATED TO ENSURE 
SINGLE CELL COLONIES (5). SINGLE CELL COLONIES CAN BE EXPANDED IN CELL CULTURE AND THE SUPERNATANT COLLECTED AND TESTED FOR 
MONOCLONAL ANTIBODIES PRODUCTION (6). 
 
From the first approved anti-CD3 mAb in 1986 (Thistlethwaite et al., 1984), there are now 
over 40 mAbs approved for therapeutic use targeting a range of diseases including various 
cancers and autoimmune diseases (Ecker et al., 2015). Nevertheless, the hybridoma 
technology is not without its pitfalls. The reliance on immunizing mice does not allow the 
production of mAb targeting toxic or conserved self-antigens. Other limitations include the 
time constraints and the uncertain target/affinity of the antibodies produced. However, the 
most obvious issue with this technique is the ethical issues around use of animals in research, 
as it is now widely accepted that the number of animals used in research should be reduced 
due to the principles of human experimental technique (Balls and Straughan, 1996).   
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1.5.2 RECOMBINANT DNA TECHNOLOGIES 
 
After the development of polymerase chain reaction (PCR) techniques and the identification 
of the sequence of the immunoglobulin genes that encode antibodies, DNA recombinant 
technologies were developed such as phage, yeast and ribosome display. All display 
technologies are based on the physical connection of the genotype (gene coding for an 
antibody) and the phenotype (the characteristics of the expressed antibody) displayed on the 
surface of a recombinant microorganism or particle and screened against the antigen of 
interest (Bradbury et al., 2011).  
Another important observation was that the specificity of an antibody lies in the antigen-
binding site, which consists of the variable regions of the heavy chain and light chain of an 
immunoglobulin (Figure 1-10). The variable regions of the heavy and light chain can be cloned 
by PCR and linked by a short peptide, which is typically a number of repeats of 4 Glycine and 
1 Serine. The linked variable regions are then known as single chain variable fragments (scFv) 
(Hammers and Stanley, 2014). Each display technology then has a unique method for 
identifying and isolating antibodies that specifically target the antigen of choice.  
 
 





FIGURE 1-10: STRUCTURE OF AN ANTIBODY IN COMPARISON TO THE STRUCTURE OF SCFV (ADAPTED FROM DE GENST ET AL., 2014).  
 
THE BASIC STRUCTURE OF A WHOLE IMMUNOGLOBULIN MOLECULE (1), THE ANTIGEN BINDING FAB FRAGMENT (2) AND A SCFV (3).  
 
The most well-known display technologies are described below. Whilst each method can be, 
and is indeed commonly, used to isolate all types of proteins, the techniques will only be 
described in the context of scFv isolation. 
 
 
1.5.2.1 PHAGE DISPLAY 
 
In phage display, the scFv library is cloned into phagemids which express the scFv fused to a 
surface protein of the phage such as the pIII capsid protein of M13 phages (Barbas et al., 
1991). These phagemids, containing the scFv library, are introduced by transformation into 
permissive E.coli.  Infection of these bacteria with helper phages is required because the 
phagemids do not contain all of the necessary bacteriophage genes for propagation. This 
leads to the production of phages expressing the pIII minor coat protein fused to each of the 
scFv from the library. The scFv, displayed on phages, are then screened against the antigen of 
choice, which is usually immobilized on a plate or on beads. If a phage binds, the scFv must be 
targeting the antigen of interest and can therefore be isolated. Following purification washes, 
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phages that do not possess a scFv that targets the antigen are removed. Bound phages can 
then be eluted, used to infect E.coli for bulk production, their phagemids isolated and 
sequenced (Smith and Scott, 1993). To enrich the population of positive phages, several 
rounds of panning against the immobilized target antigen are performed. Each time, phages 
that bind the antigen of interest are selected by washing the non-binding phages away 
resulting in a population of highly antigen-specific scFv expressed on phage. 
Whilst the development of phage display was a leap forward in the production of high 
affinity, high specificity antibodies, the technology still has limitations. There is some 
expression bias due to a different codon usage between the prokaryotic host and the 
eukaryotic scFv (Rodi et al., 2002). This could lead to the loss of high affinity antigen-specific 
scFv. Additionally, the different fitness of bacteria producing different scFv could lead to the 
loss of high affinity antigen-specific scFv that were toxic to the prokaryotic host. The 
advantages of phage display over other display technologies include the ease of use and the 
rapid isolation of scFv (Pande et al., 2010).  
Examples of approved therapeutic antibody therapies that have been isolated through the 
use of phage display include adalimumab (AbbVie Inc., North Chicago, IL) and belimumab 
(GlaxoSmithKline, London, UK). The antibody adalimumab binds to TNFα blocking the 
activation of its receptors. This treatment is approved for several diseases including 
rheumatoid arthritis and Crohn disease. Belimumab binds to the human B-lymphocyte 
stimulator (BLyS); the function of BLyS is to promote B cell survival and differentiation. This 
antibody has been approved for use as a treatment for systemic lupus erythematosus (Nixon 
et al., 2014).  
 
1.5.2.2 YEAST AND BACTERIAL DISPLAY TECHNOLOGIES 
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Other display technologies such as yeast or bacterial display can also be used for the 
screening of a scFv library. In both cases, the scFv are fused to a protein attached to the cell 
wall which is followed by selection using both magnetic-activated cell sorting (MACS) and 
fluorescence-activated cell sorting (FACS) (Bessette et al., 2004; Boder and Wittrup, 
1997).  The screening in this case works by incubating yeast/bacteria expressing scFv with a 
target antigen that is either fluorescently tagged or bound to magnetic beads. After washing, 
only the yeast/bacteria expressing scFv that bind to the target antigen with the highest 
affinity remain fluorescent/magnetic and can be isolated by FACS/MACS (Boder et al., 2012). 
This method of selection is highly discriminative and therefore produces the highest affinity 
antibodies (Boder et al., 2000). However, the bacterial display method still has the same 
disadvantages as phage display in that the scFv has to be translocated across the inner 
membrane and out onto the surface of the bacteria.  Whilst yeast display does not have the 
secretion limitation or expression bias, the library size is limited and requires fluorescence-
activated cell sorting (FACS) for sorting the scFv-expressing cells. The other major advantage 
of yeast display is that this eukaryotic system allows protein folding and processing in a 
similar way to that in mammalian cells (Arbabi-Ghahroudi et al., 2005).  
 
1.5.2.3 RIBOSOME DISPLAY 
 
Ribosome display, which takes place entirely in vitro, is a further development of the display 
technologies (Figure 1-11). Relying on the same principle of coupling genotype and 
phenotype, this technique has several advantages to other display technologies including the 
production of scFv against toxic proteins and the reduction of bias from using a host 
organism. This technique is also much faster and a larger library can be screened as the only 
limitation is the number of ribosomes available in the reaction (Zahnd et al., 2005).  
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For this technique, a scFv library is constructed. During the construction of this library, scFv 
are fused to a spacer that lacks a stop codon to ensure that after scFv transcription and 
translation, the ribosome holds on to both the translated scFv and the mRNA encoding it. 
These Antibody-Ribosome-mRNA (ARM) complexes can then be screened against 
immobilized antigen. Non-specific scFv are washed away through several wash steps allowing 
any bound complexes expressing target antigen-specific scFv to be eluted.  The mRNA from 
these eluted complexes is isolated and reverse transcribed. It has been suggested that for 
each round of ribosome display, any specific scFv are enriched between 100-1000-fold 
therefore multiple rounds of screening are generally performed (Chen et al., 2010; J. Hanes et 
al., 1998; Hanes and Plückthun, 1997; Schaffitzel et al., 1999a; Takahashi et al., 2002; Xin et 
al., 2013; Zhao et al., 2009a).  
One of the benefits of using display technologies, including ribosome display, is the ability to 
select for antibodies with a higher affinity, higher stability or with a broader spectrum by 
changing the selection conditions. Previously, antibodies have been isolated from ribosome 
display with enhanced stability or affinity through the addition of DTT into the selection step 
or by using off-rate selections over several days (Jermutus et al., 2001). Additionally, random 
mutations can be introduced into scFv libraries, the scFvs screened and high affinity antigen-
specific scFv isolated thereby mimicking affinity maturation of antibodies (Groves et al., 
2006).  
The final stage of ribosome display involves isolating the antigen-specific scFv cDNA and 
subsequent cloning into expression vectors. The encoded antibodies can then be expressed in 
protein expression systems, such as prokaryotic hosts. Antibodies are later analysed to 
determine their specificity and affinity against the initial target antigen (He and Khan, 2005). 





FIGURE 1-11:  SCHEMATIC REPRESENTATION OF RIBOSOME DISPLAY TECHNOLOGY (ADAPTED FROM HE AND KHAN, 2005). 
 
IN RIBOSOME DISPLAY, A SCFV LIBRARY IS CONSTRUCTED FROM IMMUNOGLOBULIN GENES (1). THIS LIBRARY CONTAINS THE V REGIONS FROM 
THE HEAVY AND LIGHT CHAIN THAT ARE JOINED BY A LINKER. THE T7 PROMOTER AND KOZAK SEQUENCE IS ADDED TO 5’ ENDS OF SCFV TO AID 
WITH DOWNSTREAM EXPRESSION OF SCFV. A SPACER IS ADDED TO 3’ END OF SCFV TO ENSURE THE COMPLETE PROTRUSION OF THE SCFV 
FROM THE RIBOSOME. THIS LIBRARY IS THEN TRANSCRIBED (2) AND TRANSLATED IN VITRO (3). ARM COMPLEXES ARE SCREENED AGAINST A 
TARGET ANTIGEN (4). ANY UNBOUND, AND NON-SPECIFIC COMPLEXES ARE LOST DURING WASH STEPS. THE MRNA ENCODING THE SCFV THAT 
ARE ABLE TO BIND TO TARGET ANTIGEN IS ISOLATED AND REVERSE TRANSCRIBED (5). THIS SCFV CDNA IS USED TO EXPRESS THE SCFV FOR 
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1.5.2.4 ALTERNATE DISPLAY TECHNOLOGIES 
 
Other display-based technologies have been developed but are not commonly used, 
especially for antibody selection. These include selecting antibody fragments displayed on 
mammalian cells, retroviruses, microbeads or biotin labels in emulsion compartments 
(Hoogenboom, 2005). Other methods such as a protein fragment complementation assay and 
the yeast two-hybrid system have also been used to determine interactions between proteins 
and therefore have the potential to be used for antibody selection. These techniques are 
based on linking the two proteins to be studied with domains of a protein that can interact 
and result in an output that can be measured, for example, resulting in gene activation and 
yeast survival (Fields and Song, 1989).  However, the three main platforms for antibody 
production and evolution remain phage, yeast and ribosome display. Each of these 
technologies has different advantages and disadvantages and are chosen based on the 
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 Advantages Disadvantages Antibodies produced 
Phage display • Robust method with 
many protocols 
available 
• Easy to use 
• Harder to introduce 
diversity 




• Limited by transformation 
efficiency 
• Anti-gp120 (Ditzel 
et al., 1995) 
• Anti-TNFα (Salfeld 
et al., 2001) 
• Anti-PA from B. 
anthracis (Harvey 
et al., 2004) 
Yeast display • Fast 
Direct screening for 
high affinity 
antibodies 
• Eukaryotic protein 
folding and 
processing  
• Cell sorting equipment 
needed  
• Limited by transformation 
efficiency  
• Larger libraries hard to 
produce (generally 107-
1010 members) 
• Affinity maturation difficult  
• Anti-Huntington 
protein (Swers et 
al., 2004) 





Largest library size 
(generally 1012-1014 
members) 
• Easy to introduce 
diversity 
• Technically sensitive due to 
RNA handling and stability 
• Heavily reliant on PCR, 
which introduces 
mutations 
• Anti-GCN4 (Zahnd 
et al., 2004) 
• Anti-IL13 








1.6 PSEUDOTYPED RETROVIRAL VECTORS 
 
 
1.6.1 RETROVIRUS GENOME STRUCTURE 
 
The family Retroviridae has 7 genera: alpharetroviruses, betaretroviruses, 
gammaretroviruses, deltaretroviruses, epsilonretroviruses, lentiviruses and 
spumaretroviruses (Linial et al., 2005). Retroviruses have single stranded, positive sense RNA 
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genomes of around 7-11 kilobases in size; two copies of the viral genome are encapsulated in 
each virion within the protein core and wrapped in a lipid envelope from which the envelope 
proteins protrude (see Figure 1-12). Typically, the viral genome encodes 4 basic genes: gag 
(encoding the structural proteins such as the matrix, capsid and nucleoproteins), pro 
(encoding viral protease), pol (encoding reverse transcriptase and integrase), and Env 




FIGURE 1-12: TYPICAL STRUCTURE AND COMPONENTS OF A RETROVIRAL PARTICLE (ADAPTED FROM PEDERSEN ET AL., 2011). 
 
Some retroviruses have a more complex genome structure. Whilst these complex 
retroviruses, such as lentiviruses including human immunodeficiency virus (HIV), contain all of 
the basic retroviral proteins and associated retroviral genes, they also have several accessory 
and regulatory proteins (Rajarapu, 2014). These proteins often play an important role in 
pathogenesis. This is clearly demonstrated by null mutations in these accessory proteins of 
simian immunodeficiency virus that lead to the attenuation of the virus in vivo (Desrosiers et 
al., 1998).  
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HIV, an example of a complex retrovirus, has two regulatory proteins, Tat and Rev, and four 
accessory proteins, Nef, Vpu, Vif and Vpr (Rajarapu, 2014). The Tat protein, a transcriptional 
activator, acts to stimulate the efficient elongation of HIV gene transcripts (Gaynor, 1995; 
Jones and Peterlin, 2003). Indeed, without this protein, there is a build-up of prematurely 
terminated HIV transcripts (Adams et al., 1994). Rev, on the other hand, transports unspliced 
viral mRNAs from the nucleus to the cytoplasm (Felber et al., 1989; Malim et al., 1989; Rosen 
et al., 1988). In eukaryotic cells, mRNA must be processed before nuclear export (Libri et al., 
2002; Maniatis and Reed, 2002); Rev therefore allows the export of viral RNA that is not 
processed and contains introns. The accessory proteins are also known to have a range of 
functions including immune evasion, suppression of restriction factors that limit viral entry 
and ensuring efficient release of virus from infected cells (Malim and Emerman, 2008). 
In addition to these viral genes, there are repeat regions (R) and unique regions called U3 and 
U5 at either end of the viral genome (Pedersen et al., 2011). During reverse transcription, 
these regions are duplicated to form long terminal repeats (LTR) consisting of U5, R and U3 at 
either end of the viral genome. A primer binding site (PBS) lies after U5 to prime synthesis of 
the first DNA strand. The polypurine tract (PPT), which lies before U3, primes the synthesis of 
the second DNA strand (Coffin et al., 1997). The psi signal sequence (ψ) is also encoded in the 
5’- untranslated region (UTR) and is involved in retroviral particle packaging (Kuzembayeva et 








FIGURE 1-13: TYPICAL GENOME ORGANISATION OF A SIMPLE RETROVIRUS (ADAPTED FROM COFFIN, 1997). 
 
THIS FIGURE SHOWS TWO FORMS OF THE VIRAL GENOME: THE INITIAL RNA GENOME AND THE DNA-BASED FORM THAT IS CREATED DURING 
REVERSE TRANSCRIPTION TO ALLOW THE SUBSEQUENT INSERTION OF THE VIRAL GENOME INTO THE HOST CELL GENOME.  
 
 
1.6.2 RETROVIRAL LIFECYCLE 
 
The retrovirus lifecycle begins with virus attachment to the host cell surface and to specific 
receptors, which leads to conformational changes of the envelope protein and host cell surface 
receptors and the subsequent fusion of the host cell membrane with the viral membrane 
(Nisole and Saïb, 2004). Once fused, the capsid core of the virus is released into the cytoplasm. 
The retrovirus can then begin reverse transcription, using its error-prone viral reverse 
transcriptase (RT), to create a double stranded DNA (dsDNA) copy of the viral genome (Hizi and 
Herschhorn, 2008).  
The process of reverse transcription is primed by a host transfer RNA (tRNA) that binds to the 
PBS within the 5’UTR promoting reverse transcription of the RNA genome (Eckwahl et al., 
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viruses: e.g. wild-type HIV use tRNALys, murine leukaemia viruses (MLV) use tRNAPro and avian 
leucosis viruses use tRNATrp (Harada et al., 1975; Peters et al., 1977; Rhim et al., 1991).  
Initially, R and U5 at the 5’end of the viral genome are transcribed due to the annealing of the 
host tRNA at the PBS (Coffin et al., 1997; Gilboa et al., 1979). After the RNase H activity of the 
RT has digested the corresponding RNA to this segment (Schultz and Champoux, 2008), the 
newly synthesised minus-strand DNA is transferred to the 3’ end where transcription continues 
(Gilboa et al., 1979). This transfer occurs due to homology between the two repeat regions and 
results in the creation of the first long terminal repeat (LTR) region (Dang and Hu, 2001). RNase 
H removes the corresponding RNA segment except the PPT which can then act as a primer for 
synthesising the second complementary strand of DNA (plus-strand). This plus-strand DNA 
synthesis continues until reaching the initial tRNA primer at the 5’ end leading to its removal 
but also the creation of the second LTR. The plus strand DNA is then transferred to the PBS in 
the minus-strand DNA whereby both strands are completed to produce double stranded DNA 












FIGURE 1-14: THE BASIC SEVEN STAGES OF REVERSE TRANSCRIPTION OF RETROVIRAL GENOMES (ADAPTED FROM PEDERSEN, PYRZ AND 
DUCH, 2011). 
 
REVERSE TRANSCRIPTION IS INITIATED BY THE BINDING OF THE HOST TRNA (GREEN) TO THE PBS OF THE VRNA GENOME (RED) (1). WITH THE 
TRNA SERVING A PRIMER, THE R AND U5 REGION ARE TRANSCRIBED TO DNA (BLUE) (2). RNASEH DEGRADES THE VRNA ONCE THE VIRAL 
DNA IS SYNTHESIZED. THE DNA-TRNA COMPLEX IS THEN TRANSFERRED TO THE 3’ END OF THE VRNA AND TRANSCRIPTION CONTINUE (3). 
RNASEH REMOVES THE VRNA EXCEPT FOR THE HIGHLY-RESISTANT PPT SITE WHICH THEN SERVES AS A PRIMER FOR SECOND DNA STRAND 
SYNTHESIS (4). THIS SYNTHESIS CONTINUES UNTIL THE TRNA SITE WHEREBY IT IS TRANSFERRED TO THE PBS SITE ON THE VIRAL DNA 
MOLECULE (5) ALLOWING THE TRANSCRIPTION OF BOTH STRANDS TO BE COMPLETED (6). 
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Alongside the process of reverse transcription, the viral genome is thought to shed its capsid 
coat (Nisole and Saïb, 2004). Historically, it was thought that once inside a host cell, the virus 
is uncoated immediately to free the viral genome however, for at least HIV, this is now disputed 
(Campbell and Hope, 2015; Nisole and Saïb, 2004). There are three possible theories for how 
HIV particles are uncoated: the particle immediately uncoats as suggested by early biochemical 
studies, partial uncoating of the viral particle as suggested by imaging studies or uncoating at 
the nuclear pore complex. Supporting the latter theories, the capsid protein has been found 
associated with the pre integration complex within the nucleus (a complex of viral DNA, host 
factors and viral proteins such as integrase) (Campbell and Hope, 2015). Additionally, it is 
known that the capsid core of the virus, containing the viral genome, is trafficked to the nucleus 
of the host cell via the microtubule network further suggesting that some copies of the capsid 
protein remain associated with the viral genome in the host cell cytoplasm (Naghavi and Goff, 
2007).  
Ultimately, the dsDNA viral genome arrives at the nucleus and must be inserted into the host 
cell genome (Matreyek and Engelman, 2013). Mitosis is generally required for import of the 
viral DNA into the nucleus as the nuclear membrane is temporarily degraded during this 
process; lentiviruses, such as HIV, however, are able to use the cellular nuclear import 
pathways to enter the nucleus (Bukrinsky et al., 1992; Matreyek and Engelman, 2013). Through 
the use of the viral integrase, the viral DNA is integrated permanently into the host cell genome 
forming a stable provirus (Andrake and Skalka, 1996). Integrase recognises a very short 
integration sequence within the LTRs of the retrovirus allowing the processing of the viral ends 
and subsequent joining within the target cell genome (Hindmarsh and Leis, 1999).  
The provirus is transcribed by the host cellular RNA polymerase II, which is promoted by the 
strong viral promoter within the 5’ LTR (Berry et al., 1988; Gorman et al., 1982; Klaver and 
Berkhout, 1994). The transcribed viral mRNA molecules, which are either full length genomes 
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or spliced mRNA, are transported to the cytoplasm and translated (Pedersen et al., 2011). Full 
length viral mRNA molecules are used to produce the Gag precursor polyprotein (containing 
the structural proteins) and the GagPol precursor polyprotein (containing structural proteins 
and enzymes) whereas the spliced mRNA is translated at the RER into the envelope proteins. 
The translated envelope proteins are then transported to the plasma membrane of the host 
cell via the Golgi apparatus and secretory pathway. Gag recruits full length viral RNA through 
the recognition of the ψ packaging element, oligomerises and locates to the host cell plasma 
membrane. The retroviral particles assemble at the plasma membrane and bud off leaving the 
particle coated in the plasma membrane and envelope proteins (Goff, 2006).  
 
1.6.3 RETROVIRAL VECTORS 
 
Retroviral vectors have a wide range of applications from cancer immunology and gene 
therapy to studying the biology of highly pathogenic viruses and serology assays (Cavazzana-
Calvo et al., 2000, King et al., 2016). Their use stemmed from understanding that retroviruses 
could integrate their genome into a host cell genome but also the discovery that oncogenic 
retroviruses had often acquired sequences from host proto-oncogenes and could therefore 
support insertions in their genome (Sinkovics, 1984). Several laboratories produced retroviral 
vectors encoding foreign genes, however, these insertions in the retroviral genome often 
impacted viral replication and meant that these retroviral vectors could only be produced in 
the presence of replication-competent helper viruses (Shimotohno and Temin, 1981; Tabin et 
al., 1982; Wei et al., 1981). Due to the use of helper viruses, these vectors could not be used 
in gene therapy because of safety concerns, primarily based on the possibility of generation 
of replication-competent retroviruses (Miller and Rosman, 1989; Otto et al., 1994). 
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Improvements in the safety of these retroviral vectors were achieved by reducing the number 
of viral coding regions and elements to the minimum required for high-efficiency transfer of a 
foreign gene (Miller and Rosman, 1989). These vectors are based on the fact that viral protein 
synthesis is not required for the early steps of the viral lifecycle. An example of this 
generation of vectors was the vector used for gene therapy of patients with X-linked Severe 
Combined Immunodeficiency (SCID). In this study, the genes for Gag, Pol and Env are 
replaced with the gene of interest, the gamma subunit of the interleukin‐2 receptor. By 
encoding this gamma subunit gene in a murine leukemia virus (MLV)-based vector, 
hematopoietic stem progenitor cells (HSPC) could be transduced ex vivo with this vector and 
reinfused into the patient. These progenitor cells, with the correct version of the gamma 
subunit gene, allow the HSPC cells to differentiate into functional immune cells such as T cells 
(Cavazzana-Calvo et al., 2000). This treatment was initially thought to be successful although 
three of the children developed T cell leukemia as the vector had inserted near the LMO2 
oncogene, activating its expression (Cavazzana-Calvo and Fischer, 2007; Hacein-Bey-Abina et 
al., 2008). Lentiviral vectors are now more commonly used in clinical trial applications as 
these do not integrate near transcription start sites reducing this safety issue (Yi et al., 2011).  
To further increase the safety of using these retroviral vectors, the components of the viral 
genome could be split between several plasmids to reduce the possibility of recombination 
resulting in replication-competent virus and therefore a complete viral genome (Naldini et al., 
1996; Soneoka et al., 1995). This is particularly important in gene therapy. More recent 
generations of viral vectors have further improved the safety of using these vectors (Sakuma 
et al., 2012). These improvements include the deletion of accessory genes in HIV-based 
vectors and the generation of self-inactivating vectors. Self-inactivating vectors contain a U3 
deletion at the 3’ end resulting in the U3 promoter only supporting one round of replication.  
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1.6.4 PSEUDOTYPED VIRAL PARTICLES 
 
A further use of retroviral vectors has been to create pseudotyped viral particles (PV). The 
first pseudotyped viral particles, based on Rous sarcoma virus (RSV), were produced by Rubin 
and colleagues (Hanafusa et al., 1963; Rubin, 1965). They determined that infectious RSV 
particles could only be produced if permissive cells were co-infected with a helper virus, Rous 
associated virus (RAV). Infectious viral particles were produced from both viruses but RSV 
particles could express the envelope of RAV instead of its native envelope. Other retroviruses 
were also seen to exhibit the same ability, for example, HIV can incorporate Human T 
lymphotropic virus, type I, (HTLV-1) envelope proteins and vice versa (Landau et al., 1991). 
This incorporation of other viral envelopes increased the tropism of the virus and changed 
the course of disease. 
PV are based on, typically, either a retrovirus (e.g. Moloney mouse leukaemia virus, MLV) or 
lentivirus (e.g. HIV) that expresses a reporter gene instead of its own genome and the 
envelope proteins of another virus (Zavada et al., 1972). To produce these PV, a producer cell 
line is transfected with three plasmids: one containing the gag-pol genes, one or two 
containing the Env gene of the virus desired and the last containing either the reporter gene, 
or transgene to be delivered, flanked by LTRs which is known as the retroviral vector (Figure 
1-15). Expression of this transgene can be measured in the case of a therapeutic gene or 
reporter gene. The packaging signal is also included on the vector containing the gene of 
interest to ensure it’s incorporated into the PV (Coffin et al., 1997). Whilst lentiviruses and 
gammaretroviruses are the most commonly used in pseudotyping studies, other families of 
viruses, such as VSV from the Rhabdoviridae family, have also been used (Mebatsion, 1996). 




















FIGURE 1-15: PV PRODUCTION (ADAPTED FROM TEMPERTON, WRIGHT AND SCOTT, 2015). 
 
PV PRODUCTION IS TYPICALLY BASED ON THE CO-TRANSFECTION OF A PRODUCER CELL LINE, SUCH AS HUMAN EMBRYONIC KIDNEY 293T 
CELLS, WITH 3 PLASMIDS: A PLASMID CONTAINING THE ENVELOPE GENE, A PLASMID CONTAINING THE GAG-POL GENES AND A PLASMID 
CONTAINING THE REPORTER GENE FLANKED BY LTRS FOR DOWNSTREAM INTEGRATION IN THE HOST CELL AND THE PACKAGING SIGNAL (Ψ) TO 
ENSURE PACKAGING OF THE GENE IN THE PV. PROMOTERS ARE INCLUDED IN ALL PLASMIDS AND ARE USUALLY CONSTITUTIVE. AFTER 48-72 
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1.6.5 APPLICATIONS OF PSEUDOTYPED VIRAL PARTICLES 
 
Pseudotyped viral particles have been used successfully in a range of fields including cancer 
immunology, gene therapy, virology, serosurveillance, antiviral drug testing and vaccine 
immunogenicity testing. Examples of several fields can be seen below. 
 
1.6.5.1 GENE THERAPY 
 
One of the disadvantages of using standard retroviral vectors in gene delivery is their limited 
host range. This issue of limited tropism was solved by using different viral envelopes such as 
the G protein of vesicular stomatitis virus (VSV-G), which is able to facilitate entry into a wide 
range of cell types from different species. This has been utilised successfully in gene delivery 
(Cronin et al., 2005; Lee et al., 2001). The VSV-G envelope is also highly stable allowing 
concentration of retroviral particles by ultracentrifugation (Burns et al., 1993). 
1.6.5.2 VIROLOGICAL STUDIES 
 
PV are regularly used in the study of highly pathogenic viruses or viruses that are difficult to 
propagate in cell culture. The use of PV eliminates the need for high-containment 
laboratories for highly pathogenic viruses, such as Ebola or rabies (Bentley et al., 2015). This 
use of different viral envelope proteins allows the study of the biology of virus interaction 
with the host of enveloped pathogenic viruses such as the influenza virus or enveloped 
viruses that do not replicate efficiently in cell culture such as HCV. For example, CD81 was 
discovered as one of the host receptors used for HCV entry through the use of PV bearing an 
HCV envelope (Cormier et al., 2004). The tropism of viruses and the effect of innate antiviral 
responses, such as restriction factors, can also be confirmed using PV (Bae and Jung, 2014; 
Desmaris et al., 2001). 
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Alongside the study of different viruses, PV also allow the study of the virus that the PV is 
based on, e.g. HIV or MLV. For example, HIV-based PV pseudotyped with different envelopes 
have been used to study HIV biology and the effects of antiviral drugs (Harrison et al., 2011; 
Spector et al., 1990; Yu et al., 2009).  
 
1.6.5.3 ANTIVIRAL DRUG SCREENING AND VACCINATION STUDIES    
 
Several studies screening antiviral drugs against a variety of viruses using PV have been 
employed in the last 10 years. These reports include a recent study testing 1,012 Food and 
Drug Administration - approved drugs against Ebola PV (Madrid et al., 2013) and another 
study that involved screening 100,000 chemical compounds against influenza pseudotypes 
(Basu et al., 2014). These studies led to the discovery that chloroquine could protect mice 
from Ebola infection in vivo and the identification of two new influenza virus entry inhibitors. 
The use of PVs are well-suited for high-throughput screening due to their relative simplicity to 
produce, safety and scalability (Bentley, Mather and Temperton, 2015).  
In addition to being used as immunogens in vaccines for both influenza and HIV (Breckpot et 
al., 2010; Szécsi et al., 2006), PV are also used to monitor the immune response to vaccines 
through the development of PV neutralisation assay (PVNA). Previous studies include those 
based on the use of rabies PV for studying antibody neutralisation in vaccinated 
individuals/animals and various studies based on using PV to monitor vaccine response by 
using vaccinated patient sera (Alberini et al., 2009; Ewer et al., 2016; Wright et al., 2008). 








FIGURE 1-16: SUMMARY OF A PV-BASED NEUTRALISATION ASSAY (ADAPTED FROM BENTLEY, MATHER AND TEMPERTON, 2015). 
 
A PRODUCER CELL LINE IS CO-TRANSFECTED WITH 3 PLASMIDS TO PRODUCE PV BEARING THE SPECIFIC VIRAL ENVELOPE OF THE VIRUS TO BE 
STUDIED. PV ARE COLLECTED AND PURIFIED FROM THE SUPERNATANT OF TRANSFECTED PRODUCER CELLS. PURIFIED PV ARE PRE-INCUBATED 
WITH THE ANTIBODIES TO BE TESTED AND THIS MIXTURE IS THEN TITRATED ON TARGET CELLS. AFTER 72 HOURS, TARGET CELLS ARE WASHED, 
LYSED AND THE REPORTER GENE EXPRESSION IS MEASURED. IF THE ANTIBODIES TO BE TESTED ARE NEUTRALISING, NO REPORTER GENE 
EXPRESSION IS SEEN. IF THE ANTIBODIES ARE NOT NEUTRALISING, PV WILL INFECT THE TARGET CELL, INCORPORATE THE REPORTER GENE INTO 
THE TARGET CELL GENOME AND REPORTER GENE EXPRESSION IS SEEN.  
 
 
1.6.6 CHALLENGES ASSOCIATED WITH PV PRODUCTION 
 
Despite the success of pseudotyping a variety of viruses, some have proven difficult to 
pseudotype (King et al., 2016). The pseudotyping of flaviviruses has proven to be particularly 
challenging with HCV being one of the few successes. This is likely to be due to the difference 
in the lifecycle of flaviruses in comparison to retroviruses (see section 1.1.6 and 1.6.2 for 
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further details on each respective family of viruses). Even so, the generation of HCV PV from 
clinical samples remains challenging with one study reporting a success rate of just 78 out of 
900 primary isolates (Urbanowicz et al., 2015).    
Viral envelope incorporation appears to be an important factor for high titre PV production. 
Several factors can affect the efficient incorporation of viral envelope protein into PV. For 
example, viral envelope incorporation onto the PV requires the envelope to be expressed on 
the producer cell plasma membrane for the retroviral PV system (King et al., 2016; Murakami 
and Murakami, 2012). Some viral envelope proteins, such as those that belong to viruses in 
the Flaviviridae family, contain endoplasmic reticulum(ER) retention signals in the 
transmembrane domain (Cocquerel et al., 1998a; Op De Beeck et al., 2004). These signals 
lead to the retention of the viral envelope proteins at the ER, therefore PV will not 
incorporate these proteins into the particle. This can occasionally be overcome if the 
envelope protein is overexpressed causing ‘leaky expression’, as seen with HCV (Bartosch et 
al., 2003). Additionally, the truncation of some envelope proteins is required for efficient 
incorporation into the PV, as seen with PV bearing Measles virus envelope proteins (Frecha et 
al., 2008). Indeed, some envelope proteins are not efficiently incorporated into lentiviral or 
retroviral-based PV (Takeuchi et al., 1992). For example, MLV PV can efficiently incorporate 
by C-type, but not D-type, retroviral envelope proteins. A similar system based on using 
vesicular stomatitis virus (VSV) can be used although this system is more complex (King et al., 
2016, Whitt, 2010). Due to the high efficiency of VSV-G incorporation, PV can often be 
produced with a VSV-G envelope instead of the desired foreign envelope. Additionally, this 








The first part of this project aimed to investigate the pathology of GBV-B through the 
production of antibodies that could be used in immunohistochemistry to analyse the 
presence of GBV-B in various tamarin organs. This immunohistochemistry can now be used to 
track the virus throughout infection and aid in determining the tropism of GBV-B. These 
pathology studies will help to further validate GBV-B infection in tamarins as a useful animal 
model of acute HCV infection. 
The second part of this project aimed to understand the immunological events that lead to 
GBV-B clearance via the development of a neutralisation assay based on GBV-B PV, as GBV-B 
does not replicate in cell culture. The identification of neutralising antibodies will help to 
determine the role of the humoral immune response in viral clearance and may potentially 
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CHAPTER 2 : METHODS AND MATERIALS 
 
2.1 MATERIALS  
 
BUFFERS/SOLUTIONS RECIPE 
MOLECULAR BIOLOGY  
AVE BUFFER (QIAGEN) RNase-free water with 0.04% NaN3  
1X PBS 1.9 mM NaH2PO4, 8.1 mM Na2HPO4, 
154 mM NaCl, pH 7.4 
1X TAE 40 mM Tris (pH 7.8), 20 mM sodium 
acetate, 1 mM EDTA 
BLUE/ORANGE 6X LOADING BUFFER 
(PROMEGA) 
0.4% orange G, 0.03% bromophenol blue, 
0.03% xylene cyanol FF, 15% Ficoll 400, 
10mM Tris-HCl (pH 7.5) and 50mM EDTA 
(pH 8.0) 
SOLUTION A FOR PREPARATION OF 
CHEMICALLY COMPETENT BACTERIA 
10 mM MnCl2, 50 mM CaCl2, 10 mM 
2-(N-morpholino) ethanesulfonic acid 
(MES) pH6.3 
LURIA-BERTANI (LB) BROTH 1% (w/v) bacto-tryptone, 0.5% (w/v) 
Bacto yeast extract, 1% NaCl, pH 7.0 
2X YT MEDIUM (SIGMA-ALDRICH-
ALDRICH) 
16 g/L Tryptone, 10 g/L Yeast Extract, 5 g/L 
NaCl 
LB AGAR 1% (w/v) bacto-tryptone, 0.5% Bacto 
yeast extract, 1% NaCl, 1.5% (w/v) 
bacto-agar, pH 7.0 
EB BUFFER (QIAGEN) 10 mM Tris-Cl, pH 8.5 
WASH BUFFER FOR PROTEIN 
PURIFICATION  
0.02M Tris pH 8.0, 0.5M NaCl, 10mM 
imidazole 
ELUTION BUFFER FOR PROTEIN 
PURIFICATION 
0.02M Tris pH 8.0, 0.5M NaCl, 500mM 
imidazole 
LYSIS BUFFER FOR PROTEIN 
PURIFICATION UNDER NATIVE 
CONDITIONS 
1x PBS with 0.25% N-Lauroylsarcosine 
sodium salt  
CELL CULTURE  
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RIPA BUFFER 50 mM Tris-HCl (pH 7.5), 150 mM 
NaCl, 1% (v/v) Igepal ca-630, 0.5% 
(w/v) sodium deoxycholic acid, 10% 
(w/v) SDS, 1% (v/v) Triton X-100 
4X LAEMMLI BUFFER 200 mM Tris-HCl (pH 6.8), 40% (v/v) 
glycerol, 8% (w/v) SDS, 0.2% (w/v) 
bromophenol blue, 10% (v/v) β- 
mercaptoethanol 
2X LAEMMLI BUFFER 4x Laemmli buffer diluted 1:1  
10X TRIS-GLYCINE SDS RUNNING 
BUFFER (LIFE TECHNOLOGIES) 
25 mM Tris Base, 192 mM Glycine, 0.1% 
SDS pH 8.3 
1X TRANSFER BUFFER 10% (v/v) Tris-Glycine SDS running buffer, 
20% (v/v) methanol  
 
TABLE 2-1: BUFFERS AND SOLUTIONS COMPOSITION  
 
2.2 MOLECULAR BIOLOGY METHODS 
 
All primers and plasmids used throughout the project are included in Tables 7-1―7-5. 
 
2.2.1 RNA EXTRACTION 
 
Archived splenocytes from an acutely GBV-B infected tamarin that had cleared its infection 
were washed twice in PBS and resuspended in 350μl RTL lysis buffer (Qiagen) containing 
guanidine isothiocycanate supplemented with 1% (v/v) ß-mercaptoethanol. After vortexing 
cells for 1 minute, samples were frozen at -80°C. Cell lysate was then thawed, an isovolume 
of 70% (v/v) ethanol added and the RNA extracted using an RNeasy mini kit (Qiagen) 
following manufacturer’s instructions. The suggested optional step to remove cellular DNA 
using DNase I (Qiagen) was always performed. RNA was eluted in 50μl RNase-free water and 
the concentration and purity of the preparation was determined using a NanoDrop 2000c UV-
Vis spectrophotometer (Thermo Scientific). 
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2.2.2 VIRAL RNA EXTRACTION 
 
A purpose-bred red-bellied tamarin (Saguinus labiatus) had been previously infected with 1 × 
107 genome equivalents of GBV-B in serum. Sera samples were collected weekly. Of these 
sera samples, 140μl of a sample from week 20 (post viral clearance) was lysed by adding 
560μl AVL buffer (Qiagen) containing guanidine thiocyanate and 5.6μl of carrier RNA diluted 
at 1μg/μl in AVE buffer (Qiagen). Viral RNA was then extracted from the sample using a 
QIAamp Viral RNA Mini kit (Qiagen) following manufacturer’s instructions. Viral RNA was 
eluted in 60μl AVE buffer and the concentration determined as above.    
 
2.2.3 CDNA SYNTHESIS 
 
cDNA was synthesised from 200ng of extracted RNA or vRNA using AccuScript High Fidelity 
1st Strand cDNA Synthesis Kit (Stratagene) following manufacturer’s instructions using either 
random primers or, for single chain variable fragment (scFv) library production, dT29VN 
primer. DTT, RNase block and High Fidelity Reverse Transcriptase were added after the 
denaturation step to avoid heat inactivation. A PCR Express thermal cycler HBPX110 (Thermo 
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Components RNA vRNA 
AccuScript RT buffer 2μl 2μl 
Oligo(dT) primer (0.5μg/μl) 1μl  
Random primers (0.1μg/μl)  3μl 
dNTP (100mM) 0.8μl 0.8μl 
DTT (100mM) 2μl 2μl 
RNase Block (40U/μl) 0.5μl 0.5μl 
AccuScript High Fidelity RT μl 1μl 1μl 
RNase-free water up to a final volume of 20μl 
 
TABLE 2-2: THE COMPONENTS OF THE CDNA SYNTHESIS REACTION 
 
Cycle parameters Function 
65°C 5 minutes Denaturation  
Room temperature 5 minutes Annealing of primers 
25°C 10 minutes Extension of primers* 
42°C 60 minutes cDNA Synthesis  
70°C 15 minutes Terminate synthesis 
 
TABLE 2-3: THE CYCLE PARAMETERS USED FOR CDNA SYNTHESIS  
* THIS STEP IS ONLY CARRIED OUT WHEN USING RANDOM PRIMERS. 
 
 
2.2.4 POLYMERASE CHAIN REACTION (PCR) 
 
PCRs were carried out using either KOD Hot Start (Novagen), FastStart Taq (Roche), AmpliTaq 
Gold (Roche) or Phusion High-Fidelity (New England Biolabs) DNA polymerases in a 50μl 
reaction. The required components of each reaction are stated below: 








PCR buffer 5μl (10x) 5μl (10x) 5μl (10x) 10μl (5x) 
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1μl (10mM each) 
Forward 
primer 
1.5μl of 10μM 
primer 
2.5μl of 5μM 
primer 
2.5μl of 5μM 
primer 




1.5μl of 10μM 
primer 
2.5μl of 5μM 
primer 
2.5μl of 5μM 
primer 
2.5μl of 10μM 
primer 
Mg source 3μl of 25mM 
MgSO4 
4μl of 25mM 
MgCl2 
4μl of 25mM 
MgCl2 
Included in PCR 





1μl 0.4μl 0.25μl 0.5μl 
Distilled 
water 
Up to a final volume of 50μl 
 
 
TABLE 2-4: THE REACTION MIXTURES FOR EACH PCR REACTION 
 
Cycle conditions: 
Once set up, a T3 thermocycler (Biometra), with a heated lid, was used to produce the cycle 
conditions below. 
 
KOD DNA polymerase 
Step Temp (°C) Time (s) Use 
1. Initialisation 95 120 Cloning of GBV-B E1E2 
envelope proteins 2. Denaturation 95 20 
3. Annealing Table 7-1 10 
4. Extension 70 40 
Number of cycles (steps 2-4): 30 
FastStart Taq DNA polymerase 
1. Initialisation 95 240 
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2. Denaturation 95 30 Cloning of GBV-B core, NS3 
and NS5B proteins 3. Annealing Table 7-1 30 




Number of cycles (steps 2-4): 30  
AmpliTaq Gold DNA polymerase 




Time (s) Aim 
1 1. Initialisation 94 600 Cloning of variable regions, 
Kozak sequence (red line), part 
of linker (green line) and part of 
spacer (purple line). 
 
2. Denaturation 94 30 
3. Annealing 54/56 30 




Number of cycles (steps 2-4): 30 
2 1. Initialisation 94 600 Elongating linker and adding part 
of T7 promoter (yellow line). 
 
2. Denaturation 94 30 
3. Annealing 56 30 




Number of cycles (steps 2-4): 16 
3 1. Initialisation 94 600 Joining variable regions together 
via a complete linker. 
 
2. Denaturation 94 30 
3. Annealing 52 45 




Number of cycles (steps 2-4): 16 
5 1. Initialisation 94 600 Adding spacer (CH) to scFv. 
 2. Denaturation 94 30 
3. Annealing 52 45 
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Number of cycles (steps 2-4): 16 
6 1. Initialisation 94 600 Completing scFv by elongating 
T7 promoter (yellow line). 
 
2. Denaturation 94 30 
3. Annealing 52 45 




Number of cycles (steps 2-4): 20 
Phusion High-Fidelity DNA Polymerase 
Step Temp (°C) Time (s) Use 
1. Initialisation 98 180 Amplification of CDR3 
sequences within 
immunoglobulin variable 
regions for deep sequencing. 
2. Denaturation 98 10 
3. Annealing Table 7-1 15 
4. Extension 72 30 
Number of cycles (steps 2-4): 25 
 
TABLE 2-5: THE CYCLE PARAMETERS USED FOR PCR 
 
For recovery of scFv after the screening of a scFv library against GBV-B proteins using 
ribosome display, a combined reverse transcription reaction and PCR was performed. 
Recovered, eluted mRNA was cleaned up using the RNeasy Mini kit (Qiagen) to remove EDTA 
and used as the input mRNA for the One-Step RT-PCR kit (Qiagen). This kit includes the 
enzymes Omniscript Reverse Transcriptase, Sensiscript Reverse Transcriptase, and 
HotStarTaq® DNA Polymerase which allows reverse transcription and PCR to take place in the 
same tube. Reactions were performed in 50μl volumes and were kept on ice. A T3 
thermocycler (Biometra), with a heated lid, was used to produce the cycle conditions below.  
The components for this reaction are included below alongside the conditions used: 
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Component Volume/reaction 
PCR buffer (5x) 10μl  
dNTP (10mM of each dNTP) 2μl 
Forward primer (10μM) 3μl 
Reverse primer (10μM) 3μl 
Enzyme mix 2μl 
Template mRNA Varied  
Distilled water Up to a final volume of 50µl 
 




Time (seconds) Use 
1. Reverse 
transcription 
50 1800 Reverse transcription and 
amplification of recovered 
scFv from ribosome display. 2. Initial PCR 
activation 
95 900 
3. Denaturing 95 30 
4. Annealing Table 7-1 30 
5. Extension 72 120 
6. Final extension 72 600 
Number of cycles (steps 3-5): 30, unless stated 
 
 
TABLE 2-7: THE CONDITIONS USED FOR THE ONE-STEP RT-PCR REACTION 
 
2.2.5 AGAROSE GEL ELECTROPHORESIS 
 
Agarose gels were produced by dissolving agarose powder (Invitrogen) in 50-100ml 1 TAE. 
Gels were supplemented with 5μl SafeView (NBS biologicals) per 100ml agarose suspension 
for nucleic acid visualisation using a UltraBright LED Transilluminator (Applied Biological 
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Materials). Loading buffer to 1 concentration (6 stock, Promega) was added to each 
sample prior to gel electrophoresis. Approximately 500ng of a 100bp or a 1Kb DNA ladder 
(Promega) was also run with samples to allow for size determination of DNA fragments. 
In the case of CDR3 PCR products, the Safe-Green (Applied Biological Materials) nucleic acid 
stain was used at a dilution of 1:5 (dye: sample). Agarose gels were prepared in the manner 
above minus the addition of dye. The remainder of the protocol remains as described above.  
 
2.2.6 PURIFICATION OF DNA FROM AGAROSE GEL 
 
DNA was purified from agarose gel using the QiaQuick Gel Extraction kit (Qiagen) following 
manufacturer’s instructions. DNA was eluted in 30μl elution buffer and the concentration 
determined using a NanoDrop 2000c UV-Vis spectrophotometer (Thermo Scientific). 
 
2.2.7 PURIFICATION OF DNA FROM PCR SAMPLES 
 
DNA was purified directly from PCR samples using the High Pure PCR Cleanup Micro Kit 
(Roche), following manufacturer’s instructions, to maximise the recovery of DNA. DNA was 
eluted in 10μl Elution buffer (kit supplied). Again, the concentration was determined using a 
NanoDrop 2000c UV-Vis spectrophotometer (Thermo Scientific). 
 
2.2.8 PREPARATION OF CHEMICALLY COMPETENT BACTERIAL CELLS 
 
To prepare chemically competent bacteria, 5μl of Competent Subcloning Efficiency DH5α 
Escherichia Coli bacterial cells (Invitrogen) were inoculated in 5ml of LB broth and incubated 
in a shaker incubator at 250rpm overnight at 37°C. This culture was then diluted into 500ml 
LB broth containing 15mM MgCl2 and further incubated at 37°C in the shaker incubator until 
the OD600 reached 0.5. Bacterial cells were pelleted at 4000rpm for 15 minutes at 4°C using a 
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Sorvall Super T21 centrifuge. Pellets were then resuspended in 125ml of ice-cold solution A, 
spun down as before and resuspended in 12.5ml of solution A with 15% (v/v) glycerol. 
Bacterial cells were aliquoted and stored at -80°C. 
2.2.9 TRANSFORMATION OF COMPETENT BACTERIA 
 
Aliquots of chemically competent bacteria were transformed following the manufacturer’s 
instructions. For home-made competent bacterial cells, 50µl of bacterial cell suspension was 
incubated with 100-200ng of plasmid DNA or 5μl of a ligation reaction on ice for 30 minutes. 
Bacteria were heat shocked at 42°C for 45 seconds. After the addition of 450μl of LB broth, 
samples were incubated for 1 hour at 37°C shaking at 250rpm and then 120μl spread on LB 
agar plates supplemented with 100μg/ml of carbenicillin (Sigma-Aldrich-Aldrich). Commercial 
bacterial cells were purchased in single use aliquots and transformed using the 
manufacturer’s provided protocols. Commercial bacterial cells were purchased from the 
following companies: BL21 (New England Biolabs), SHuffle® T7 Express (New England 
Biolabs), Rosetta-Gami B DE3 (Novagen) and NiCo21 (New England Biolabs). 
2.2.10 PLASMID DNA MINI PREPARATIONS 
 
Individual bacterial colonies, picked from LB agar plates, were grown overnight in 5ml LB 
broth containing an appropriate concentration of antibiotic at 37°C in a shaker incubator at 
200-250rpm. Bacteria were then pelleted and plasmid extraction was performed using 
Qiaprep Spin miniprep kit (Qiagen) following the manufacturer’s instructions. Purified 
plasmid DNA was eluted in 30μl EB buffer and the concentration determined using a 
NanoDrop 2000c UV-Vis spectrophotometer (Thermo Scientific). If the absorbance ratio at 
wavelength 260nm/280nm was 1.8-2.0, purified plasmid samples were considered good 
quality. Please see Appendix for plasmid maps of protein production plasmids (Figure 7-1-7-
6). 
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2.2.11 ENZYMATIC REACTIONS 
 
Restriction digests were carried out with the required enzymes (New England Biolabs), in the 
appropriate buffer, and distilled water at a final volume of 20μl for single digestions or 50μl 
for double digestions. Digestion reactions were then incubated at 37°C overnight in a PCR 
Express thermal cycler HBPX110 (Thermo Hybaid) with a heated lid. 
DNA ligations were performed using 1μl of T4 DNA ligase (3U/μl, Promega) in the supplied 
buffer, using 50ng backbone and the insert at a ratio of 1 backbone: 3 insert in a final volume 
of 10μl overnight at 16°C in a PCR Express thermal cycler HBPX110 (Thermo Hybaid). After 
this incubation period, ligations were inactivated at 65°C for 10 minutes and used to 
transform a suitable bacterial host. 
 
2.2.12 SANGER SEQUENCING 
 
Samples to be sequenced were set up in 8 x 0.2ml tube strips (Thermo Scientific) with the 
following components: 2.5μl of BigDye terminators (Applied Biosystems), 2μl of 5 
sequencing buffer (Applied Biosystems), 1μl of 5mM sequencing primer (forward or reverse), 
400-500ng of template DNA and PCR-grade H20 up to 10μl. A T3 thermocycler (Biometra) 
with a heated lid was then used to produce 25 cycles of the following conditions: 96°C for 30 
seconds, 50°C for 15 seconds and 60°C for 4 minutes. Reactions were then either stored at -
20°C or cleaned up. 
To clean up PCR products for sequencing, 10μl of PCR grade H20, 5μl of 125mM EDTA and 
80μl of 100% ethanol were added to samples and mixed by inversion. After a 15-minute 
incubation at room temperature, samples were centrifuged at 3800rpm for 30 minutes using 
the ST-H750 rotor in the Sorvall Super T21 centrifuge. The supernatant was then discarded 
and spun inverted for 1 minute at 800rpm. The DNA pellet was then washed with 200μl of 
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70% ethanol. Samples were centrifuged for a further 15 minutes at 3800rpm before the 
inversion spin step was repeated.  
DNA pellets were then resuspended in highly deionized (Hi-Di) Formamide before loading on 
to a 3130 Genetic Analyser (Applied Biosystems).   
 
2.1.13 ANALYSIS OF DNA SEQUENCES 
 
All DNA sequence files obtained from the 3130 Genetic Analyser were processed using 
DNADynamo (Blue Tractor Software). Forward and reverse reads for each sequence were 
imported into this software and aligned using the default settings. As the sequences are 
linked with chromatogram data, a visual check of each sequence can confirm the called 
sequence is correct.  
 
2.1.14 ANALYSIS OF IMMUNOGLOBULIN SEQUENCES 
 
Once immunoglobulin sequences were gathered by Sanger sequencing, IgBLAST (accessed 
online at: http://www.ncbi.nlm.nih.gov/igblast/) was used to screen each nucleotide 
sequence against the human germline immunoglobulin gene database using the ‘blastn’ 
program. All search parameters and formatting options were kept at the default setting. As 
tamarin immunoglobulins appear to be highly similar to human immunoglobulin sequences 
(see table 4-4), this allows the relevant V/D/J segments and CDR3 sequences to be identified.  
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2.2.15 DEEP SEQUENCING OF SCFV LIBRARIES 
 
The highly-variable CDR3 sequences of PCR-generated scFv libraries before and after 
screening against an antigen in ribosome display, were deep sequenced. This led to the 
sequencing of 4 libraries. As scFv consist of both the variable region from the heavy chain and 
the variable region from the light chain of antibodies, CDR3 sequences were obtained for 
both regions. Additionally, all reactions were duplicated to increase the reliability and 
accuracy of the obtained sequences. This resulted in 16 reactions.  
The first step, prior to deep sequencing, was the amplification of CDR3 regions by PCR using 
the high fidelity polymerase, Phusion (see 2.2.4). Degenerate primers were designed to 
capture as many CDR3 regions as possible (see table 7-1). Three primers were designed to 
cover the region preceding the CDR3 sequence and one primer to cover the sequence 






IN THE HEAVY CHAIN OF AN IMMUNOGLOBULIN, THE CDR3 REGION ORIGINATES FROM THE SEQUENCES FROM THE END OF THE V GENE 
SEGMENT, THE D GENE SEGMENT AND THE BEGINNING OF THE J GENE SEGMENT, AND BY NUCLEOTIDES ADDED OR LOST WHEN THESE GENE 
SEGMENTS ARE JOINED DURING LYMPHOCYTE DEVELOPMENT. AS SUCH PRIMERS WERE DESIGNED TO COVER THIS AREA (F: FORWARD, R: 
REVERSE). THE EXON FOR THE CDR3 LOOP OF THE LIGHT CHAIN IS FORMED BY THE JOINING OF SEQUENCES FROM V AND J GENE SEGMENTS 
(NOT SHOWN). FW: FRAMEWORK REGION, CDR: COMPLEMENTARITY DETERMINING REGION 
FIGURE 2-1: DESIGN OF CDR3 PRIMERS 
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These primers were designed by comparing previously sequenced variable regions containing 
CDR3 sequences (see table 7-6). PCR products were then run in a 3% agarose gel (see 2.2.5 
for details) and purified (see 2.2.6 for details). Purified PCR products were then submitted to 
the Deep Sequencing group at NIBSC for sequencing on the MiSeq platform. 
 
2.2.16 ANTIBODY MINING TOOL 
 
Although forward and reverse reads of scFv sequences were produced for each sample from 
deep sequencing, only the quality-filtered forward reads from CDR3 samples for each library 
were obtained from the Deep Sequencing group at NIBSC. Due to the short length of CDR3 
sequences (approximately 250 basepairs), only forward sequences were required for analysis 
and these were analysed using the Antibody Mining Tool (downloadable, D’Angelo et al., 
2013).  
The files containing the filtered forward reads for both the heavy chain and light chain CDR3 
sequences for each scFv library were analysed using the ‘cdr3_pipeline’ or ‘lcdr3_pipeline’ 
python script using the default settings, as these are recommended and have been 
determined experimentally by D’Angelo and colleagues using the MiSeq platform (D’Angelo 
et al., 2013). The output of this script is an Excel file containing all CDR3 sequences within 
each library along with the number of appearances of this sequence in each library. All 16 
samples (4 libraries, heavy and light chain and duplicates) were run in these pipelines. To 
analyse this data, the number of unique CDR3 sequences were categorised by frequency and 
presented in a stacked column chart. A logarithmic scale was used due to the high number of 
sequences analysed. 
To further analyse this data, the enrichment of the top ten CDR3 sequences for each sample 
were investigated. The percentage of each CDR3 sequence in each library was calculated by 
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dividing the average frequency of a particular CDR3 sequence (as they were duplicated) by 
the total number of CDR3 sequences. The percentages for each of the top ten CDR3 
sequences for each library (before and after panning) were then plotted on a stacked line 
graph.  
 
2.2.17 RIBOSOME DISPLAY 
 
The ribosome display protocol was from Zhou and colleagues (Zhou et al., 2009). Plates were 
coated overnight with 10µg of recombinant target antigen or BSA diluted in RNase-free Tris 
pH8.0 (Ambion). After 16 hours, the plate was washed with PBS containing 5mM MgCl2 (PBS-
M) and blocked with 5% powdered milk (w/v, Marvel) in PBS-M for 30 minutes. After this 
time, the plate was washed with PBS-M and blocked for a further 2 hours with PBS-M 
containing 1% BSA (Miltenyi Biotec). Three washes with PBS-M were then performed and the 
plate was incubated for 10 minutes on ice.  
During the two hour blocking stage, the scFv library was transcribed and translated using the 
TnT T7 Quick-Coupled Transcription Translation system (Promega). This reaction was set up in 
a 0.5-ml RNase-free, protein lo-bind tube (Eppendorf) as follows: 40µl TnT T7 Quick Master 
Mix, 1µl DNA enhancer, 1µl 1mM methionine, 4µl of the scFv library at a concentration of at 
least 100ng/µl, and 4µl of RNase free H20. This mixture was incubated at 30°C for 90 min; 6µl 
of RNase-free DNase I (Roche) (10,000 U/ml) was then added and the mixture was incubated 
for a further 20 min at 30°C. Immediately after this stage, 50µl of ice-cold PBS-M containing 
1% BSA was added to stop the reaction and the mixture was added to the BSA-coated well for 
1 hour at 4°C. Later, this mixture was transferred to the target antigen-coated well and 
incubated at 4°C for a further hour. 
Finally, the mixture was discarded and the well washed three times with ice-cold PBS-M 
containing 0.05% Tween-20 and two times with ice-cold PBS-M. Bound scFv were dissociated 
108 | P a g e  
 
with PMBS-M containing 20mM EDTA (Invitrogen) for 10 minutes on ice. ScFv mRNA 
purification was performed using the RNeasy Mini kit (Qiagen) following the manufacturer’s 
instructions and was then used immediately in the OneStep RT-PCR kit (Qiagen).  
For further rounds of ribosome display panning, scFv DNA was then elongated by repeating 
the PCR for the 6th stage of scFv library construction, however 30 cycles were needed to 
obtain a sufficient amount of scFv DNA. This DNA was then purified and used as the input 
library for ribosome display. 
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2.3. PROTEIN PRODUCTION METHODS 
 
 
2.3.1 INDUCTION OF TARGET PROTEINS IN BACTERIAL CELLS 
 
Bacterial cells were transformed with protein expression plasmids containing genes of 
proteins to be expressed, such as His-tagged GBV-B proteins. Colonies of bacteria containing 
these plasmids were picked after 24 hours and grown overnight in 2 yeast extract-tryptone 
(YT) broth supplemented with 100μg/ml Carbenicillin. Cultures were then used to inoculate 
either 50ml (for scFv expression) or 300ml (GBV-B protein expression) of 2x YT broth 
supplemented with 100μg/ml Carbenicillin and 0.5% glucose. These cultures were grown to 
an OD600 of 0.6 and protein expression was induced using 1mM Isopropyl β-D-1-
thiogalactopyranoside (IPTG) for 20 hours at 20°C (for scFv) or 4 hours at 25°C for GBV-B 
proteins. Cells were harvested by centrifugation at 4000rpm for 15 minutes using the ST-
H750 rotor and the Sorvall Super T21 centrifuge. 
 
2.3.2 SDS-PAGE AND COLLOIDAL BLUE STAINING 
 
Proteins were resolved by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) using 4-12% Tris-Glycine polyacrylamide gels in the XCell SureLock Mini-Cell system 
and 1x Novex Tris-Glycine SDS Running Buffer (Life Technologies). Samples were heated for 5 
minutes at 95°C (or incubated for 15 minutes at 37°C for viral envelope proteins), loaded 
along with SeeBlue Plus2 Pre-Stained Protein Standard into gels and run at 130 volts for 90 
minutes (Life Technologies). Proteins were then visualized by staining gels for 3 hours with 
the Colloidal Blue Staining Kit (Life Technologies) and de-stained for a minimum of 7 hours in 
distilled water, following manufacturer’s instructions. 
110 | P a g e  
 
2.3.3 DISRUPTION OF BACTERIAL MEMBRANES 
 
Bacterial pellets were frozen at -80°C, thawed, and resuspended in PBS containing 0.25% 
(w/v) N-Lauroylsarcosine sodium salt (Sarkosyl, Sigma-Aldrich-Aldrich) at 1/30 of its original 
volume. Cells were sonicated at 30% amplitude (volumes of 10ml) or 60% amplitude 
(volumes over 10ml) for 6 times at 30 seconds, with 45 second rest intervals, on ice. Triton X-
100 (Sigma-Aldrich-Aldrich) was added to a final concentration of 0.5% v/v before incubating 
lysate for 60 minutes on a rolling spin. Cell debris was removed by centrifugation at 5000rpm 
for 30 minutes at 4°C in an Sorvall Legend RT centrifuge using the Swinging Bucket Rotor 7500 
6445. 
 
2.3.4 PURIFICATION OF HIS-TAGGED PROTEINS  
 
To purify His-tagged proteins produced in bacterial cells under native conditions using a 
Nickel affinity column, supernatant from 2.3.3 was applied to a chromatography column 
(Sigma-Aldrich-Aldrich) containing 1ml Ni-NTA sepharose (Sigma-Aldrich-Aldrich) and 
incubated for 1 hour at room temperature on a rolling spin.  After washing the gel with 30ml 
wash buffer (Table 2-1), His-tagged proteins were eluted with elution buffer (Table 2-1). 
Column elutions and washes were run on an SDS-PAGE and stained as above to confirm 
successful purification. 
To purify and concentrate His-tagged proteins produced in mammalian cells, the Ni-NTA Spin 
kit (Qiagen) was used following the manufacturer’s instructions.  
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2.3.5 QUANTIFICATION OF PROTEIN 
 
To calculate the concentration of proteins produced in a prokaryotic system, eluates 
containing His-tagged protein were electrophoresed by SDS-PAGE along with serial dilutions 
of bovine serum albumin of known concentration.  Protein concentrations were calculated 
using GeneTools software (Syngene) by comparison to the BSA standard curve. 
Purified monoclonal antibodies were quantified using the Mouse IgG Total Ready-SET-Go! 
(eBioscience), which uses NUNC 96-well plates (eBioscience), following manufacturer’s 
instructions. A mouse IgG standard (provided in the kit) was serially diluted and also included 
in the assay. Plates were read at both 570nm and 450nm using a FLUOstar Omega microplate 
reader (BMG Labtech). The 570nm values were then subtracted from the 450nm values to 
account for background fluorescence. A standard curve was created from the values obtained 
from the mouse IgG standard of known concentration and used to calculate the 
concentration of monoclonal antibody in each sample.  
 
2.3.6 ISOTYPING OF MONOCLONAL ANTIBODIES 
 
 
The isotype of monoclonal antibodies was determined using the Mouse Monoclonal Antibody 
Isotyping Test Kit (Bio-Rad) following the manufacturer’s instructions. This kit is based on a 
lateral flow membrane that has specific antibodies targeting each mouse isotype or light 
chain on specific strips of the membrane. Briefly, concentrated monoclonal antibody samples 
to be tested were diluted in a solution containing colloidal gold particles. These particles, 
which bind to the monoclonal antibodies in the samples, were then exposed to the 
membrane allowing the migration of the antibody-colloidal gold particle complexes to the 
specific band of the membrane that contains the corresponding anti-mouse isotype/light 
chain antibodies. A band is seen due to the colloidal element that indicates the isotype of the 
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monoclonal antibody and which light chain is used. 
 
2.3.7 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
 
ELISAs were performed in 96-well plate formats using Nunc MaxiSorp plates (eBioscience). 
Plates were coated overnight with 1µg/ml of antigen diluted in PBS. The next day, plates 
were washed with PBS containing 0.05% Tween-20 (Sigma-Aldrich-Aldrich) and blocked for 2 
hours with PBS containing 5% (w/v) skimmed milk powder (Marvel). Plates were then washed 
again using the same wash buffer containing Tween-20. Primary antibodies were then added 
to the plate for 1 hour at room temperature; scFv antibodies and monoclonal antibodies 
were generally used undiluted, unless stated otherwise. After a further five rounds of 
washing, the secondary antibody, diluted in PBS containing 2% (w/v) skimmed milk powder 
(Marvel), were added for 45 minutes at room temperature at the following dilutions:  
• 1:5000 of anti-human IgG-HRP, Fc-specific, Sigma-Aldrich-Aldrich. 
• 1:5000 of anti-mouse IgG-HRP, Sigma-Aldrich-Aldrich. 
• 1:5000 of anti-His-HRP, Cambridge Biosciences. This antibody was also used at 
1:20000 in Chapter 4.2.7. 
Excess secondary antibody was removed through a further five rounds of washing before 
enhanced K-Blue TMB substrate (Neogen Corporation) was added and the plates were 
incubated for 10 minutes at room temperature. Peroxidase reactions were stopped using 
sulphuric acid and the intensity of each well at 450nm was read using a FLUOstar Omega 
microplate reader (BMG Labtech). 
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2.4 CELL CULTURE METHODS 
 
2.4.1 CELL LINES USED 
 
CELL LINES USED CELL TYPE  CULTURE MEDIA REFERENCE 
293T CELLS Human embryonic 
kidney cells 
expressing the SV40 




supplement (GIBCO) with 
added 10%(v/v) Foetal 




To stop N-glycosylation, 
0.5µg/ml tunicamycin 
was added into the 
medium 
DuBridge et al., 
1987 
NS-0 CELLS Murine myeloma 
cells that do not 
secrete 
immunoglobulins 
RPMI 1640 medium 
(GIBCO) containing L-
Glutamine with added 
10% (v/v) Foetal Calf 
Serum (FCS) and 1% (v/v) 
Penicillin/ Streptomycin 
(Sigma-Aldrich-Aldrich). 
Prior to fusion with 
splenocytes, medium 










Splenocytes fused to 
NS-0 cells 
RPMI 1640 medium 
(GIBCO) containing L-
Glutamine with added 
Galfrè and 
Milstein., 1981 
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10% (v/v) Foetal Calf 
Serum (FCS) and 1%(v/v) 
Penicillin/ Streptomycin 
(Sigma-Aldrich-Aldrich).  
STAR CELLS  293T cells that are 
stably transfected 
with HIV-1 Gag and 
Pol proteins 
See 293T cells 
 
Ikeda et al., 2003 
HUH7 Human hepatoma 
cells 





cells isolated from 
tamarin 
RPMI 1640 medium 
(GIBCO) with added 10% 
(v/v) Foetal Calf Serum 




FRHK-4 Rhesus monkey 
kidney cells  
Dulbecco's Modified 
Eagle's medium (GIBCO) 
with added 10% (v/v) 




Wallace et al., 
1973. 
VERO African Green 
monkey kidney cells 
  Yasumura and 
Kawakita, 1963. 




HUH7.5 Human hepatoma 
cells 
 Blight, McKeating 
and Rice, 2002. 
TABLE 2-8: LIST OF CELL LINES USED  
ALL CELLS WERE GROWN AT 37°C WITH 5% CO2. 
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2.4.2 HYBRIDOMA PRODUCTION  
 
To produce monoclonal antibodies, mice were immunised with recombinant GBV-B core 
protein. This was carried out by the Biological Services Division at NIBSC, where mice were 
housed and maintained in accordance with UK Home Office guidelines. Briefly, two mice 
were immunised with 200µl of a mixture containing 0.2mg/ml recombinant GBV-B core 
protein and Sigma-Aldrich Adjuvant System oil at a ratio of 1:1. Mice were immunised at day 
1, 28 and 56 and terminated at day 59. Spleens were collected at termination and maintained 
on ice for same-day use.  
Harvested spleens were placed in sterile Petri dishes with 5ml of culture medium (serum-free 
RPMI with glutamine and 1% penicillin/streptomycin, GIBCO). Splenocytes were collected by 
scraping spleens with forceps and scissors; cells were then collected in a Falcon tube and 
centrifuged for 5 min at 1,000rpm using a Hettich Rotanta 460R centrifuge and the 5624 
swinging bucket rotor. Cells were then resuspended in 10ml media and the wash stage was 
repeated a further two times.  NS-0 cells were washed in an identical manner in parallel to 
splenocytes. 
To fuse splenocytes and NS-0 cells together, both cells suspensions were mixed together at a 
1:4 (splenocyte: NS-0) ratio. The mixed cell suspension is then centrifuged at 1000rpm for 10 
minutes, the supernatant discarded and the cell pellet partially air-dried. This pellet was 
loosened by gentle tapping and 1ml polyethylene glycol (50% w/v in distilled water, Sigma-
Aldrich) was added slowly over one minute, whilst gently stirring the cells. The mixture was 
left for 1 min and serum-free media was added slowly over a period of 10 min to a final 
volume of 10ml. Cells were then centrifuged again for 15 minutes at 1000rpm and the 
supernatant discarded.   
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The fused cell pellet was resuspended in 200ml RPMI supplemented with 20 % FCS, 20 pg/ml 
of human IL-6 and 2% HAT Media Supplement Hybri-Max (50x, all Sigma-Aldrich) and 
dispensed into 12 96-well tissue culture plates at 150µl/well. Fused cells were incubated for 
around 3 weeks at 37°C in 5% CO2. After this period, HAT supplement was substituted for HT 
media supplement Hybri-Max (50x, Sigma-Aldrich) for a further month. 
 
2.4.3 HYBRIDOMA SINGLE CELL TITRATION 
 
Following the 7-8 week hybridoma growth period after the initial fusion of mouse splenocytes 
and NS-0 cells, colonies of hybridomas contained within the 96-well plates were screened for 
the presence of GBV-B core-specific antibodies by ELISA.  Any wells that showed evidence of 
core-specific binding were then cloned by limiting dilution and screened by ELISA again.   
Limiting dilutions of hybridomas were performed by removing hybridoma cells from an 
individual well of the tissue culture 96-well plate and diluting them to a concentration of 
2x104 cells/ml. To stain cells, cells were mixed at a 1:1 ratio with trypan blue stain (0.4%, Life 
Technologies). Stained cells were then counted using the Countess II Fl Automated cell 
counter.  
Of these diluted cells, 200µl was placed in well A1 of Figure 2-1 for each plate. The remaining 
wells were filled with 100µl of medium. Two dilutions series were performed to obtain single 
cells dilutions; the first from wells A1 to H1 and the second from columns 1-12 using a 
multichannel pipette (see Figure 2-1).  Cells were then incubated for two weeks at 37°C in 5% 
CO2. Cells in wells containing single colonies were isolated and cell-growth was scaled up. 
 




FIGURE 2-2: 96-WELL PLATE SETUP FOR SERIAL DILUTION OF HYBRIDOMA CELLS  
 
2.4.4 PURIFICATION OF HYBRIDOMA CELLS 
 
Hybridoma cell supernatant was collected and cells were removed by centrifugation at 
3000rpm for 20 min at 4°C in an Sorvall Legend RT centrifuge using the Swinging Bucket Rotor 
7500 6445. The pellet was disregarded and the supernatant mixed at a 1:1 ratio with 50% 
ammonium sulphate, to a final volume of 50ml, to allow precipitation of monoclonal 
antibodies. Supernatant was rotated overnight at 4°C. Precipitated antibodies were collected 
by centrifugation 3000rpm for 30 min at 4°C. The pellet was then resuspended in 1ml of PBS.  
 
2.4.5 CELL TRANSFECTION  
 
To express proteins in a mammalian cell line, 293T cells or STAR cells were seeded in a 6 well 
plate at a density of either 1  106 or 2.5  106, respectively, one day before transfection to 
achieve 80-90% confluence. To transfect cells, plasmid DNA, diluted in TE buffer (Sigma-
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Aldrich) to a final volume of 5µl, was mixed with an appropriate transfection reagent (Fugene 
6, Fugene HD or XtremeGeneHP) diluted in Optimem (Life Technologies). Transfections were 
then carried out according to manufacturer’s instructions.   
 
2.4.6 PSEUDOTYPED VIRUS PRODUCTION 
 
Pseudotyped viruses were produced through the co-transfection of 293T or STAR-HV cells 
with a mix of two or three plasmids encoding the necessary elements: Gag and Pol genes, a 
retroviral vector containing a reporter gene flanked by LTRs and the viral envelope to be 
studied (see Table 2-7). 
Initially, 293T cells were transiently co-transfected using Fugene-6 (Promega) with three 
plasmids: pCMV8.91 containing HIV-1 gag and pol, HIV-based vector pCSGW encoding the 
reporter gene, Green Fluorescent Protein (GFP) and a plasmid containing the desired 
envelope protein at a ratio of 1:1:1.5 respectively (Besnier et al., 2002). Plasmids containing 
envelope proteins included pcDNA3_E1E2, pCAGG_E1E2, and pMDG containing vesicular 
stomatitis virus glycoprotein G (VSV-G) (Naldini et al., 1996).  
Similarly, STAR cells that were stably transfected with pCMV8.91 were transduced with self-
inactivating pHV (Ikeda et al., 2003) encoding GFP and then transfected with a plasmid 
containing the envelope protein. To produce pseudotyped viral particles with no envelope 
protein as a negative control, the native plasmid without the cloned envelope protein/s was 
used. A mix of the 3 plasmids at the correct ratio and TE buffer to a final volume of 15μl was 
added to 18μl of Fugene-6 diluted in 200μl Optimem. This mix was incubated at room 
temperature for 15 minutes and added to cells that had been seeded in a 6 well plate that 
were 80% confluent. The medium of the transfected cells was replaced after 24 hours. After 
both 48 and 72 hours, pseudotyped viruses (PV) were harvested, filtered through a 0.45μm 
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Whatman membrane (GE healthcare) to remove cell debris from the culture medium and 
stored at -80°C. 
An altered PV production protocol was later adopted (Tarr et al., 2007; Urbanowicz et al., 
2015).  For this protocol, 293T cells were seeded in a 10cm dish at a density of 1.2x106 one 
day before transfection to achieve 40-50% confluence. This should help to reduce the level of 
cellular debris due to overgrowth of cells and the subsequent leaking of envelope proteins. 
Plasmids used to transiently transfect to create PV are as follows: 
• Lentiviral three-plasmid system: 2µg of pCMV8.91 containing HIV-1 gag and pol, 2µg 
of HIV-based vector pCSFLW that was previously created in the lab by substituting 
the GFP gene from pCSGW for the Firefly luciferase gene and varying concentrations 
of the plasmid containing the desired envelope protein, pCAGG_E1E2 or 
pcDNA3.1D_HCVE1E2. The plasmid containing GBV-B envelope proteins was used at 
a concentration of either 2µg, 400ng, 80ng or 16ng. The plasmid containing HCV 
envelope proteins was used at concentration of 2µg.  
• Lentiviral two-plasmid system: 2µg of a packaging vector, pNL4-3.Luc.R-E-, containing 
the HIV-1 genome with the Firefly luciferase gene inserted into the nef gene, and a 
plasmid containing the viral envelope of interest, 400ng of pCAGG_E1E2 or 2µg of 
pcDNA3.1D_HCVE1E2.  
• Retroviral three-plasmid system: 1µg pCMVi containing Moloney murine leukaemia 
virus Gag and Pol genes, 1µg of pCFCR_luc containing the Firefly luciferase gene and 
a plasmid containing the viral envelope of interest, 80ng of pCAGG_E1E2 or 2µg of 
pcDNA3.1D_HCVE1E2.  
As a negative control, PV bearing no envelope were created in all three systems through the 
omission of the plasmid containing envelope proteins.  
120 | P a g e  
 
Cells were transfected using TurboFect transfection reagent following manufacturer’s 
instructions (Thermofisher). Supernatant, containing PV, were collected at 48 and 72 hours or 
72 hours alone, filtered through a 0.45μm Whatman membrane (GE healthcare) and stored 
at -80°C, as before.  
 
2.4.7 CELL TRANSDUCTION 
 
STAR cells were transduced with pHV (Ikeda et al., 2003), a lentiviral vector containing the 
GFP gene flanked by wild type HIV LTRs, at a Multiplicity of Infection (MOI, number of particle 
available to infect each cell) of 5 in the presence of 8μg/ml polybrene onto cells that had 
been seeded the previous day at a density of 2.5x106. Culture medium was replaced with 
fresh DMEM supplemented with 10% FCS after 24 hours. After 72 hours, a sample of these 
cells was isolated, fixed in 2% paraformaldehyde (Sigma-Aldrich-Aldrich) in PBS and analysed 
for GFP expression by flow cytometry (FACSCalibur, BD Biosciences) using the Flowjo 
software (FlowJo, LLC). 
 
2.4.8 CELL LYSATE COLLECTION 
 
Transfected 293T/STAR cells from a 6 well plate were lysed in 100μL of radio 
immunoprecipitation assay (RIPA) buffer with 1x proteinase inhibitor cocktail, Complete mini 
(Roche), for 30 minutes on ice. Samples were then spun down at 13000rpm in a Biofuge Pico 
bench-top centrifuge (Heraeus) with the 7500 3328 microlitre rotor at 4°C for 8 minutes and 
the supernatant saved and frozen at -80°C. 
 
2.4.9 PV CONCENTRATION 
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On a small scale, 900µl of 293T transfected cell supernatant containing PV was concentrated 
by centrifugation at 13,000rpm for 4 hours in a Biofuge Pico bench-top centrifuge (Heraeus) 
with the 7500 3328 microlitre rotor at 4°C. PV were then resuspended in 25µl of 2x Laemmli 
buffer containing 10% β-mercaptoethanol. To concentrate supernatant by 2000x, PV were 
instead resuspended in 900µl of 293T cell culture media (Table 2-8) and the centrifuge step 
repeated.  
For large scale purification, collected supernatant from transfected 293T cells was pooled and 
layered on top of 5ml 50nm sodium phosphate containing 20% sucrose (w/v; Sigma-Aldrich-
Aldrich) in polyallomer tubes (Beckmann). These tubes were then loaded into a SW28 rotor in 
a Beckman Optima LE-80K Ultracentrifuge and centrifuged at 23,000rpm for 2 hours at 4°C. 
After this, supernatant was discarded and PV were resuspended in 500µl 293T cell 
supernatant (Table 2-8). PV were then used immediately or frozen at -80°C.  
 
2.4.10 WESTERN BLOTTING 
 
 
PV pellets or all other proteins were resuspended in 2x or 4x Laemmli buffer, respectively, 
containing 10% β-mercaptoethanol. Once resuspended, protein or PV samples were heat 
treated at either 95°C for 5 minutes or 37°C for 15 minutes. Samples could then be separated 
by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS PAGE) using 4-12% Tris-
Glycine Mini Gels with 1x Tris-Glycine SDS running buffer on the XCell SureLock Mini platform 
(Life Technologies). Gels were run at 130V for 2 hours.  
A wet blotting system based on a Mini Trans-Blot electrophoretic transfer cell was used to 
transfer proteins from the Tris-Glycine gel onto a nitrocellulose membrane (Amersham 
Biosciences) at a 100V for 1 hour. This membrane was subsequently blocked in 5% (w/v) non-
fat dried milk (Marvel) in PBS and washed in PBS. The following primary antibodies were 
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diluted in PBS containing 2% skimmed milk powder (w/v; Marvel) and added to the 
membranes for 1 hour at room temperature: 
Antibody 
target 
HA GBV-B E2 VSV-G HIV-1 
p55/p24 





1:1000 1:2000 1:1000 1:1000 1:1000 1:1000 1:2000, or 
1:5000-
1:20:000 if 
used as a 
secondary 
antibody  
















Host Mouse Rabbit Mouse Mouse Mouse Mouse Mouse 






























TABLE 2-9: DETAILS OF PRIMARY ANTIBODIES USED IN THIS THESIS 
 
After washing the membrane three times in 0.05% (v/v) Tween-20 in PBS, an anti-mouse 
A4416 or anti-rabbit W4011 IgG horse radish peroxidase (HRP) conjugated secondary 
antibody (Sigma-Aldrich-Aldrich and Promega, respectively) diluted 1:3000 in 2% (w/v) milk in 
PBS was added to membranes and incubated for 45 minutes at room temperature. The 
membrane was washed a further three times with 0.05% (v/v) Tween-20 in PBS, once in PBS 
alone. In the case of detecting tamarin antibodies, the anti-IgG 2B11 (Kerafast) antibody was 
used by diluting it 1:1000 in 2% (w/v) milk in PBS, which in turn could be detected by the anti-
mouse IgG-HRP antibody. 
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Chemiluminescence was detected by incubation with ECL Prime or the highly sensitive ECL 
Select western blotting detecting reagent following the manufacturer’s instructions 
(Amersham Biosciences).  
 
2.4.11 IMMUNOSTAINING FOR FLOW CYTOMETRY ANALYSIS 
 
Prior to flow cytometry analysis, transfected 293T cells were fixed with 2-4% 
paraformaldehyde for 20 minutes at room temperature and then permeabilised with 0.2% 
saponin for a further 10 minutes at room temperature. From this point, all buffers contained 
0.2% saponin to maintain membrane permeabilisation. Samples were then blocked on ice for 
30 minutes with PBS supplemented with 10% FCS and washed with wash buffer (PBS 
containing 2% FCS). An anti-HA primary antibody, diluted 1:100 in wash buffer, was added to 
samples and kept on ice for an hour. After two washes, samples were incubated with a 
fluorescein isothyocyanate (FITC)-conjugated anti-mouse IgG secondary antibody (BD 
Pharmingen) diluted 1:100 in wash buffer for an hour in ice. After a further two washes, 
samples were analysed on a FACSCanto using FACSDiva software (BD Biosciences). 
 
2.4.12 IN VITRO INFECTION ASSAYS 
 
Target cell lines were seeded at 1  104 per well in culture medium in a 96-well cell culture 
plate (Corning) and incubated for 24 hours at 37°C. Culture medium was then removed and 
replaced with 50µl PV diluted either three-fold or five-fold in red phenol free culture medium 
in the presence of polybrene (final concentration 4µg/ml, hexadimethrine bromide, Sigma). 
Cells were either incubated for a further six hours or centrifuged for 30 minutes at 2500rpm 
using a Hettich Rotanta 460R centrifuge and the 5624 plate rotor before a further 100µl of 
red phenol free medium was added; cells were then incubated for 48 hours. After the 48-
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hour incubation, culture medium was removed and replaced with 100µl of fresh culture 
medium and 100µl of BrightGlo reagent, which serves to both lyse cells and provide the 
luciferase substrate (Promega). Cells were pipetted, incubated for 5 minutes in the dark and 
150µl was transferred to a white 96-well plate. The luminescence was then read on a 
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CHAPTER 3 : PRODUCTION OF GBV-B PROTEINS AND 





The study of viral pathogenesis is crucial for the development of vaccine candidates to 
effectively control viral infections. As the pathology of acute HCV infection is not well 
understood, this project aims to investigate the pathology of the closely-related GBV-B in 
tamarins. To contribute to the definition of the pathology caused by GBV-B, diagnostic 
reagents are required, such as virus-specific antibodies. Currently, the availability of 
diagnostic reagents for GBV-B is limited; no commercial antibodies exist and therefore 
laboratories must produce their own.   
Ribosome display is an in vitro display-based technology used to isolate and evolve proteins 
against a specific ligand.  Display technologies, such as ribosome, phage and yeast display, 
have been used successfully to produce antibodies for a variety of targets and applications 
(Bradbury et al., 2011). These methods have several advantages over the traditional method 
of producing antibodies through the immunisation of animals, such as the ability to control 
selection conditions, the affinity maturation of isolated antibodies and the availability of the 
sequence of the selected antibodies.  For example, a human antibody targeting HIV gp120 
was successfully mutated in the complementarity-determining regions (CDRs) by phage 
display leading to a 420-fold increase in affinity (Yang et al., 1995). However, phage display is 
limited by bacterial cell transformation efficiency whereas ribosome display is only limited by 
the number of ribosomes in the reaction. Additionally, antibodies isolated in phage display 
must be expressed in bacteria introducing an element of codon usage bias whilst ribosome 
display is cell-free; isolated antibodies from ribosome display can be expressed in a variety of 
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expression systems to overcome codon usage bias. For these reasons, ribosome display was 
chosen to produce recombinant tamarin antibodies that can target GBV-B proteins.  
To produce recombinant tamarin antibodies, GBV-B proteins and a library of scFvs were first 
produced. Previous studies have shown that tamarins produce antibodies against various 
GBV-B proteins; these proteins include the nucleocapsid of the virus, Core, the serine 
protease used by the virus in polyprotein processing, NS3, and the RNA-dependent RNA 
polymerase used for viral replication, NS5B (Ishii et al., 2007; Iwasaki et al., 2011; Pilot-Matias 
et al., 1996; Sbardellati et al., 2001). These three GBV-B proteins, Core, NS3 and NS5B, were 
therefore chosen as the screening targets for ribosome display. Additionally, all three 
proteins had been previously produced in a prokaryotic system in other laboratories thereby 
simplifying protein production. 
In parallel to GBV-B protein production, a scFv library was constructed. Antibodies consist of 
four polypeptide chains − two heavy chains and two light chains- that are held together by 
disulphide bonds. Each of these polypeptide chains comprise of variable regions that are 
involved in antigen binding and constant regions that are involved in determining the class 
and functionality of the antibody. Historically, producing whole recombinant antibodies has 
proved to be difficult due to improper protein folding and solubility issues in prokaryotic 
systems (Boss et al., 1984; Cabilly et al., 1984). However, the various constituents of 
antibodies can be produced in bacteria such as the fragment antibody-binding (Fab) region, 
the two variable regions of an antibody linked together (scFv) and the fragment crystallisable 
(Fc) region (Jendeberg et al., 1997; Shibui and Nagahari, 1992; Skerra et al., 1991). As Skerra 
and Plϋckthorn had previously determined that the two variable regions, one from the heavy 
chain and one from the light chain, otherwise known as scFvs, were the minimal unit required 
for antigen recognition, display methods are based on producing these types of antibodies 
(Skerra and Plückthun, 1988). Therefore, a library made from millions of combinations of the 
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variable regions of tamarin antibodies was produced to be screened against GBV-B proteins 
to isolate any tamarin antibodies that recognise either GBV-B core, NS3 or NS5B. Any 
antibodies isolated would be used in immunohistochemistry to help define the pathology of 
GBV-B with the aim to further validate the use of GBV-B infection in tamarins as an animal 
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3.2 GBV-B PROTEIN PRODUCTION 
 
3.2.1 CLONING OF CORE, NS3 AND NS5B 
 
 
To select antibodies against GBV-B proteins, GBV-B core, NS3 serine protease and NS5B were 
chosen as target antigens (see Figure 3-1A for genome organisation of GBV-B). The non-
structural proteins NS3 serine protease and truncated NS5B (NS5B∆23) were amplified by 
PCR as described in Chapter 2.2.4 (Figure 3-1B). Restriction sites were included in primer 
design for both proteins to allow subsequent cloning into a suitable expression vector. The 
RNA-dependent RNA polymerase NS5B was cloned as a truncated version of the protein with 
the last highly hydrophobic 23 amino acids removed to aid with protein purification, as 
described previously (Ranjith-Kumar et al., 2003). PCR products of the correct size were 
visualised on a 1% agarose gel and later cloned into the pGem T easy vector for safekeeping 
(see Chapter 2.2.5 for further details). The correct identity of the fragments in this vector was 
confirmed by Sanger sequencing (as described in Chapter 2.2.12). The structural core protein 
of GBV-B had been cloned previously into the expression vector pET22b+; Sanger sequencing 
of this vector confirmed the genes’ correct sequence. 




FIGURE 3-1: GBV-B PROTEIN CLONING STRATEGY  
 
A: DESIGN OF PRIMERS FOR CLONING OF GBV-B PROTEINS. IN THIS DIAGRAM, THE THREE GBV-B PROTEINS TO BE GENERATED ARE SHOWN 
ALONGSIDE THE GENOME STRUCTURE OF GBV-B. CORE HAD BEEN PREVIOUSLY CLONED AND THEREFORE PRIMER DESIGN IS NOT INCLUDED. 
FOR NS3, THE RESTRICTION SITES ECORI AND HINDIII ARE ADDED TO THE FORWARD OR REVERSE PRIMER, RESPECTIVELY. THE FORWARD 
PRIMER ALSO CONTAINS A RANDOM ADDITIONAL ‘G’ NUCLEOTIDE BEFORE THE START OF THE GENE TO ENSURE THAT NS3 IS KEPT IN FRAME. 
LIKEWISE, NS5BΔ23 PRIMERS ALSO CONTAIN THE NCOI AND NOTI RESTRICTION SITES NECESSARY FOR DOWNSTREAM SUBCLONING INTO AN 
EXPRESSION VECTOR. THE NS5BΔ23 FORWARD PRIMER CONTAINS 2 RANDOM ADDITIONAL NUCLEOTIDES, A C AND T, TO ENSURE NS5BΔ23 
IS KEPT IN FRAME.  
B: CLONING OF GBV-B PROTEIN GENES BY PCR. 
 1% AGAROSE GELS VISUALISING PCR PRODUCTS OF GBV-B NS3 SERINE PROTEASE (545BP) AND GBV-B NS5B∆23 (1700BP). 
 
 
3.2.2 EXPRESSION OF CORE, NS3 AND NS5BΔ23 
 
 
For the production of GBV-B proteins in a prokaryotic host, GBV-B core, NS3 and NS5B∆23 
were subcloned into suitable expression vectors. GBV-B NS3 serine protease gene was cloned 
into the vector pET32b+ using restriction enzymes EcoRI and HindIII whilst GBV-B core and 
130 | P a g e  
 
NS5B∆23 genes were cloned into the modified expression vector p4D5 using restriction 
enzymes NcoI and NotI (Markiv et al., 2011, see Chapter 2.2.11 for further details). This 
vector, p4D5, had been previously created by digesting pET32b+ using NdeI and NotI to 
remove all but one C-terminus His tag to simplify protein purification as additional tags would 
not have to be cleaved downstream in the purification procedure. Sanger sequencing 
confirmed that each GBV-B protein had been successfully moved into the correct expression 
vector. 
Expression vectors containing GBV-B core, NS3 and NS5B∆23 were used to transform BL21 
E.coli bacterial cells (as described in Chapter 2.2.9). One colony of BL21 containing either 
core, NS3 or NS5B∆23 was grown overnight and used to inoculate 1 L of 2*YT broth. Once 
each bacterial culture had reached an OD of 0.6, GBV-B protein expression was induced using 
1mM IPTG (as described in Chapter 2.3.1). 
Non-induced and induced bacterial cultures (500 µl samples) were lysed using 2 Laemmli 
buffer containing 10% β-mercaptoethanol and boiled; bacterial proteins were separated by 
SDS-PAGE using 4-12% Tris-Glycine polyacrylamide gels and subsequently stained using a 
Colloidal Blue staining kit (Figure 3-2, methods described in Chapter 2.3.2). All three proteins 
were seen to be induced in the BL21 E.coli strain and electrophoresed at their expected 









FIGURE 3-2: INDUCTION OF GBV-B PROTEIN EXPRESSION IN BL21 BACTERIAL STRAIN.  
 
SAMPLES OF NON-INDUCED (LANE 1) AND INDUCED (LANE 2) BL21 TRANSFORMED WITH EITHER P4D5-CORE (ESTIMATED PROTEIN SIZE: 
20KDA), PET32B-NS3 (ESTIMATED PROTEIN SIZE: 39KDA) OR P4D5-NS5B∆23 (ESTIMATED PROTEIN SIZE: 65KDA) WERE LYSED AND 
DENATURED BEFORE RUNNING ON AN SDS-PAGE TO SEPARATE PROTEINS BY SIZE.  
 
 
3.2.3 SMALL-SCALE PURIFICATION OF GBV-B CORE, NS3 SERINE PROTEASE AND NS5BΔ23 




C-terminal His-tagged GBV-B core, NS3 serine protease and NS5B∆23 produced in a 
prokaryotic system (see Chapter 2.1.2) were purified under native conditions using a nickel 
affinity column. After induction of GBV-B protein expression in BL21 cells, proteins were 
isolated through lysis in a buffer containing mild detergents Sarkosyl and Triton-X100 and 
sonication to disrupt bacterial membranes (Tao et al., 2010). His-tagged GBV-B proteins were 
subsequently purified under native conditions on a nickel affinity column. For each protein, 
each stage of the purification process was analysed by SDS-PAGE and Colloidal Blue staining 
(Figure 3-3A, D and F). Western blots of each protein using an anti-His antibody (Figure 3-3B, 
E and G) or tamarin sera (Figure 3-3C) confirmed each protein’s identity by size (as described 
in Chapter 2.4.10). 
NS5BΔ23 





FIGURE 3-3: PRODUCTION OF SOLUBLE GBV-B PROTEINS 
 
SDS-PAGE SHOWING INDUCTION AND PURIFICATION OF GBV-B CORE IN THE P4D5 EXPRESSION VECTOR(A), NS3 SERINE PROTEASE IN THE 
EXPRESSION VECTOR PET32B (D) AND NS5B∆23 IN P4D5 (F). CORE, NS3 AND NS5BΔ23 ELUTION SAMPLES WERE THEN RUN SEPARATELY 
BY SDS-PAGE, TRANSFERRED TO A NITROCELLULOSE MEMBRANE AND THE MEMBRANE BLOTTED WITH ANTI-HIS ANTIBODIES (B, E, G 
RESPECTIVELY). THE MEMBRANE CONTAINING THE CORE ELUTION SAMPLE WAS LATER STRIPPED WITH 0.1M GLYCINE-HCL AND REPROBED 
WITH TAMARIN SERA (C) TO DETERMINE THE BIOLOGICAL RELEVANCE OF THE RECOMBINANT GBV-B CORE PROTEIN GENERATED. UP: NON-
INDUCED PELLET, IP: INDUCED PELLET, L: LYSATE, UL: UNBOUND LYSATE, W: WASH, E: ELUATE. 
 
3.2.4 LARGE SCALE PRODUCTION OF GBV-B PROTEINS 
 
 
Once the protocols for native purification of GBV-B proteins in a prokaryotic host (see 
Chapter 3.1.3) were established, a larger scale protein production was carried out at the 
Protein Facility at Queen Mary University of London with the following modifications to the 
NS5BΔ23 
(65kDa) 
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protocols to optimise the upscaling. Core was produced in a different bacterial strain, NiCo21, 
that limits contaminating bacterial proteins in the eluate from a nickel affinity column. NS3 
serine protease was produced in a BL21 derivative, pLysS, and purified on a nickel affinity 
column with additional glycerol, CHAPS, DTT and EDTA. The bacterial strain BL21 containing 
the plasmid pLysS was chosen as this plasmid encodes T7 lysozyme. T7 lysozyme inhibits 
basal expression of proteins under the control of the T7 promoter, such as NS3 in the 
expression vector pET32b+. Leaky basal expression is known to slow the growth of bacteria if 
the target protein is toxic (Rosano and Ceccarelli, 2014). Glycerol, CHAPS and EDTA were used 
during the nickel affinity purification procedure to aid with protein stability, solubility and 
maximise protein elution whilst DTT was added to limit protein aggregation (Bornhorst and 
Falke, 2000; Gräslund et al., 2008). Identical protocols were used for production and 
purification of NS5B∆23 as described in Chapter 3.2.3. Protein samples from each stage of 
GBV-B protein purification were then separated by SDS-PAGE and visualised by Colloidal Blue 
staining (Figure 3-4). 
 
 




FIGURE 3-4: LARGE SCALE PRODUCTION OF GBV-B PROTEINS 
 
SDS-PAGE SHOWING INDUCTION AND PURIFICATION PROCESS OF GBV-B CORE (A), NS3 SERINE PROTEASE (B) AND NS5B23 (C) 
FOLLOWING NICKEL AFFINITY PURIFICATION. UP: NON-INDUCED PELLET, IP: INDUCED PELLET, S: SUPERNATANT, L: LYSATE, UL: UNBOUND 
LYSATE, W: WASH, E: ELUATE. 
 
3.3 SINGLE CHAIN VARIABLE REGION LIBRARY CONSTRUCTION 
 
 




To isolate recombinant tamarin antibodies directed against GBV-B proteins, a library of single 
chain variable fragments (scFv) was created by recombinant DNA technology, as previously 
described in (see Chapter 1.5.2). This consists of a series of six consecutive PCRs whereby a 
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the heavy and lights chains along with several essential elements. The basic structure is seen 
in Figure 3-5. A scFv consists of a variable region from the heavy chain and light chain, linked 
by a 20-mer (G4S)4, with the T7 promoter and Kozak sequence at the 5’ end for downstream 
expression of the scFv and a spacer at the 3’ end to allow for complete protrusion of the scFv 
from the ribosome. A library of up to 1014 recombinant tamarin scFv can be produced using 
this technology and be used to screen against GBV-B proteins allowing the isolation of GBV-B 




FIGURE 3-5: THE BASIC STRUCTURE OF A COMPLETE SINGLE CHAIN VARIABLE FRAGMENT 
 
THE SPACER IN THIS DIAGRAM IS NOTATED AS CH AS THE SPACER USED IN SCFV LIBRARY CONSTRUCTION WAS A CONSTANT REGION FROM THE 
HEAVY CHAIN OF A HUMAN IGG. 
 
 
The first step of scFv library construction is the cloning of variable regions from tamarin 
immunoglobulin genes. Total RNA was extracted from splenocytes of a tamarin 
experimentally infected with GBV-B which subsequently had cleared its infection naturally, 
and was reverse transcribed using random primers (as described in Chapter 2.2.2 and 2.2.3). 
The resulting cDNA was used as a template for the first round of PCR to clone the variable 
regions from both the heavy chain (VH) and light chain (VL) from tamarin immunoglobulin 
genes using degenerate primers. Degenerate primers were designed to allow complete 
coverage of the highly diverse families of variable regions (Matsuda et al., 1998; Schäble and 
Zachau, 1993). However, as the tamarin genome has yet to be sequenced, primers were 
designed based on the closely-related marmoset equivalent (von Büdingen et al., 2002). 
Primers were therefore designed on the characterised immunoglobulin heavy chain variable 
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regions (containing V gene segment from families VH1, 3, 4, 5, 6 and 7) and kappa light chain 
variable regions (containing V gene segments from families Vκ1-5). 
These PCR products were visualised on agarose gels (Figure 3-6). Generation of PCR products 
for each known family was successful and were shown to be of the expected size of 400-
500bp. During this initial cloning step, the primers used contain a Kozak sequence, part of the 
linker and part of the spacer as represented in the scheme of the design of scFv shown in (see 
Chapter 2.2.4 and Table 2-2) and Figure 3-5. More specifically, the Kozak sequence was added 
to the 5’ end of the VL region, 1 G4S repeat to both the 3’ end of the VL region and 5’ end of 
the VH region and part of the spacer was added to the 3’ end of the VH region (Figure 3-6B). 
Variable sequences were then cloned into the pGem T-easy vector and used to transform 
DH5α bacterial cells. For each VH and VK family of variable regions, 12 individual colonies, 
containing 12 unique plasmids, were cultured overnight and minipreparations of the 96 
plasmids were performed using the QIAprep Spin Miniprep kit (Qiagen). Sanger sequencing 
was performed for each of these plasmids to confirm the identity and diversity of the isolated 
tamarin variable regions as no repetition of variable region sequences was identified.  
 
 




FIGURE 3-6: PCR PRODUCTS OF THE TAMARIN VH AND VL REGIONS 
A: 2% AGAROSE GEL OF TAMARIN VARIABLE REGIONS BELONGING TO DIFFERENT VH OR VK FAMILIES. SOME PRIMERS COVERED 2 FAMILIES OF 
VH REGIONS, FOR EXAMPLE, VH1&7, DUE TO THE SIMILARITY OF SEQUENCES AT THE BEGINNING AND END OF THE VARIABLE REGIONS.  
 




3.3.2 PRODUCTION OF A TAMARIN SINGLE CHAIN IMMUNOGLOBULIN LIBRARY 
 
After the initial cloning of the tamarin variable regions (Chapter 3.3.1), five consecutive PCRs 
were performed incorporating various elements required for ribosome display. The aims of 
these PCRs were as follows: 
1. Stage 2: addition of part of the T7 promoter at the 5’ end of the VL region, extension 
of the linker by addition of G4S repeat at both the 3’ of the VL region and the 5’ end of 
the VH region.  
2. Stage 3: overlapping PCR to join the G4S linker of both variable regions together. 
3. Stage 4: cloning of the human constant region (CH1) for use as a spacer. 
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4. Stage 5: addition of the spacer to the scFv constructs. 
5. Stage 6: elongation of the T7 promoter and amplification of the complete scFv 
constructs. 
In advance of stage 2 scFv production, all cloned tamarin variable regions (Chapter 3.3.1) 
were electrophoresed through 2% agarose gels, the correct bands excised and purified using 
the Qiagen QIAquick Gel Extraction kit. These purified PCR products were then pooled into 
either VH or VL pools and used as the templates for the stage 2 PCRs for either the VH or VL 
regions, respectively. An equimolar mix of stage 2 gel purified PCR products were added as 
templates for the stage 3 PCR of scFv production. To confirm that the variable regions had 
been successfully joined together, stage 3 PCR product was cloned into the vector pGem-T 
easy. Twenty-four of these plasmids were used to transform DH5α E.coli, individual colonies 
were cultured overnight and a minipreparation of plasmid DNA from each colony was 
prepared using the Qiagen QIAprep kit. Sanger sequencing was performed on these samples. 
This revealed that the stage 3 scFv were in the correct conformation in 83% of samples. 
In parallel, the spacer, the human constant region (CH1), was amplified. This spacer was 
chosen as it had been previously cloned and would allow easy identification of scFv as several 
commercially available antibodies exist to this region. Once cloned, this spacer was gel-
purified, as described previously, and used alongside the gel-purified stage 3 PCR product as 
the template for stage 5 of scFv construction. To obtain an equimolar mix of both PCR 
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Using gel-purified stage 5 PCR product as a template, the final stage of scFv production, stage 
6 PCR, was performed, gel-purified and quantified. Further rounds of stage 6 scFv production 
were performed, gel-purified and pooled to ensure a final concentration of > 100ng/µl, as 
required for ribosome display. 
The correct identity of full-length scFv was confirmed before starting ribosome display. As 
such, stage 6 PCR products were cloned in the vector pGem T easy. These vectors were used 
to transform DH5α E.coli and individual colonies were cultured overnight. Plasmid 
minipreparations from these colonies were once again prepared and the generation of full 
length scFv confirmed by Sanger sequencing.  
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FIGURE 3-7: PCR PRODUCTS FOR EACH STAGE IN THE GENERATION OF THE SCFV LIBRARY.  
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ALL PCR PRODUCTS FROM EACH STAGE OF SCFV LIBRARY CONSTRUCTION WERE VISUALISED ON 2% AGAROSE GELS AND SHOWN TO BE OF THE 
CORRECT SIZE. THE SCHEME FOR LIBRARY CONSTRUCTION IS SHOWN ALONGSIDE EACH STAGE OF PCR.    
 
A: 2% AGAROSE GEL SHOWING STAGE 2 PCR PRODUCT. POOLED VH AND VL REGIONS ARE AMPLIFIED SEPARATELY TO ELONGATE THE LINKER 
AND ADD PART OF THE T7 PROMOTER TO THE 5’ END OF THE VL REGION. EACH VH AND VL ARE EXPECTED TO BE 400-500BP.  
 
B: 2% AGAROSE GEL OF STAGE 3 PCR PRODUCT. VH AND VL REGIONS HAVE NOW BEEN LINKED TOGETHER; PCR PRODUCT SIZE EXPECTED TO 
BE ~800BP. 
 
C: 2% AGAROSE GEL OF STAGE 4 PCR PRODUCT. AMPLIFICATION OF HUMAN CH1 REGION. EXPECTED SIZE: ~300BP.  
 
D: 2% AGAROSE GEL OF STAGE 5 PCR PRODUCT. ADDITION OF CH1 TO SCFV CONSTRUCT. EXPECTED SIZE: ~1100BP.  
 



























Studies of GBV-B pathology have been hampered by the lack of specific reagents against GBV-
B such as monoclonal antibodies. Greater characterisation of the pathology of this virus 
would further validate the use of this animal model as a model of acute HCV infection. In this 
Chapter, GBV-B target proteins were generated and they will be used in the next chapter to 
screen a scFv library of recombinant tamarin antibodies.  
Despite previous successful attempts at producing soluble GBV-B protein in the literature 
(Ishii et al., 2007; Ranjith-Kumar et al., 2003; Scarselli et al., 1997; Zhong et al., 1999), it was 
found that GBV-B proteins, produced in similar prokaryotic systems, were difficult to purify 
under native conditions. For large scale protein production, GBV-B core was produced in 
NiCo21 cells to limit the contaminating proteins from the bacteria eluted using a nickel 
affinity column. These cells have four proteins that commonly bind to nickel (GlmS, SlyD, 
ArnA and Can) deleted or tagged to aid removal of contaminating proteins. GBV-B NS3 serine 
protease was only produced to low levels with relatively high levels of contaminating 
bacterial host proteins in nickel column eluates in both small scale and large scale protein 
production. As NS3 was problematic to purify, additional glycerol and CHAPS to aid with 
protein stability and solubility, DTT to limit protein aggregation and EDTA to maximise protein 
elution was used during the purification procedure (Bornhorst and Falke, 2000; Gräslund et 
al., 2008). GBV-B NS5B23 was successfully produced in both small scale and large scale 
protein production. Mass spectrometry data (Appendix, Table 7-1) determined that NS5B23 
had been successfully produced as a truncated version of the protein. 
Although GBV-B proteins were produced in a prokaryotic system, and will therefore lack 
glycosylation, previous studies have confirmed that the proteins are still produced in an 
active, enzymatic form (Ranjith-Kumar et al., 2003; Scarselli et al., 1997). Western blots have 
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also confirmed that the recombinant GBV-B core is recognised by convalescent tamarin sera 
thereby confirming its biological relevance (Figure 3-3C, as described in Chapter 2.4.10). 
In parallel to the production of soluble GBV-B proteins, the scFv library was successfully 
constructed (see Chapter 2.2.4). Degenerate primers allowed the coverage of as many 
potential families of immunoglobulins as possible. However, these primers were partly 
designed based on a study that used marmosets (von Büdingen et al., 2002). This study failed 
to amplify variable regions from the VH2 family. This could be due to a failed PCR or that the 
marmosets do not contain VH2 family immunoglobulins. Unfortunately, the tamarin genome 
has not been sequenced meaning that the scFv library construction primers were based on 
the primers used in von Budingen et al. and are therefore not thought to cover VH2 family 
immunoglobulins. The other possible limitation of this library is due to the separate 
amplification of VH and VL regions from tamarin splenocytes; the combinations of VH and VL 
regions in this scFv library will not represent what would be seen in nature. However, this is 
not an issue for this particular study as any recombinant antibodies isolated from ribosome 
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CHAPTER 4 : ISOLATION AND CHARACTERISATION OF 
RECOMBINANT GBV-B-SPECIFIC ANTIBODIES 
 
 
4. 1 INTRODUCTION 
 
Monoclonal antibodies (mAbs) are a key research tool for the understanding of vaccine 
function through identification of epitopes that are critical for a vaccine’s efficacy (such as 
neutralising epitopes), viral or bacterial pathogenesis by facilitating the detection and 
tracking of the pathogen in tissues and throughout infection, and as therapeutics (Alamares 
et al., 2005; Burton, 2002; Chow and Casadevall, 2012; Lin et al., 2006; Tabll et al., 2015; Tang 
et al., 2015). Monoclonal antibodies can be generated in different ways. Traditionally, mAbs 
are produced by hybridoma technology which is based on the immunisation of animals with a 
target antigen, followed by immortalisation of the antibody-producing cells (Köhler and 
Milstein, 1975). Cloning of the antibody genes led to the construction of combinatorial 
libraries of scFv, generated by PCR-directed fusion of the variable regions of heavy (VH) and 
light (VL) chains of antibodies to recreate the antigen-recognition domain (Hoogenboom, 
2005). Isolation of recombinant antibodies from scFv libraries offers several advantages in 
comparison with the traditional hybridoma technology, such as a wider choice of target, the 
possibility to easily “humanise” the antibodies for human therapy, and the improvement of 
the characteristics of the antibody by affinity maturation (Bradbury et al., 2011; 
Hoogenboom, 2005).  
Monoclonal antibodies targeting HCV proteins have been used successfully as serological 
markers in a huge range of studies, including those investigating the effect of current therapy 
regimens in chronic HCV infection (Kurt et al., 2015), the effect of novel anti-viral therapies 
(Zhang et al., 2013), HCV lipoviral formation (Boyer et al., 2014), HCV protein interaction 
(Eyre et al., 2014; Jones et al., 2011) and the identification of novel virus-host interactions 
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(Germain et al., 2014). These studies have been crucial for the characterisation of the 
lifecycle and pathology of HCV, along with aiding the understanding of the progression of 
infection and the investigation of the effectiveness of novel therapies. In the case of GBV-B, 
the limited availability of reagents has resulted in a lack of similar studies, despite the need 
for them to validate GBV-B infection in tamarins as an ideal animal model of acute HCV 
infection.  
Antibodies against GBV-B proteins would be of high value to further the study of the tissue 
tropism and pathology of the virus. Two different approaches were used to generate GBV-B-
specific antibodies: ribosome display technology and hybridoma technology. Initially, 
ribosome display was used to screen a library of scFv antibodies created from a GBV-B 
infected tamarin, constructed in Chapter 3.3.2, against recombinant GBV-B core or NS5BΔ23 
proteins, produced in Chapter 3.2.4. Technical difficulties and delays in the production of 
specific anti GBV-B antibodies by this method prompted the use of the hybridoma technology 
by immunisation of mice with the GBV-B core protein, as an alternative system. 
In both cases, GBV-B core-specific antibodies were produced and will have future use in 
immunohistochemistry for studying the localisation of GBV-B in infected tamarin tissues, 
which will allow the comparison of the pathology (distribution and kinetics of the viral 
infection) in the GBV-B animal model with literature data from HCV infection in humans. 
However, this is only one of the possible applications of these antibodies; future studies can 
now be designed to investigate the lifecycle and pathology of GBV-B, for example the role of 
lipids in the GBV-B life cycle, which are known to be bind to HCV core protein, or the tracking 
of virus in virus entry receptor studies (Benedicto et al., 2009; Boyer et al., 2014). 
Understanding the lifecycle of GBV-B is of particular interest as most of what is known of the 
GBV-B lifecycle is inferred from the knowledge of the HCV lifecycle.  
 





4.2.1 ISOLATION OF SCFV ANTIBODIES AGAINST RECOMBINANT GBV-B NS5BΔ23 FROM 
THE SCREENING OF A GBV-B INFECTED TAMARIN-DERIVED ANTIBODY LIBRARY 
 
The scFv antibody library, created in Chapter 3.3.2 from GBV-B infected tamarin, was probed 
against recombinant GBV-B NS5BΔ23 protein produced in Chapter 3.2.4. Presence of 
recombinant NS5BΔ23 in the protein preparation had been confirmed by both western blot 
and mass spectrometry (Figure 3-3, Table 7-1, see Chapter 2.4.10 for further details on 
western blotting). NS5BΔ23 was chosen as target because antibodies reactive to this protein 
in tamarins have been reported in the literature (Martin et al., 2003; Sbardellati et al., 2001).  
The screening was conducted on a 96-well plate coated with 10µg of NS5BΔ23 protein.  The 
scFv library was transcribed and translated in vitro using TNT T7 Quick Coupled 
Transcription/Translation System and pre-adsorbed in a well coated with 10ug of BSA for an 
hour. This step was performed to reduce the amount of non-specific antibodies within the 
translated library mix. The translated scFv library mix was then transferred to the well coated 
with GBV-B NS5BΔ23. After several washes to eliminate non-binding, non-specific scFv 
antibodies, antibody-ribosome-mRNA complexes were dissociated with EDTA, and the mRNA 
purified using RNeasy Mini kit. This protocol is described in detail in Chapter 2.2.17.  
The RNA recovered was then amplified by PCR using the OneStep RT-PCR Kit, as described in 
Chapter 2.2.4.  Specific bands were seen at the correct size (1100bp) confirming scFv 
antibodies had been recovered from the ribosome display screening (Figure 4-1). To 
determine if the number of amplification cycles during this PCR stage was sufficient for the 
efficient amplification of scFv, PCR reactions were performed in triplicate, with an increase in 
the number of amplification cycles. Specific bands were seen at the correct size for all PCR 
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samples, however, the highest number of amplification cycles (40 cycles) led to a reduced 




FIGURE 4-1: AMPLIFICATION OF MRNA ENCODING SCFV RECOVERED AFTER SCREENING OF A SCFV LIBRARY AGAINST GBV-B NS5BΔ23 
USING RIBOSOME DISPLAY 
 
RECOVERED MRNA FROM ONE ROUND OF SCREENING AGAINST GBV-B NS5BΔ23 WAS AMPLIFIED BY PCR IN TRIPLICATE WITH A VARYING 
NUMBER OF AMPLIFICATION CYCLES. PRODUCTS WERE VISUALISED ON A 1% AGAROSE GEL; THE PRODUCTS CORRESPONDING TO THE FUSION OF 
VH AND VL WERE DETECTED AT THE EXPECTED SIZE OF 1100BP. LANE 1: 30 CYCLES, LANE 2: 35 CYCLE, LANE 3: 40 CYCLES. 
 
To confirm that the amplified mRNA coded for scFv sequences, the PCR product from 30 
cycles (Figure 4-1, lane 1) was subcloned into a pGEM-T Easy vector for sequencing (see 
Chapter 2.2.12).  Plasmids derived from 96 single colonies were initially assessed by 
enzymatic restriction using the restriction enzymes NcoI and NotI, which lie at the 5’ and 3’ 
end of each scFv antibody (Chapter 3.3.2).  Of these 96 plasmid preparations, only 20 
contained an insert of the correct size of 1100bp, corresponding to the VH region fused to the 
VL region.  
These 20 plasmids were then sequenced by the Sanger method. Consensus sequences 
obtained from two reactions using a forward and reverse primer were processed using 
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DNADynamo software.   These consensus sequences were then analysed by comparison to a 
database of human antibody (Ig BLAST, Table 4-1). Whilst 11 samples (55% of sequenced 
samples, 11% of all prepared samples) were shown to represent antibody sequences, only 
one scFv (5% of sequenced samples, 1% of all prepared samples) contained a full-length 
sequence corresponding to a complete full-length linker fusing the VL to the VH region. Linker 
length plays a role in the association of the two variable regions in scFv antibodies and as a 
result, the minimum linker length used is generally 15 amino acids (Huston et al., 1988; 
Schaefer et al., 2010). For this reason, the specific binding properties of only two scFv were 


















Top V match Top D match Top J match Number of 
G4S repeats 
CDR3 






VK IGKV1-27*01 - IGKJ1*01 QKYNSVPWT 
NS5BΔ23.4 VH IGHV1-8*01, 
IGHV1-8*02 
IGHD1-26*01 IGHJ4*02 2 ARVVGAHYYFEY 
VK IGKV1-27*01 - IGKJ1*01 QQYYSTWT 
NS5BΔ23.5 VH IGHV1-46*01 IGHD3-3*02, 
IGHD2-15*01, 
IGHD3-10*02 
IGHJ2*01 1 ARGYVSYYWYFDV 
VK IGKV1-39*02 - IGKJ1*01 QYGYRTPYT 
NS5BΔ23.6 VH IGHV1-8*02 IGHD5-12*01 IGHJ2*01 1 ARSGYVRFFDV 
VK IGKV3D-15*01 - IGKJ2*02, 
IGKJ2*01 
QQYNDRPTLT 
NS5BΔ23.7 VH IGHV4-38-2*02 IGHD6-13*01 IGHJ4*03, 
IGHJ4*02 
1 ARWGIRSSWYTIQY 
VK IGKV3D-15*01 - IGKJ4*01 QQYYSTPLT 







VK IGKV6D-41*01 - IGKJ1*01 QQTNYWPLA 
NS5BΔ23.9 VH IGHV1-46*01 IGHD2-15*01, 
IGHD5-12*01, 
IGHD4-23*01 
IGHJ4*03 2 ARDRFSWHYEGYFEF 
VK IGKV3D-15*01 - IGKJ1*01 QQYNNRRT 





IGHJ2*01 2 ARGGNYLRVWYFDV 










VK IGKV1-NL1*01 - IGKJ1*01 QHGYSTPYA 




IGHJ3*02 2 ARVFSNWADAFDI 
VK IGKV6-21*02 - IGKJ2*02, 
IGKJ2*01 
QQSNNWPLT 
NS5BΔ23.20 VH IGHV4-38-2*01 IGHD2-8*01 IGHJ3*02 2 LRWHCTSSHCSPSDA
LDI 




TABLE 4-1: CHARACTERISATION OF SCFV ANTIBODIES RECOVERED AFTER THE SCREENING OF THE SCFV LIBRARY AGAINST GBV-B NS5BΔ23 
PLASMIDS CONTAINING POTENTIAL SCFV WERE ANALYSED BY SANGER SEQUENCING. CONSENSUS SEQUENCES WERE CREATED FROM REACTIONS 
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4.2.2 ONE ROUND OF SCREENING OF THE GBV-B INFECTED TAMARIN-DERIVED ANTIBODY 
LIBRARY AGAINST GBV-B NS5BΔ23 DID NOT PRODUCE ANTI-GBV-B NS5BΔ23-SPECIFIC 
SCFV ANTIBODIES 
 
The two scFv (NS5BΔ23.11 and NS5BΔ23.12) that were isolated from the screening of a GBV-
B infected tamarin-derived antibody library against recombinant GBV-B NS5BΔ23 were 
expressed in a prokaryotic system to allow the investigation of their binding properties.   
Antibody sequences were subcloned into the prokaryotic expression vector, p4D5_Fc 
plasmid, using restriction enzymes NcoI and NotI, as previously described in Markiv et al., 
2011 (Figure 4-2). The vector p4D5 had been modified from pET32b+ through the removal of 
all N-terminal tag sequences, retaining only the C-terminal 6x His-tag in frame with the 
restriction site XhoI, and by the addition of human CH2/CH3 regions inserted into the vector 
using NotI and XhoI (Markiv et al., 2011). ScFv antibodies were designed to have a NcoI site at 
their 5’ end and a NotI site at the 3’ end, which allows the subcloning of scFv antibodies into 
this plasmid, creating a scFv-CH2/CH3/His-tag construct. Human CH2 and CH3 regions from IgG, 
otherwise known as the Fc domain are also in frame after NotI site allowing the fusion to the 
scFv antibody; this endows the scFv antibody with several advantages including an increase in 
the solubility and stability, and the use of the Fc domain as a tag for identification and 
purification of the scFv antibody in downstream applications such as immunohistochemistry 
(Czajkowsky et al., 2012; Liu, 2003; Moutel et al., 2009). Sanger sequencing confirmed the 
correct identity of scFv sequences within the p4D5_Fc vector.  
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FIGURE 4-2: SCHEMATIC REPRESENTATION OF THE VECTOR USED FOR THE EXPRESSION OF THE SCFV IN A PROKARYOTIC HOST (ADAPTED 
FROM MARKIV ET AL., 2011). 
 
 
NS5BΔ23.11 and NS5BΔ23.12 scFv antibody expression was induced in BL21 bacterial cells 
using IPTG (see Chapter 2.3.1). BL21 bacterial cells were chosen as they are routinely used for 
recombinant protein expression under the T7 promoter. Samples pre- and post-induction 
were analysed by SDS-PAGE and Colloidal Blue staining (Figure 4-3). Both NS5BΔ23.11 and 

















FIGURE 4-3: EXPRESSION OF THE SCFV RECOVERED AFTER PANNING AGAINST NS5BΔ23 IN A PROKARYOTIC SYSTEM 
 
NS5BΔ23.11 AND NS5BΔ23.12 SCFV ANTIBODIES WERE PRODUCED IN BL21 CELLS AND THE BACTERIAL CELL LYSATES WERE RUN 
THROUGH A 4-12% SDS-PAGE AND STAINED WITH COLLOIDAL BLUE DYE. UN: NON-INDUCED, IN: INDUCED. EXPECTED SIZE: 55KDA. 
 
The binding specificity of the isolated NS5BΔ23.11 and NS5BΔ23.12 scFv antibodies was then 
explored using an enzyme-linked immunosorbent assay (ELISA, as described in Chapter 2.3.7). 
The assay was performed on a 96-well plate coated with either 1µg/ml of recombinant GBV-B 
NS5BΔ23 protein or bacterial cell lysate from untransformed BL21. Unpurified supernatant 
from induced BL21 containing scFv NS5BΔ23.11 and NS5BΔ23.12 were applied to the plate 
and detected with an human IgG HRP-conjugated antibody, which recognises the Fc domain. 
Neither of the two scFv antibodies isolated bind specifically to recombinant GBV-B NS5BΔ23 
protein as the absorbance values for each scFv antibody were similar for both the NS5BΔ23-




NS5B.11        NS5B.12 
55kDa 




FIGURE 4-4: SCFV ANTIBODIES ISOLATED FROM SCREENING THE SCFV LIBRARY AGAINST NS5BΔ23 DURING RIBOSOME DISPLAY DO NOT 
SPECIFICALLY BIND NS5BΔ23. 
 
BACTERIAL CELL LYSATE CONTAINING TWO UNIQUE SCFV ANTIBODIES WERE USED IN AN ELISA TO ASSESS THEIR BINDING SPECIFICITIES. PLATES 
WERE COATED WITH GBV-B NS5BΔ23 OR UNTRANSFORMED BL21 CELL LYSATE. THE MEAN ABSORBANCE OF TWO REPLICATES, NORMALISED 
TO BLANK WELLS, WERE PLOTTED. BELOW THE GRAPH ARE THE OD VALUES.  
 
 
4.2.3 ISOLATION OF SCFV ANTIBODIES AGAINST GBV-B CORE FROM THE SCREENING OF A 
GBV-B INFECTED TAMARIN-DERIVED ANTIBODY LIBRARY  
 
 
As the isolated anti-GBV-B NS5BΔ23 scFv antibodies did not specifically bind to the target 
protein, the original scFv library was also used to screen against a different recombinant GBV-
B viral protein, the nucleocapsid protein, Core, produced in Chapter 3.2.4. GBV-B core was 
chosen as the target protein as it is the nucleocapsid of the virus and therefore likely to be a 
prominent target for antibodies. Indeed, GBV-B core-specific antibodies have previously been 
more readily identified than GBV-B NS5BΔ23-specific antibodies in vivo (Bukh et al., 2008; 





















Target on plate: 
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Woollard et al., 2008). Additionally, tamarin antibodies targeting GBV-B core were previously 
identified by western blot in Figure 3-3 in Chapter 3.2.3.   
Similar to the panning against GBV-B NS5BΔ23 (Chapter 4.2.1), the library screening was 
performed on a 96-well plate coated with 10µg of recombinant GBV-B core. After in vitro 
transcription and translation of the scFv library using the TNT T7 Quick Coupled 
Transcription/Translation System, the scFv library was adsorbed on a BSA-coated well before 
being transferred to the well coated with GBV-B core.  After several washes ARM complexes 
were then dissociated with EDTA and the mRNA purified using RNeasy Mini kit.  
The RNA recovered was then amplified by PCR using the OneStep RT-PCR Kit. The presence of 
recovered scFv antibody sequences was confirmed by gel electrophoresis (Figure 4-5). 
 
FIGURE 4-5:  AMPLIFICATION OF THE MRNA RECOVERED FROM THE SCREENING OF SCFV LIBRARY AGAINST GBV-B CORE 
 
MRNA PURIFIED FROM THE FIRST ROUND OF PANNING AGAINST GBV-B CORE WAS AMPLIFIED BY 30 CYCLES OF RT-PCR. MRNA SAMPLES 
WERE RUN IN DUPLICATE (LANE 1 AND 2) AND VISUALISED ON A 1% AGAROSE GEL.  EXPECTED SIZE OF PRODUCT: ~1100BP. 
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The identity of recovered scFv sequences was then investigated using Sanger sequencing 
after subcloning into a pGEM-T easy plasmid. From 72 cultures, plasmid preparations were 
analysed by enzymatic restriction using NcoI and NotI enzymes (see Chapter 2.2.11): 29 
cultures contained pGEM T-easy plasmids encoding an insert of the correct size, 1100bp.  
The identity of these 29 scFv antibodies was investigated using Sanger sequencing and then 
analysed using Ig BLAST. Only six scFv antibodies (21% of sequenced samples, 8% of all 
prepared samples) were confirmed to represent antibody sequences that were in frame and 
had unique sequences (Table 4-2A). A further five scFv antibodies (17%) were also confirmed 
to represent antibody sequences; however, these contained early stop codons and shorter 
linkers (Table 4-1B). One of these scFv antibodies (Core.5 in Table 4-2A) was chosen as a 
negative control for downstream expression and characterisation of scFv antibody. These 
seven scFv antibodies (Core.1- Core.7 in Table 4-2A) were then expressed to investigate their 
binding property towards GBV-B core specifically. 
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TABLE 4-2: CHARACTERISATION OF RECOVERED SCFV AFTER ONE ROUND OF RIBOSOME DISPLAY PANNING AGAINST GBV-B CORE PROTEIN 
 
ISOLATED SCFV ANTIBODIES WERE SEQUENCED BY SANGER SEQUENCING AND ANALYSED USING THE IMMUNOGLOBULIN BASIC LOCAL 
ALIGNMENT SEARCH TOOL (IG BLAST) TO FIND THE CLOSEST GENE SEGMENT MATCHES FOR EACH SCFV. IN-FRAME SCFV ARE INCLUDED IN 
TABLE 4-1A WHILST OUT-OF-FRAME SCFV WERE INCLUDED IN TABLE 4-1B. 
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4.2.4 LACK OF SPECIFIC ANTI-GBV-B CORE SCFV ANTIBODIES AFTER ONE ROUND OF 
SCREENING OF THE GBV-B INFECTED TAMARIN-DERIVED ANTIBODY LIBRARY 
 
 
The six in-frame scFv antibodies, and the negative control scFv (Core.5) that was out of frame 
due to an early stop codon in the VL region, isolated from one round of panning of the GBV-B-
infected tamarin-derived antibody library against recombinant GBV-B core, were produced in 
a prokaryotic system and tested for GBV-B core binding specificity. To permit this, scFv were 
cloned into the p4D5_Fc vector using NcoI and NotI restriction enzymes. 
Production of eukaryotic proteins in a bacterial host can potentially impact their solubility 
and functionality as proteins can incorrectly fold in a prokaryotic system (Arbabi-Ghahroudi 
et al., 2005; Vendel et al., 2012). For this reason, different prokaryotic hosts were 
investigated for their scFv antibody production. One of the scFv antibodies, p4D5_Core.3_Fc 
was arbitrarily chosen to setup the conditions for the optimal production of the scFv. Three 
bacterial strains were compared: BL21, SHuffle T7 Express and Rosetta-Gami. Whilst BL21 is 
routinely used for recombinant protein expression under the T7 promoter, SHuffle T7 express 
and Rosetta-Gami strains both have additional advantages for scFv antibody expression. 
Shuffle T7 Express cells have enhanced disulphide bond formation via the expression of the 
isomerase DsbC. The Rosetta-Gami cells also have improved disulphide bond formation 
through the mutation of two reductase genes, but also a better expression of eukaryotic 
proteins due to the expression of rare tRNAs in bacteria. Antibody expression in prokaryotic 
cells was induced using IPTG and samples of bacterial cultures taken before and after 
induction were analysed by SDS-PAGE and subsequent Colloidal Blue staining.  Although the 
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expression levels were very low with all of the bacterial strains, the BL21 strain appears to be 
the best suited to scFv antibody expression of the three strains investigated (Figure 4-6A). 
The remaining six scFv antibodies were expressed in BL21 bacterial cells alongside a positive 
control, the scFv 4D5-8RFP (Markiv et al., 2011), kindly donated by Dr. A. Kang. This scFv 
contains a red fluorescent protein (RFP) gene between the VH and VL sequence thereby 
providing a rapid, visual confirmation of protein expression in bacteria. After IPTG induction, 
antibody expression for each scFv protein was analysed by SDS-PAGE. Unfortunately, Core.1-
7 scFv antibody expression could not be confirmed as no clear induced band was visible for 
any of the scFv antibodies. This is most likely due to low protein expression levels rather than 
the scFv not being induced; indeed, scFv 4D5-8RFP could not be seen by SDS-PAGE, but the 
antibody was induced as indicated by the pink colour of the pelleted, induced bacteria 
culture, which could be seen with naked eye (Figure 4-6B-C). 
To determine whether the expression of the scFv antibodies was lower than the detection 
limit of the Colloidal blue staining, bacterial cell lysates were analysed in a western blot with 
an anti-His tag antibody. Core.2, 3, 4, 6, 7 scFv antibodies and scFv 4D5-8RFP had been 
successfully induced in BL21 cells, whilst the Core.5 scFv antibody had not been expressed as 
expected due to the early stop codon in the scFv antibody sequence. The Core.1 scFv 














FIGURE 4-6: EXPRESSION OF THE ISOLATED ANTI-CORE SCFV ANTIBODIES IN BACTERIAL CELLS 
CELL LYSATES FROM BACTERIAL CULTURES BEFORE AND AFTER IPTG INDUCTION WERE PROCESSED IN A 4-12% SDS-PAGE AND PROTEINS 
VISUALISED BY COLLOIDAL BLUE STAINING. (A) CORE.3 SCFV ANTIBODIES WERE EXPRESSED IN DIFFERENT BACTERIAL CELLS TO DETERMINE THE 
MOST SUITABLE STRAIN. (B)  CORE.1, 2, 4 AND 5 SCFV ANTIBODIES AND (C) CORE.6 AND 7 SCFV ANTIBODIES ALONGSIDE THE POSITIVE 
CONTROL PROTEIN WERE PRODUCED IN BL21 BACTERIAL CELLS. (D) THE LYSATE FROM ALL INDUCED BACTERIAL CELL CULTURES WERE RUN 
THROUGH AN SDS-PAGE, TRANSFERRED TO A NITROCELLULOSE MEMBRANE AND IMMUNOBLOTTED WITH AN ANTI-HIS ANTIBODY. LANE 1-7: 
CORE.1-CORE.7, LANE 8: POSITIVE EXPRESSION CONTROL. 
THE ESTIMATED SIZE OF SCFV ANTIBODY-FC FUSION PROTEINS BASED ON THEIR NUCLEOTIDE SEQUENCES WAS 55KDA AND 76 KDA FOR THE 
POSITIVE CONTROL, USING THE SOFTWARE DNADYNAMO (BLUETRACTORSOFTWARE, UK). 
UN: INDUCED; IN: IPTG INDUCED; IN50: INDUCED SAMPLES DILUTED BY 50% TO ENSURE A CLEAR SCFV ANTIBODY STAINING. 
 
The binding specificity of the bacterial cell lysates containing scFv antibodies was then 
explored by ELISA: 96-well plates were coated overnight with 1µg/ml of recombinant GBV-B 
core or coating buffer alone. ScFv antibodies, Core.2, Core.3, Core.4, Core.6 and Core.7, along 
with the negative control supernatant that contains no expressed recombinant protein 
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(Core.5), were added to the plate and detected with an anti-His HRP-conjugated antibody.  
No specific binding to GBV-B core was observed (Figure 4-7).  
 
 
FIGURE 4-7: LACK OF SPECIFIC BINDING TO GBV-B CORE OF SCFV ANTIBODIES ISOLATED FROM RIBOSOME DISPLAY 
 
SUPERNATANT CONTAINING FIVE UNIQUE SCFV ANTIBODIES WERE RUN IN AN ELISA ALONGSIDE THE NEGATIVE CONTROL UNEXPRESSED 
CORE.5 SCFV ANTIBODY. PLATES WERE COATED WITH EITHER GBV-B CORE (RED) OR WITH JUST THE COATING BUFFER TRIS (BLUE). RESULTS 




4.2.5 EXPRESSION OF SCFV ANTIBODIES IN A MAMMALIAN CELL LINE DID NOT RESCUE 
SPECIFIC BINDING OF THE SCFV TO GBV-B CORE PROTEIN 
 
Whilst the binding of scFv antibodies, Core.2-Core.7, were non-specific if expressed in a 
prokaryotic host, this may be due to improper protein folding in the prokaryotic cell and a 
difference in codon usage (Arbabi-Ghahroudi et al., 2005). It has been previously 
documented that bacterial scFv antibody expression can lead to the improper folding of scFv 
antibodies which impacts their functionality and specificity (Vendel et al., 2012). ScFv were 
therefore expressed in a mammalian cell line to determine if their lack of specific binding 
Core.2 Core.3 Core.4 Core.5 Core.6 Core.7
Tris 0.25 0.65 1.10 0.06 2.39 1.36
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properties was due to improper protein folding. 
All seven scFv antibodies were subcloned into the eukaryotic expression plasmid 
pSF_CMV_NH2_InsulinSP1 (pSF) using the restriction enzymes NcoI and XhoI (Figure 4-8). 
These enzymes were used as this allowed the transfer of both the scFv antibody gene and the 
Fc receptor. This plasmid adds a secretory signal peptide to the N-terminus of the protein of 
choice allowing scFv secretion into the cell culture supernatant thereby simplifying scFv 
purification. The vector had been previously modified through the addition of annealed 
oligonucleotides to encode a 6x His tag and stop codon at the C-terminus of the protein of 
choice for downstream identification and purification. Sanger sequencing confirmed that 
most of the scFv had been successfully subcloned into the pSF plasmid, however, the 











FIGURE 4-8: SCHEMATIC REPRESENTATION OF THE VECTOR USED FOR THE EXPRESSION OF THE SCFV IN A EUKARYOTIC HOST 
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To express scFv in mammalian cells, pSF_scFv_Fc plasmids were transfected into HEK 293T 
cells using the transfection reagent XtremeGeneHP (as described in Chapter 2.4.5). As a 
negative control, 293T cells were treated with the XtremeGeneHP alone. Cell culture 
supernatant was collected, purified and concentrated using a Ni-NTA Spin Kit (as described in 
Chapter 2.3.4). To confirm that scFv antibodies were indeed present in the purified, 
concentrated supernatant, supernatant was analysed by western blot with an anti-His 
antibody. This western blot confirmed that scFv antibodies had been expressed, albeit at a 








FIGURE 4-9: SCFV-FC PROTEINS, ISOLATED FROM RIBOSOME DISPLAY, CAN BE EXPRESSED AND SECRETED FROM HEK 293T CELLS 
SCFV-FC-TRANSFECTED HEK 293T CELL CULTURE SUPERNATANT WAS RUN ON A 4-12% SDS-PAGE, THE PROTEINS TRANSFERRED TO A 
NITROCELLULOSE MEMBRANE AND DETECTED WITH AN ANTI-HIS TAG ANTIBODY. UN: UNTRANSFECTED 293T CELL SUPERNATANT. EXPECTED 
SIZE OF SCFV: 55KDA. 
 
Cell culture supernatant was then tested by ELISA to confirm the binding properties of the 
scFv. A 96-well plate was coated overnight with 1µg/ml of either recombinant GBV-B core 
protein or recombinant His-tagged HIV-1 p24 protein as a negative control (Centre for AIDS 
reagents, NIBSC). Cell culture supernatant containing the six scFv or the negative control cell 
culture supernatant was added and detected with both an anti-His tag or an anti-human IgG 
HRP-conjugated antibody. In both cases, no binding of scFv to either GBV-B core or the His-
tagged p24 was seen (OD values <0.1).  
~55kDa 
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4.2.7 A SMALLER PROPORTION OF SCFV ANTIBODIES ARE ISOLATED AFTER THREE ROUNDS OF 
PANNING AGAINST GBV-B CORE 
 
 
As non-specific scFv antibodies have been isolated from one round of screening of the GBV-B 
infected tamarin-derived antibody library against GBV-B antigens, ribosome display was 
repeated with three rounds of screening, as it is well documented that antigen-specific scFv 
antibody populations within scFv libraries can be enriched by a factor of 100-1000 after each 
round of ribosome display (J Hanes et al., 1998; Hanes and Plückthun, 1997).  
To further screen the scFv antibody library, the recovered cDNA amplified in Chapter 4.2.3 
was elongated to reconstitute the 3’ end of the spacer of the scFv antibodies, which was lost 
in the ARM complex attached to the ribosome. After the elongation of the scFv by PCR, the 
scFv library is then purified and used as the input library for another round of screening 
against recombinant GBV-B core protein using ribosome display.  
For each round of screening against recombinant GBV-B core protein, the intensity of the 
band representing amplified, recovered scFv sequences decreased and non-specific bands 
were also present suggesting either a poor amplification of recovered mRNA or a decrease in 
the input mRNA through the loss of non-specific scFv sequences (Figure 4-10A, B and C).  To 
increase the efficiency of the mRNA amplification of the recovered scFv library, input mRNA 
was diluted 50 times which gave a stronger signal (Figure 4-10D, lane 3-4). To further 
optimise the recovery PCRs, a range of annealing temperatures were also evaluated (Figure 
4-10E), showing that an annealing temperature of 62°C produced the most intense band, 
although without increase in specificity (Figure 4-10E, lane 4).   
 
 




FIGURE 4-10: DIFFERENT EFFICIENCIES OF AMPLIFICATION OF RECOVERED MRNA AFTER 3 ROUNDS OF SCREENING OF GBV-B ANTIBODY 
LIBRARY AGAINST GBV-B CORE. 
 
MRNA WAS RECOVERED FROM THE SCREENING OF THE SCFV ANTIBODY LIBRARY AGAINST GBV-B CORE AND AMPLIFIED USING A ONESTEP 
RT-PCR KIT. THESE TRUNCATED PCR PRODUCTS, REPRESENTING SCFV ANTIBODY GENES, WERE VISUALISED ON A 1% AGAROSE GEL. PCR 
PRODUCTS, CONSISTING OF RECOVERED SCFV AFTER ONE ROUND (A), TWO ROUNDS (B) AND THREE ROUNDS (C), OF PANNING. ALL PCR 
REACTIONS WERE RUN IN DUPLICATE (LANES 1 AND 2 FOR EACH GEL, RESPECTIVELY). D) DUPLICATES OF RT-PCRS WERE PERFORMED WITH 
EITHER NEAT, RECOVERED MRNA (LANES 1 AND 2) OR A 1:50 DILUTION OF MRNA (LANES 3 AND 4). E) USING A 1:50 DILUTION OF INPUT 
MRNA, THE RT-PCR WAS CONDUCTED WITH A RANGE OF DIFFERENT ANNEALING TEMPERATURES: 54°C, 58°C, 60°C, 62°C AND 64°C 
(LANES 1-5 RESPECTIVELY). 
 
The PCR product from the third round of screening against GBV-B core was subcloned into 
the pGEM T-easy vector for downstream sequencing.  Plasmids from 96 overnight cultures 
were isolated and analysed by enzymatic digestion using the restriction enzymes NcoI and 
NotI; only four (4%) were possible scFv antibodies, represented by an insert size of 
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approximately 1100bp. This recovery rate is much lower than that seen after the first round 
of screening (30%), and could suggest enrichment of antigen-specific scFv antibodies and 
therefore less scFv diversity.  
 These four plasmids were sequenced using Sanger technology and analysed using Ig BLAST 
(Table 4-3). All four sequences were in-frame antibody sequences, although scFv.27 and 
scFv.59 could potentially be the same scFv sequence as both scFv have very similar 
sequences. Additionally, scFv.65 appeared to have a truncated VL region which lacked a CDR3 
sequence. This type of sequence, a variable region lacking a CDR3 paired with an in-frame 
constant region, has been reported previously by a laboratory in China (GenBank: 
AAS88328.1). For this reason, the binding properties of all four scFv sequences was explored. 
 
 
TABLE 4-3: CHARACTERISATION OF SCFV SEQUENCES ISOLATED FROM THREE ROUNDS OF SCREENING OF AN ANTIBODY LIBRARY AGAINST 
GBV-B CORE PROTEIN 
 
FOUR SCFV RECOVERED FROM THREE ROUNDS OF PANNING AGAINST GBV-B CORE PROTEIN USING RIBOSOME DISPLAY WERE SEQUENCED BY 


















- IGKJ4*01 QQYYSTPLT 
scFv.27 VH IGHV4-38-2*01, 
IGHV4-38-2*02 
IGHD1-26*01 IGHJ2*01 4 ARSGSGSFYWYFD
V 
VK IGKV3D-7*01 - IGKJ1*01 QHGSHTPPWT 
scFv.59 VH IGHV4-38-2*01, 
IGHV4-38-2*02 
IGHD1-26*01 IGHJ2*01 4 ARSGSGSFYWYFD
V 
VK IGKV3D-7*01 - IGKJ1*01 QHGSHTPPWT 








- - - 
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4.2.8 THE SCFV ANTIBODIES RECOVERED FROM THREE ROUNDS OF PANNING USING 
RIBOSOME DISPLAY ARE GBV-B CORE-SPECIFIC 
 
The four scFv antibodies recovered from three rounds of panning against GBV-B core were 
then expressed in a prokaryotic system to investigate their binding specificities. The antibody 
sequences were first cloned into the expression plasmid, p4D5_Fc, which contains the human 
Fc receptor, using the restriction enzymes NcoI and NotI (Figure 4-2).  
Expression of scFv.13, scFv.27, scFv59 and scFv.65 was induced using IPTG and protein 
production confirmed by SDS-PAGE (Figure 4-11A) and western blot analysis using an anti-His 
antibody (Figure 4-11B). 
 
  
FIGURE 4-11: EXPRESSION AND ISOLATION OF SCFV_FC RECOVERED FROM THREE ROUNDS OF RIBOSOME DISPLAY USING GBV-B CORE 
PROTEIN IN BACTERIAL CELLS 
 
(A) BL21 BACTERIAL CELL LYSATE BEFORE AND AFTER IPTG INDUCTION WERE RUN BY SDS-PAGE AND PROTEINS WERE STAINED WITH 
COLLOIDAL BLUE DYE. UN: NON-INDUCED, IN: IPTG INDUCED. (B) INDUCED BACTERIAL CULTURES BY LYSED AND RUN ON A SEPARATE SDS-
PAGE. PROTEINS WERE TRANSFERRED TO A NITROCELLULOSE MEMBRANE AND DETECTED WITH AN ANTI-HIS ANTIBODY. ESTIMATED SIZE OF 
SCFV_FC: 55KDA, USING DNADYNAMO SOFTWARE (BLUETRACTORSOFTWARE, UK).  
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Binding specificity of each scFv antibody was investigated by ELISA using GBV-B core protein 
as target or His-tagged HIV-1 p24 protein, as negative control. Bacterial lysate samples, 
containing isolated scFv.13, scFv.27, scFv.59 and scFv.65, were added to the plate and 
subsequently detected with an anti-His HRP-conjugated antibody. All scFv antibodies were 
able to bind to specifically to GBV-B core protein (Figure 4-12A). ScFv.65, which has a 
truncated VL region, showed binding specificity to GBV-B core but with higher background 
than the other scFvs.  Specificity of the antibodies was also confirmed by serial dilutions of 





scFv 13 scFv 27 scFv 59 scFv 65
core 1.07 1.27 1.06 1.30



























FIGURE 4-12: GBV-B CORE-SPECIFIC SCFV ANTIBODIES ISOLATED AFTER THREE ROUNDS OF PANNING AGAINST GBV-B CORE LOSE THEIR 
BINDING SPECIFICITY IF DILUTED FOUR-FOLD 
 
A: CELL LYSATE SUPERNATANT CONTAINING SCFV ANTIBODIES WERE RUN IN AN ELISA. PLATES WERE COATED WITH EITHER GBV-B CORE 
(RED) OR WITH HIS-TAGGED HIV-1 P24 (BLUE). RESULTS REPRESENT THE MEAN ABSORBANCE VALUE OF TWO REPLICATES, NORMALISED TO 
THE VALUES FROM WELLS ANTI-HIS ANTIBODY ALONE. THE OD VALUES ARE PROVIDED BELOW THE CHART. THIS ASSAY WAS REPEATED THREE 
TIMES IN TOTAL, THE RANGE OF ABSORBANCE VALUES IS REPRESENTED ON THE GRAPH BY ERROR BARS.  
B: THE BINDING SPECIFICITY OF BACTERIAL CELL LYSATES, CONTAINING SCFV.13 (ORANGE), SCFV.27 (BEIGE), SCFV.59 (RED) AND SCFV.65 
(YELLOW), WERE EVALUATED BY ELISA. PLATES WERE COATED WITH EITHER GBV-B CORE PROTEIN OR HIS-TAGGED HIV-P24 AND THE MEAN 
ABSORBANCE VALUE OF TRIPLICATES, NORMALISED VALUES FROM WELLS CONTAINING EACH PROTEIN WITH THE ANTI-HIS ANTIBODY ALONE ARE 
SHOWN. THE OD VALUES ARE PROVIDED BELOW THE CHART. THIS ASSAY WAS REPEATED THREE TIMES IN TOTAL, THE RANGE OF ABSORBANCE 





1 2 4 8
scFv 13 1.04 0.31 0.09 0.09
scFv 27 1.32 0.41 0.11 0.09
scFv 59 1.13 0.46 0.06 0.06



















scFv 13 scFv 27 scFv 59 scFv 65
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4.2.10 DEEP SEQUENCING OF COMPLEMENTARITY DETERMINING REGION 3 (CDR3) OF 
SCFV ANTIBODIES LIBRARIES BEFORE AND AFTER PANNING AGAINST GBV-B CORE PROTEIN 
SHOWS A WEAK SELECTION OF SCFV AGAINST GBV-B CORE 
 
Within each variable region of an antibody, there are three highly conserved framework 
regions (FR) and three highly variable complementarity determining regions (CDR) (Sela-
Culang et al., 2013). The CDR regions are thought to be involved in antigen recognition whilst 
the FR regions are considered to primarily act as a scaffold for CDRs. In particular, it is 
thought that the diversity of antigen specificity of antibodies is largely due to the third CDR 
(CDR3) of the heavy chain variable region (Xu and Davis, 2000). Consequently, to investigate 
the diversity of the scFv libraries before and after panning against GBV-B core protein, the 
CDR3 regions of scFv libraries were deep sequenced with the aim to visualise the selection of 
core-specific scFv. 
4.2.10.1 DESIGN OF PRIMERS FOR THE AMPLIFICATION OF TAMARIN CDR3 REGIONS 
 
To perform the deep sequencing of the scFv libraries, the CDR3 within the tamarin variable 
regions were amplified (see Chapter 2.2.4). As the sequence of tamarin CDR3 are unknown, 
the PCR products of the variable regions of tamarin antibodies used to construct the initial 
scFv library in Chapter 3.3.1 were sequenced by Sanger sequencing to allow the design of 
primers. Four different variable regions for each family from both the heavy chain and light 
chain were sequenced (32 sequences in total). Each sequence was analysed by comparing the 
sequence to the database of human antibodies using the Ig BLAST tool, and the FR and CDR 
identified. To design primers to amplify the CDR3 regions, all sequences were aligned and a 
consensus sequence of the sequences before the CDR3 regions was obtained. The sequences 
used to design the primers are provided in Table 4-4 below. Using this information, four 
degenerate primers were designed for both the CDR3 of the heavy chain and the light chain 
due to the diversity within the different variable region families.  

















TABLE 4-4: AMINO ACID SEQUENCES IMMEDIATELY BEFORE TAMARIN CDR3 SEQUENCES ARE SIMILAR TO THEIR HUMAN COUNTERPARTS 
 
TAMARIN VARIABLE REGIONS, CLONED IN CHAPTER 3.3.1, WERE SEQUENCED BY SANGER SEQUENCING AND ANALYSED USING DNA DYNAMO 
SOFTWARE (BLUE TRACTOR SOFTWARE) AND IGBLAST. IGBLAST SUCCESSFULLY IDENTIFIED THE CDR3 SEQUENCE FOR EACH VARIABLE 
REGION. THE NUCLEOTIDE AND AMINO ACID SEQUENCES IMMEDIATELY BEFORE THE IDENTIFIED CDR3 REGIONS ARE SHOWN IN THE TABLE 
ABOVE FOR EACH FAMILY OF VARIABLE REGIONS (VH=HEAVY CHAIN, VK=LIGHT CHAIN), WITH THE CONSERVED AMINO ACID KNOWN TO BE IN 
HUMAN SEQUENCES ARE HIGHLIGHTED IN BOLD. FOUR VARIABLE REGIONS FROM EACH FAMILY WERE INVESTIGATED TO ACCOUNT FOR 
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From the IgBLAST analysis of tamarin variable region, all of the sequences appeared to follow 
similar patterns to human variable region sequences (see table 7-6). For example, it was seen 
that immediately before the heavy chain CDR3 region, a consensus amino acid sequence is 
seen, C-X-X (e.g. C-A-R was seen in 56% of sequences analysed).   
 
 4.2.10.2 AMPLIFICATION OF TAMARIN CDR3 REGIONS 
 
 
To investigate the enrichment of scFv antibodies within scFv libraries before and after 
panning against GBV-B core antigen, CDR3 regions from each library were deep sequenced to 
investigate their diversity, as described in Chapter 2.2.15.  CDR3 regions from both the heavy 
chain and light chain of scFvs from each library, before and after each of the 3 rounds of 
panning, were separately amplified by PCR using a high-fidelity polymerase enzyme: library 1 
represents the input scFv library, pre-panning, library 2 is the recovered antibodies sequences 
after the first round of panning and so on. Each PCR was performed in duplicate as biological 
replicates. Specific bands were seen at the correct size of approximately 200bp; the CDR3 
regions amplified from the light chain variable regions (VK) appear to be slightly smaller at 
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FIGURE 4-13: AMPLIFICATION OF CDR3 REGIONS FROM SCFV LIBRARIES BEFORE AND AFTER PANNING AGAINST GBV-B CORE PROTEIN 
 
THE CDR3 REGIONS OF SCFV WITHIN THE GBV-B INFECTED TAMARIN-DERIVED ANTIBODY LIBRARIES, BEFORE AND AFTER EACH ROUND OF 
PANNING AGAINST GBV-B CORE (LIBRARY 1-4), WERE AMPLIFIED BY PCR AND VISUALISED IN A 3% AGAROSE GEL.  (A) THE CDR3 REGIONS 
AMPLIFIED FROM THE NAÏVE SCFV LIBRARY (LIBRARY 1), THE SCFV LIBRARY RECOVERED AFTER ONE ROUND OF PANNING (LIBRARY 2) AND THE 
SCFV LIBRARY RECOVERED AFTER TWO ROUNDS OF PANNING. (B) THE CDR3 REGIONS AMPLIFIED FROM THE SCFV LIBRARY RECOVERED AFTER 
THREE ROUNDS OF PANNING. VH: CDR3 AMPLIFIED FROM VARIABLE REGION FROM HEAVY CHAIN OF ANTIBODY. VK: CDR3 REGION 
AMPLIFIED FROM VARIABLE REGION FROM LIGHT CHAIN OF ANTIBODY. ALL PCRS WERE PERFORMED IN DUPLICATE (FOR EXAMPLE, VH1.1 AND 
VH1.2). 
 
4.2.10.3 DEEP SEQUENCING OF CDR3 REGIONS OF SCFV ANTIBODIES WITHIN SCFV 
ANTIBODY LIBRARIES BEFORE AND AFTER GBV-B ANTIGEN PANNING  
 
 
The purified PCR products were processed using the NexTera XT kit (Illumina) and sequenced 
on a Miseq platform. The raw data files were analysed using the Antibody Mining Toolbox, 
developed by D’Angelo and colleagues (D’Angelo et al., 2013) as described in Chapter 2.2.16. 
The software recognises conserved amino acid sequences immediately before and after 
human CDR3 regions. The same settings were used to analyse the data retrieved for the 
tamarin antibodies sequences as they share similar conserved amino acids.  
For each library, the number of unique CDR3 sequences for the heavy chain and light chain 
were analysed separately. If ribosome display was successful, the complexity of the library at 
each stage should decrease as the library should be enriched in GBV-B core-specific 
antibodies. The number of unique sequences in each library were separated into categories 
ranging from 1-5 repeats to 64,001-128,000 repeats). A very limited level of selection against 
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GBV-B core took place, as visually seen by lack of difference between each round of selection 
(Figure 4-14); for the heavy chain CDR3 sequences, there is a minor enrichment of CDR3 
sequences (as seen by the appearance of the 16,001-32,000 repeats category). However, the 
complexity of the scFv libraries is not decreasing. A similar minor enrichment of CDR3 is also 
















FIGURE 4-14: THE DIVERSITY OF SCFV LIBRARIES, AS REPRESENTED BY NUMBER OF UNIQUE CDR3 SEQUENCES, MINIMALLY DECREASES 
AFTER EACH ROUND OF SCREENING AGAINST GBV-B CORE PROTEIN 
 
CDR3 REGIONS WERE DEEP SEQUENCED USING THE MISEQ PLATFORM AND SUBSEQUENTLY ANALYSED USING THE ‘CDR3-PIPELINE’ IN THE 
ANTIBODY MINING TOOLBOX. THE AMINO ACID SEQUENCES OF CDR3 REGIONS WERE CATEGORISED BY THE NUMBER OF OCCURRENCES FOR 
EACH SCFV LIBRARY INTO 10 CATEGORIES FOR THE HEAVY CHAIN AND 11 CATEGORIES FOR THE LIGHT CHAIN. EACH BARREL REPRESENTS THE 
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To further analyse the minor enrichment of CDR3 regions within scFv libraries, the most 
highly repeated CDR3 sequences for all scFv libraries, for both the heavy and light chain, were 
investigated. These sequences were tracked through all four scFv libraries to see whether 
they were positive selected after each round of panning against GBV-B core protein using 
ribosome display. The percentage of each CDR3 sequence in relation to the entire CDR3 
sequenced population was calculated and visualised in a stacked line graph (Figure 4-15 and 
Figure 4-16).  
For heavy chain CDR3 sequences, there was a minor enrichment seen within the population 
investigated. For example, the number of CDR3 regions with the amino acid sequence 
CAEADGLTW in relation to the whole sequenced CDR3 population increased by around 0.8% 
over the course of 3 rounds of panning against GBV-B core. The highest enrichment of a 
specific heavy chain CDR3 (CARLYGLDLW ) only resulted in an increase of around 1.2% in 
relation to the entire sequenced CDR3 population (Figure 4-15A). As only a minor enrichment 
is seen, the disappearance of non-specific CDR3 sequences was difficult to track, with only 
one CDR3 sequence (of the sequences investigated) decreased in the number of occurences ( 
Figure 4-15C). Most CDR3 sequence occurences appeared to remain stable throughout 
ribosome display suggesting no enrichment of these CDR3 regions and possibly no 
enrichment of GBV-B core-specific scFv throughout ribosome display (Figure 4-15B).  
In comparison to the heavy chain CDR3 sequences, the enrichment of CDR3 of the light chain 
populations appeared to be even lower as most CDR3 sequences showed no enrichment 
(Figure 4-16B). A minor enrichment was seen for two similar, specific CDR3 sequences, 
CQHGYSTPYTF and CQHGYSTPWTF (Figure 4-16A) whilst three CDR3 sequences appeared to 
decrease in the number of occurrences (Figure 4-16C).    
 
 




FIGURE 4-15: VARIATION IN THE PROPORTION OF THE MOST ABUNDANT HEAVY CHAIN VARIABLE REGION CDR3 SEQUENCES AFTER EACH 
ROUND OF SCREENING AGAINST GBV-B CORE PROTEIN USING RIBOSOME DISPLAY 
 
HEAVY CHAIN VARIABLE REGION CDR3 SEQUENCES WERE SEQUENCED ON THE MISEQ SEQUENCING PLATFORM AND ANALYSED USING THE 
ANTIBODY MINING TOOL. THE ENRICHMENT OF THE TEN SCFV WITH THE HIGHEST NUMBER OF OCCURRENCES FOR EACH SCFV LIBRARY 
(BEFORE AND AFTER PANNING) WAS INVESTIGATED BY CALCULATING THE PERCENTAGE OF EACH SCFV IN RELATION TO THE ENTIRE SCFV 
LIBRARY. THESE FIGURES WERE VISUALISED ON A STACKED LINE GRAPH TO SHOW THE EVOLUTION OF CDR3 ENRICHMENT THROUGHOUT 
RIBOSOME DISPLAY.  THREE TYPES OF ENRICHMENT WERE SEEN: A POSITIVE ENRICHMENT OF CORE-SPECIFIC SCFV (A), NO ENRICHMENT (B) 
AND A DECREASE IN ENRICHMENT (C).  
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FIGURE 4-16: VARIATION IN THE PROPORTION OF THE MOST ABUNDANT LIGHT CHAIN VARIABLE REGION CDR3 SEQUENCES AFTER EACH 
ROUND OF SCREENING AGAINST GBV-B CORE PROTEIN USING RIBOSOME DISPLAY 
 
LIGHT CHAIN VARIABLE REGION CDR3 SEQUENCES WERE SEQUENCED ON THE MISEQ SEQUENCING PLATFORM AND ANALYSED USING THE 
ANTIBODY MINING TOOL. THE TOTAL PERCENTAGE OF THE TEN SCFV WITH THE HIGHEST NUMBER OF OCCURRENCES FOR EACH SCFV LIBRARY 
(BEFORE AND AFTER PANNING) IN COMPARISON TO ALL CDR3 SEQUENCES FOR EACH LIBRARY WERE CALCULATED. THESE FIGURES WERE 
VISUALISED ON A STACKED LINE GRAPH TO SHOW THE EVOLUTION OF CDR3 ENRICHMENT THROUGH RIBOSOME DISPLAY.  THREE TYPES OF 
ENRICHMENT WERE SEEN: A POSITIVE ENRICHMENT OF CORE-SPECIFIC SCFV (A), NO ENRICHMENT (B) AND A NEGATIVE ENRICHMENT (C). 
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GBV-B core-specific murine monoclonal antibodies were also produced using the traditional 
hybridoma technology (see Chapter 2.4.2). Despite the lack of novelty in using this system, it 
has been proven to be a reliable and consistent method to obtain monoclonal antibodies.  An 
overview of the immunisation schedule and generation of single clone anti GBV-B core 




FIGURE 4-17: TIMELINE FOR THE PRODUCTION OF MONOCLONAL ANTIBODIES TARGETING GBV-B CORE 
 
TWO MICE WERE IMMUNISED AT DAY 1 WITH GBV-B CORE PROTEIN AND SIGMA ADJUVANT.  BOOSTS TOOK PLACE AT DAY 28 AND 56. MICE 
WERE TERMINATED AT DAY 59 AND SPLEENS WERE HARVESTED. SPLENOCYTES WERE COLLECTED AND FUSED WITH MYELOMA CELLS. AFTER A 
GROWTH PERIOD OF AROUND THREE WEEKS, CULTURE SUPERNATANT WAS SCREENED TO TEST FOR HYBRIDOMAS SECRETING MONOCLONAL 
ANTIBODIES TARGETING GBV-B CORE. POSITIVE CULTURES WERE THEN CLONED BY SINGLE CELL TITRATION BEFORE RE-SCREENING CULTURE 
SUPERNATANT. AT THE END OF THIS PROCESS, BULK SUPERNATANT WAS COLLECTED AND STORED WHILST ANY GBV-B CORE-SPECIFIC CLONED 
HYBRIDOMA CELLS WERE FROZEN FOR STORAGE.  
 
Mice were first immunised with 20µg of His-tagged recombinant GBV-B core protein, 
generated in a prokaryotic system in Chapter 3.2.4, mixed with Sigma adjuvant (as described 
179 | P a g e  
 
in Chapter 2.4.2). This immunisation was repeated a further two times to increase the 
antibody response. After the third immunisation at approximately two months, spleen cells 
were collected and fused to murine myeloma cells, NS-0, using polyethylene glycol (PEG). 
Cells were then seeded in 96-well plates in selection culture medium, containing 
hypoxanthine-aminopterin-thymidine (HAT) that allows only fused cells to grow.  
After 3 weeks, the supernatant from each culture was tested for the presence of GBV-B core-
specific monoclonal antibodies by ELISA. Plates were coated with 1µg/ml of GBV-B core 
protein or His-tagged HIV-1 p24 protein, as negative control. Out of 576 cultures tested, 43 
























FIGURE 4-18: SCREENING OF THE HYBRIDOMAS PRODUCING GBV-B CORE-SPECIFIC MONOCLONAL ANTIBODIES 
 
HYBRIDOMA CELL CULTURE SUPERNATANT, CONTAINING SECRETED ANTIBODIES, WAS TESTED BY ELISA. PLATES WERE COATED WITH EITHER 
GBV-B CORE (RED) OR WITH HIV-P 24 (BLUE).  OF THE 576 CULTURES TESTED, ONLY THE ONES PRODUCING AN OD ABOVE BACKGROUND 

























































HIV-1 P24-His GBV-B Core-His
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The 12 colonies that produced monoclonal antibodies with the highest absorbance values 
from the initial screening were cloned by serial dilution to ensure that the hybridomas culture 
only contain one type of cell producing anti-GBV-B core antibodies. Only seven hybridoma 
cultures continued to proliferate and secrete GBV-B core-specific monoclonal antibodies once 
tested by ELISA (Figure 4-19). 
 
 
FIGURE 4-19: SPECIFIC BINDING TO GBV-B CORE OF THE 7 MONOCLONAL ANTIBODIES PRODUCED BY SINGLE CLONED HYBRIDOMAS 
 
SUPERNATANT WAS COLLECTED FROM SINGLE HYBRIDOMA CELL CLONES AND TESTED BY ELISA TO DETERMINE THE SPECIFICITY OF THE 
MONOCLONAL ANTIBODIES WITHIN THE CULTURE SUPERNATANT. THIS GRAPH ONLY SHOWS THE SINGLE CELL CULTURE SUPERNATANTS THAT 
TESTED POSITIVE FOR MONOCLONALS THAT TARGET GBV-B CORE (RED). HIV-1 P24 (BLUE) WAS USED AS NEGATIVE CONTROL. RESULTS 
REPRESENT THE MEAN ABSORBANCE VALUES OF DUPLICATED WELLS, NORMALISED TO BLANK WELLS.   
 
4.2.12 CHARACTERISATION OF GBV-B CORE-SPECIFIC MONOCLONAL ANTIBODIES 
 
 
GBV-B core-specific monoclonal antibodies were collected from cell culture supernatant of 
expanded hybridoma cell lines, and purified by ammonium sulphate purification. Purification 
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supernatant by altering the solubility of the antibodies (Duong-Ly and Gabelli, 2014). This 
method also allows the concentration of samples as antibodies can be resuspended in a much 
smaller final volume.  
Once purified and concentrated, the concentration of monoclonal antibodies in each sample 
was quantified using the Mouse IgG total ELISA Ready-SET-Go! Kit. Antibody concentrations 
are summarised in Table 4-5.  One monoclonal antibody, 4E8 was negative in this ELISA.  
The monoclonal antibodies were also isotyped using the Mouse Monoclonal Antibody 
Isotyping Test Kit (Biorad, see Chapter 2.3.6). Most of the antibodies were IgG1, with only 
one IgG2a. All of the light chains were Kappa chain (Table 4-5).  Isotyping revealed that the 
monoclonal antibody, 4E8, consisted of IgM antibodies, explaining the negative result of the 
quantification ELISA as this ELISA only detects IgG antibodies. Due to time restrictions and the 
fact that IgM antibodies are generally low affinity antibodies produced first during infection, 
the study of this antibody was not continued (Racine and Winslow, 2009). 
 
 Hybridoma Concentration (µg/ml) Isotype Light chain 
1A1.1 432 G1 Kappa 
1A1.2 1233 G1 Kappa 
1B5.7 128 G2a Kappa 
1F4.2 184 G1 Kappa 
1F4.5 79 G1 Kappa 
3D9.2 503 G1 Kappa 
4E8.2 0 M Kappa 
 
 
TABLE 4-5: CHARACTERISATION OF PURIFIED GBV-B CORE-SPECIFIC MONOCLONAL ANTIBODY SAMPLES 
 
 
To further confirm the core-specificity of the monoclonal antibodies produced, western blots 
were performed. For each blot, 50ng of either GBV-B core and HIV-1 P24 protein was run on 
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agarose gel and transferred onto a nitrocellulose membrane. These membranes were blotted 
with each monoclonal antibody sample (Figure 4-20). All but one sample were shown to 
recognise GBV-B core, whilst no antibodies were shown to recognise the P24 protein. 
However, as GBV-B core has been denatured during the process of western blotting, this 
indicates that the monoclonal antibody 1A1.1 may recognise only conformational epitopes 
within GBV-B core.  
 
 
FIGURE 4-20: GBV-B CORE-SPECIFIC MONOCLONAL ANTIBODIES CAN RECOGNISE DENATURED LINEAR EPITOPES WITHIN RECOMBINANT 
GBV-B CORE 
 
HIV-1 P24 (LANE 1) AND GBV-B CORE (LANE 2) WERE RUN ON AN SDS-PAGE AND TRANSFERRED TO A NITROCELLULOSE MEMBRANE. THIS 
MEMBRANE WAS THEN PROBED WITH 10µG/ML OF MONOCLONAL ANTIBODIES: 1A1.1, 1A1.2, 1B5.7, 1F4.2, 1F4.5 AND 3D9.2. 









Antibodies have been produced as reagents for the study of GBV-B infection of tamarins as 
an animal model of acute HCV infection. Two different approaches have been used, the 
classical hybridoma technology and the screening of a tamarin antibody library by ribosome 
display. Although hybridoma technology is simple and reliable, in vitro display technologies, 
including ribosome display, offer multiple benefits in comparison to this technology. These 
benefits include a greater level of control over the nature of isolated antibodies, through the 
careful control of selection and screening conditions, and the high throughput nature of the 
technologies, which allows for the isolation of huge numbers of antibodies in a short space of 
time (Bradbury et al., 2011). For these reasons, ribosome display was first used to isolate 
GBV-B specific antibodies. 
The tamarin scFv library produced in the previous Chapter (Chapter 3.3.2) was screened 
against two GBV-B proteins, NS5BΔ23 and core (as described in Chapter 2.2.17). GBV-B 
NS5BΔ23 was first chosen as the target antigen for ribosome display, as its production had 
been confirmed by both western blot and mass spectrometry (Figure 3-4, Table 7-1). GBV-B 
core was later chosen as tamarin sera was shown to contain antibodies that recognised this 
protein.  
Initially, only one round of selection was performed, as it has been previously shown that this 
could be sufficient for the selection of specific antibodies (Tang et al., 2012).  However, for 
both proteins, although scFv were isolated, they were either non-specific or non-functional 
(Figures 4-4 and 4-7).  Changing the host for the expression of the scFv from prokaryotic to 
mammalian cells did not improve the functionality of the antibodies isolated (Figure 4-9). Of 
note, full-length scFv antibodies were isolated from the GBV-B-infected tamarin-derived 
antibody library more readily after screening against GBV-B core protein (Table 4-2 and 4-3) 
in comparison to GBV-B NS5BΔ23 protein (Table 4-1), which could support the hypothesis 
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that antibodies targeting GBV-B core are produced at a higher level in tamarins in vivo in 
comparison to antibodies targeting NS5BΔ23. Indeed, NS5B antibodies are less regularly 
documented in the literature, in comparison to core antibodies (Bukh et al., 2008; Iwasaki et 
al., 2011; Martin et al., 2003; Woollard et al., 2008). Of note, the scFv antibodies isolated 
after screening against GBV-B core (Figure 4-7) were much more difficult to express in 
comparison to those isolated from screening against GBV-B NS5BΔ23 (Figure 4-3).  
Following other examples in the literature (Hanes et al., 1998; Yuan et al., 2009; Zhao et al., 
2009b), the tamarin scFv library was screened three consecutive times against GBV-B core 
protein. This led to the successful isolation of four GBV-B core-specific scFv (Figure 4-12A). 
Two of these antibodies appear to be of the same sequences and showed similar binding 
property.  Additionally, one of the other two antibodies had a truncated VL region and a very 
short linker, which could impact its ability to bind to GBV-B core. A previous study suggested 
that a linker this length may inhibit VH and VL pairing, thereby inducing dimer formation 
(Kortt et al., 1997). These dimers may account for the high OD values in ELISAs with this scFv 
(Figure 4-12A). Further characterisation of these scFv should include large-scale production 
and purification, and the use of BIACORE to determine affinity of these antibodies. If the 
affinity of these scFv is shown to be weak, affinity maturation could be employed in further 
ribosome display experiments. A competition ELISA could also be performed to characterise 
epitope binding of these scFv to GBV-B core.  
The isolation of only four scFv antibodies after the three rounds screening of scFv library 
against GBV-B core could suggest an inefficient protocol either during the panning or in the 
recovery of scFv mRNA. To investigate the effectiveness of the selection procedure, the 
diversity of the antibody library was investigated after each round of panning against GBV-B 
core by deep sequencing of the scFvs CDR3 sequences (as described in Chapter 2.2.15 and 
Chapter 2.2.16). CDR3 sequences analysis showed a very minimal enrichment of any scFv, 
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further suggesting an issue with the ribosome display.  Optimisation of the screening or 
recovery protocol of scFv using ribosome display is therefore required and may include 
further washes, the use of different blocking reagents, the use of different selection 
techniques (such as protein-coated magnetic beads), an increased spacer length of scFv, and 
the use of proof-reading polymerases during the elongation steps of scFv (Schaffitzel et al., 
1999a). 
Due to the technical difficulties with ribosome display, monoclonal antibodies were produced 
using hybridoma technology to obtain essential reagents for the study of GBV-B infection in 
tamarins (see Chapter 2.4.2). Mice were immunised three times, 4 weeks apart using 
recombinant His-tagged GBV-B core, and after fusion with an immortalised myeloid cell line, 
specific antibodies-producing cells were isolated. Although some monoclonal antibodies 
seem to recognise the His-tag at the C-terminus of GBV-B core (Fig 4.18: 1E5, 5D4, 6A8, 6C9, 
6F10, 6G11), the majority of the binding antibodies were specific to GBV-B core. Seven single 
cloned hybridomas were amplified and the monoclonal antibodies purified and concentrated 
for downstream applications. Both monoclonal antibodies and scFv antibodies targeting GBV-
B core will now be used in immunohistochemistry to investigate the pathology of GBV-B. For 
example, these antibodies will be used to identify GBV-B in a range of different archived 
tamarin tissues with the aim to define the tropism of the virus. This is of particular interest as 
these data exist for other HCV animal models, such as nonprimate hepacivirus infection of 
horses, and could help to further validate GBV-B infection of tamarins as an effective animal 
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CHAPTER 5 : IDENTIFICATION OF ANTIBODIES INVOLVED IN 
THE NATURAL CLEARANCE OF GBV-B THROUGH THE 




HCV, which is an important public health concern, has a high propensity for chronicity leading 
to sequelae including hepatocellular carcinoma (Lozano et al., 2012). Determining the 
mechanisms surrounding viral clearance would therefore have a significant impact on disease 
burden. However, due to the subclinical nature of acute HCV infections, the mechanisms 
involved in viral clearance are currently incompletely understood, including the role of the 
humoral immune response. To study the immunological events surrounding viral clearance, 
GBV-B infection of tamarins has been used as an animal model of acute HCV infection in this 
study.  
GBV-B clearance is also poorly understood.  A combined cellular and humoral response is 
likely important in the clearance of virus but there is a lack of appropriate immunological 
assays for the latter. T cell responses targeting GBV-B viral proteins have been described 
previously in the literature and are thought to play a role in viral clearance (Woollard et al., 
2008). Additionally, memory T cell responses are thought to be induced in secondary 
infection (Woollard et al., 2008).  
Little is known about the role of the humoral immune response in GBV-B clearance. 
Antibodies have been detected against a range of GBV-B proteins, including NS3-specific 
antibodies that have been found to increase and peak at viral clearance but decline shortly 
after (Beames et al., 2000).  In the rare cases of extended GBV-B viraemia, it has been 
suggested that this ‘persistence’ could be linked to a delayed antibody response (Iwasaki et 
al., 2011; Martin et al., 2003). HCV neutralising antibodies have been readily detected in both 
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acute and chronic HCV infections (Cashman et al., 2014). In recent years, neutralising 
antibodies have been linked to spontaneous HCV clearance and are therefore of particular 
interest (Giang et al., 2012; Law et al., 2008; William Osburn et al., 2010; Osburn et al., 2014). 
However, due to the lack of an appropriate immunological assay, it has not been possible to 
investigate whether neutralising antibodies can be detected in New World monkeys 
experimentally infected with GBV-B.  
To investigate the neutralising antibody response in GBV-B infection as a model of what 
might happen in an acute HCV infection, a GBV-B neutralisation assay is required. Retroviral-
based PV consist of a retroviral core with the envelope proteins of the virus substituted for a 
foreign virus’ envelope. This permits the study of viruses that are difficult to propagate in cell 
culture, such as HCV and GBV-B, or highly pathogenic viruses that require high level 
biocontainment facilities (Bentley, Mather and Temperton, 2015, King et al., 2016). 
Additionally, the retroviral particle genome encodes a reporter gene, flanked by LTRs, instead 
of its original viral genome making the particle replication-deficient. For these reasons, PV 
have been employed in both research and clinical applications, including the study of virus-
host interactions, determining antibody responses, serosurveillance, for use as immunogens 
and for the testing of novel antiviral therapies (Temperton et al., 2015). As HCV is difficult to 
propagate in cell culture, HCV PV have been used extensively to characterise the envelope 
glycoproteins, the receptors required for virus entry, host range, tropism and the neutralising 
capabilities of patient sera (Bartosch et al., 2003; Bartosch and Cosset, 2009; Ploss et al., 
2009; Tarr et al., 2011).   
Based on the method used for HCV (Bartosch et al., 2003), this project aimed to produce 
retroviral-based PV expressing GBV-B envelope proteins that can transduce a susceptible cell 
line. Once this neutralisation assay is established, archived GBV-infected tamarin sera will be 
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tested in this system. Neutralising antibodies found through this model could be epitope 






















5.2.1 GBV-B ENVELOPE PROTEINS, E1 AND E2 CAN BE CLONED AND EXPRESSED IN A 
MAMMALIAN CELL LINE 
 
To produce PV expressing the GBV-B envelope, the envelope proteins, E1 and E2, were first 
cloned. A cDNA fragment containing the first 3000bp of the GBV-B genome had been 
previously generated in the lab from vRNA isolated from a GBV-B-infected tamarin. Using this 
fragment as a template, a PCR was performed to amplify the final 60 nucleotides of GBV-B 
core, for use as a signal peptide for the E1E2 genes, along with the E1E2 genes (Figure 5-1A, 
see Chapter 2.2.4).   
The primers – HINDIIIE1E2_F and E1E2CLAI_R (Table 2-2)- used for E1E2 amplification include 
the restriction sites HindIII and ClaI for sub-cloning into an expression vector, a Kozak 
sequence in the forward primer to increase E1E2 protein synthesis and a nt→nt mutation in 
the reverse primer to introduce an amino acid substitution (A→R) at the C-terminal amino 
acid of E2 (Figure 5-1A,B). The Alanine to Arginine mutation was required to disrupt the 
cleavage site and allow the fusion of an HA tag downstream of the E2 sequence. The C-
terminal HA tag sequence was included for detection of E1E2 as no GBV-B envelope 
antibodies are commercially available; it was created by subcloning the E1E2 fragment into a 
pcDNA3 vector containing an HA tag sequence downstream of the ClaI restriction sites, 
available in the lab (Figure 5-1C). The E1E2 construct was cloned into pcDNA3 using the 
restriction enzymes, HindIII and ClaI and its identity was confirmed by Sanger sequencing. 
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FIGURE 5-1: THE CLONING STRATEGY OF GBV-B ENVELOPE PROTEINS, E1 AND E2 
 
(A) GBV-B GENOME STRUCTURE WITH ALIGNED PRIMERS – HINDIIIE1E2_F AND E1E2CLAI_R - FOR THE CLONING OF E1 AND E2.  
(B) MAP OF THE PLASMID PCDNA3 CODING GBV-B E1E2 SEQUENCES. 
(C)) THE FINAL PRODUCT SCHEME OF E1E2, AFTER PCDNA3_HA SUBCLONING, INCLUDING THE NECESSARY ELEMENTS FOR DOWNSTREAM 
APPLICATIONS. 
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The CMV promoter-driven expression vector pcDNA3 containing GBV-B E1E2 was used to 
transfect Human Embryonic Kidney 293T (293T) cells using the transfection reagent, Fugene 
HD (as described in Chapter 2.4.5). As a positive control for the western blot, pcDNA3 
containing an irrelevant HA-tagged protein (human PERV-A receptor 2, huPAR-2, Mattiuzzo et 
al., 2009) was transfected in parallel. After 72 hours, transfected cells were lysed using 
radioimmunoprecipitation assay (RIPA) buffer and separated by size through an SDS-PAGE, 
transferred to a nitrocellulose membrane and immunoblotted with an HA antibody (Figure 5-
2A). As showed in Figure 5-2A, GBV-B E1E2 is expressed in 293T cells in a similar manner to 
that seen in a recent study (Marnata et al., 2015). 
GBV-B E1 and E2 proteins are heavily glycosylated proteins (Ghibaudo et al., 2004) and this 
prevents the correct size determination and causes smearing when visualised in a western 
blot. Therefore, transfected 293T cells were treated with tunicamycin, a N-linked 










FIGURE 5-2: EXPRESSION OF GBV-B E1E2 IN TRANSFECTED 293T CELL LYSATE 
 
WESTERN BLOT OF LYSATE OF 293T CELLS TRANSFECTED WITH EITHER PCDNA3_GBV-B E1E2_HA OR AN IRRELEVANT HA TAGGED 
PROTEIN, USING AN HA ANTIBODY. (A) LANE 1: UNTRANSFECTED CELLS, LANE 2: GBV-B E1E2 TRANSFECTED CELLS, LANE 3:  CELLS 
TRANSFECTED WITH POSITIVE CONTROL PLASMID. (B) LYSATE OF 293T CELLS TREATED WITH TUNICAMYCIN 24HR POST TRANSFECTION TO 
INHIBIT N-LINKED GLYCOSYLATION. LANE 1: GBV-B E1E2 TRANSFECTED CELLS, LANE 2: CELLS TRANSFECTED WITH POSITIVE CONTROL 




5.2.2 CO-TRANSFECTION OF 293T CELLS LEADS TO THE PRODUCTION OF LENTIVIRAL 
PARTICLES LACKING A GBV-B ENVELOPE 
 
Once GBV-B E1E2 protein expression was confirmed, lentiviral-based PV were produced 
through the co-transfection of 293T cells with three plasmids: the packaging plasmid 
pCMV8.91 containing the structural and enzymatic HIV-1 genes gag and pol, an expression 
plasmid containing the envelope proteins of GBV-B and a vector, pCSGW, containing the 
reporter gene Green Fluorescent Protein (GFP) between the two HIV LTRs, which will be 
incorporated in the particles as genomic RNA (ratio: 1:1:1.5, see Chapter 2.4.6). In parallel, PV 
were also produced containing no envelope, through the omission of the Env-expressing 
plasmid as a negative control, or with the VSV envelope, by substituting the GBV-B envelope 
for the protein G of VSV (VSV-G) as a positive control. VSV-G was chosen as a positive control 
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Env because it produces high titre PV, is very stable and has a wide tropism (Hastie et al., 
2013).  
To check for PV production, 48 and 72 hours post transfection, supernatant from transfected 
cells containing PV was collected and concentrated by centrifugation at 13000rpm in a 
Biofuge Pico bench-top centrifuge at 4°C for 4 hours, as described in Chapter 2.4.9; proteins 
were separated in an SDS-PAGE and samples analysed by immunoblotting (Figure 5-3, see 
Chapter 2.4.10). Lentiviral particle formation was verified for all the three samples by anti-
HIV p24 staining (Figure 5-3A); p24 or capsid, is the main component of HIV core, and it is 
present in its three forms: as part of the unprocessed HIV-1 Gag polyprotein (p55), as the 
partially processed p41 and the fully processed form, p24. As p24 is present in all supernatant 
samples and can self-assemble into viral particles (Ehrlich et al., 1992), it can be assumed that 
all samples contain lentiviral particles. To verify whether the VSV or GBV-B envelope proteins 
had been successfully incorporated into PV, the same samples were probed with either an 
anti-VSV-G antibody (Figure 5-3B) or an anti-HA antibody (Figure 5-3C). Whilst a band of the 
correct size for VSV-G was visualised in only the lane containing VSV-G PV (lane 2 Fig 5-3B), 
HA-tagged GBV-B E1E2 was not detected by anti-HA staining (lane 3, Fig 5-3C), suggesting 
that GBV-B Env has not been incorporated in the lentiviral particles. 




FIGURE 5-3: PRODUCTION OF RETROVIRAL-BASED LENTIVIRAL PARTICLES EXPRESSING VSV-G OR GBV-B ENVELOPE 
   
WESTERN BLOT OF THE CONCENTRATED SUPERNATANT OF TRANSFECTED 293T CELLS, PROBED WITH AN ANTI-HIV P24 ANTIBODY (A), AN 
ANTI-VSV-G ANTIBODY (B), WHERE A BAND AT THE CORRECT SIZE OF ~57KDA IS SEEN ONLY IN THE LANE CONTAINING THE VSV-G PV, OR AN 
ANTI-HA ANTIBODY (C). NO SIGNAL IS SEEN INDICATING NO GBV-B ENVELOPE IS PRESENT. 
LANE 1: NO ENVELOPE; LANE 2: VSV-G; LANE 3: GBV-B E1E2. 
 
 
5.2.3 GBV-B E1E2 EXPRESSION IS SUBOPTIMAL WHEN CO-TRANSFECTED WITH OTHER 
PLASMIDS 
 
HCV envelope proteins contain ER retention signals that act through charged amino acids in 
the transmembrane domain of the proteins to ensure their retention (Cocquerel et al., 
1998a). As GBV-B envelope proteins have a similar organisation to HCV envelope proteins 
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and charged residues within the transmembrane domains, GBV-B envelope proteins are also 
presumed to contain similar signals. This is an issue for lentiviral PV production as lentiviruses 
bud from the cellular membrane and will therefore not obtain the GBV-B envelope during 
pseudotype virus production. However, ‘leaky’ expression of the HCV envelope proteins on 
the cellular membrane has been seen if the expression level is sufficiently high (Bartosch et 
al., 2003; Drummer et al., 2003).   
The concentration of pcDNA3_E1E2_HA needed for a sufficient E1E2 expression level was 
investigated. This was determined by co-transfection of 293T cells with pcDNA3_E1E2_HA in 
combination with an empty plasmid, pcDNA3.1. E1E2 expression was then determined by 
visibility in western blot. Cell lysate from 293T transfected with either pcDNA3_E1E2_HA 
alone or in combination with pcDNA3.1 at different ratios were analysed in a western blot 
using an anti-HA antibody (Figure 5-4A). This blot indicated that GBV-B E1E2 expression was 
suboptimal if co-transfected with any other plasmid.  
To confirm this effect, intracellular staining for the C-terminal HA tag of GBV-B E2 was 
performed on the same transfected cells and analysed by flow cytometry (Fig 5.4B, see 
Chapter 2.4.11). HA-tagged E2 was detected when co-transfected with pcDNA3.1 but at a 
lower level than a single plasmid transfection: 16% positive cells in comparison to 12%. 
Additionally, a decrease in concentration of pcDNA3_E1E2_HA below 1.25µg resulted in only 
2% HA-positive cells. 
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FIGURE 5-4: CO-TRANSFECTION OF A PCDNA3-E1E2 WITH AN EMPTY PLASMID RESULTS IN A SEVERELY REDUCED GBV-B E1E2 
EXPRESSION LEVEL 
 
A: WESTERN BLOT SHOWING THE REDUCTION IN PROTEIN EXPRESSION OF GBV-B E1E2 IN TRANSFECTED 293T CELL LYSATE DURING CO-
TRANSFECTION WITH ANOTHER PLASMID. CELLS WERE TRANSFECTED WITH LANE 1: 1.75ΜG OF PCDNA3.1 ALONE, LANE 2: PCDNA3-E1E2 
ALONE, LANE 3: 1.25ΜG PCDNA3-E1E2 AND 0.5ΜG PCDNA3.1, LANE 4: 0.75ΜG PCDNA3-E1E2AND 1ΜG PCDNA3.1, LANE 5: 
0.25ΜG PCDNA3-E1E2 AND 1.5ΜG PCDNA3.1. 
 
B: THE ABOVE EXPERIMENT WAS REPEATED AND CELLS WERE INTRACELLULARLY STAINED WITH AN HA ANTIBODY, DETECTED WITH AN ANTI-
MOUSE IGG ANTIBODY CONJUGATED WITH FITC AND ANALYSED BY FLOW CYTOMETRY.  
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5.2.4 THE TRANSFECTION OF A STABLE PACKAGING CELL LINE, BASED ON STAR CELLS, DID 
NOT LEAD TO THE INCORPORATION OF GBV-B E1E2 PROTEINS ON PV 
 
As GBV-B E1E2 expression is suboptimal if co-transfected alongside another plasmid, a stable 
packaging cell line was generated that continuously produces high titres of PV lacking an 
envelope (ΔEnv PV). The expectation was that GBV-B envelope could later be transfected into 
these cells alone potentially enabling a much higher expression level.  
HIV-1 packaging cells, STAR cells (Ikeda et al., 2003), have been kindly donated by Dr Y 
Takeuchi, UCL. These cells were produced by co-transfecting 293T cells with codon-optimised 
HIV-1 Gag-Pol and Rev within gammaretroviral vectors, which resulted in the stable insertion 
of HIV-1 gag and pol sequences into chromosomal DNA and its subsequent high-level, stable 
production. To stably express the reporter gene, STAR cells were transduced with lentiviral 
particles, produced by transient transfection of 293T cells, containing as its genome an HIV-1 
vector carrying the gfp gene under the transcription control of wild type HIV-1 LTRs (see 
Chapter 2.4.7). The lentiviral particles were generated using the Env of RDpro to allow for a 
high efficiency of transduction. Upon infection, the viral genome of the transducing particles 
integrates into genome of the STAR cells, allowing for a continuous transcription of the 
vector. The rate of transduction was measured as percentage of GFP-positive cells using flow 
cytometry analysis; after one round of transduction with the RDpro-HV virus, there was GFP 
reporter gene expression from 67% of STAR cells (Figure 5-5B).  A second round of 









FIGURE 5-5: PRODUCTION OF HIV-1 PACKAGING CELLS STAR CELLS STABLY EXPRESSING HIV-GFP PARTICLES 
 
 
FLOW CYTOMETRY ANALYSIS OF RDPRO-HV TRANSDUCED STAR CELLS MEASURING GFP EXPRESSION. A) UNTRANSDUCED STAR CELLS, (B) 
STAR CELLS AFTER A SINGLE AND (C) SECOND ROUND OF TRANSDUCTION WITH THE RDPRO-HV VIRUS.   
 
 
STAR-HV cells, stably expressing the pHV plasmid containing gfp, were subsequently 
transfected using Fugene 6 with 1µg of either a plasmid containing the VSV or GBV-B 
envelope with the aim of producing PV expressing the aforementioned viral envelopes on 
their surface. Supernatant from transfected cells was collected at 48 and 72 hours, filtered 
and concentrated by centrifugation. Viral particles in the concentrated supernatant were run 
on an SDS-PAGE to separate proteins by size and immunoblotted with one of three 
antibodies: an anti-p24 (Figure 5-6A), an anti-VSV-G (Figure 5-6B) and an anti-HA (Figure 5-
6C).  
Lentiviral particles were successfully produced as evidenced by the presence of p24, the 
processed HIV capsid protein in all three viral samples at similar levels (Figure 5-6A).  
Additionally, PV could be produced expressing VSV-G (Figure 5-6B).  Although data in Figure 
5-6C appear to show that GBV-B E2 was incorporated into PV, this result could not be 
repeated. A possible explanation for the signal in the GBV-B Env lane could be free E2 protein 
in the supernatant released from dying cells, as the transfected STAR cell lysate from PV 
production had been confirmed to contain expressed E1E2 (Figure 5-6D). 




FIGURE 5-6: ANALYSIS OF THE ENV INCORPORATION ONTO PV PRODUCED FROM STABLE CELL PACKAGING CELL LINE, STAR-HV 
 
PV IN THE SUPERNATANT OF TRANSFECTED STAR-HV CELLS WERE IMMUNOBLOT WITH AN ANTI-P24 ANTIBODY (A) AN ANTI-VSV-G 
ANTIBODY (B) OR AN ANTI-HA TAG ANTIBODY (C) LANE 1: NO ENVELOPE, LANE 2: VSV-G, LANE 3: GBV-B ENVELOPE. 
(D) WESTERN BLOT OF TRANSFECTED STAR CELL LYSATE USING AN ANTI-HA TAG ANTIBODY. 
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5.2.5 THE TRANSFECTION OF HCV AND GBV-B ENVELOPE PROTEINS INTO A PACKAGING 
CELL LINE DID NOT RESULT IN THE PRODUCTION OF INFECTIOUS PV 
 
 
To understand why GBV-B E1E2 could not be detected on the PV by western blots, an 
infectivity assay was set up using human hepatoma cell line, Huh7. These cells are known to 
be permissive for HCV PV entry (Bartosch et al., 2003). HCV PV were produced through the 
transfection of a plasmid containing HCV E1E2 (kindly supplied by Dr B. Bartosch) into STAR-
HV cells, for use as a positive control. This positive control is more relevant as the biology, 
including the life cycle, of the two viruses is much more similar than retroviruses. In parallel 
to the production of PV in STAR-HV cells, PV were also produced by transient transfection in 
293T cells as described in Chapter 5.2.2.   
Filtered supernatant from both transfected STAR-HV and 293T cells were then used to infect 
Huh7 cells, in the presence of polybrene. After 48 hours, GFP expression in cells was analysed 
by flow cytometry. None of the samples was positive for GFP expression, and therefore 
infection. This was somewhat surprising as HCV PV production has been well documented in 
the literature which indicates that there is a more general issue with PV production (Bartosch 
et al., 2003; Bartosch and Cosset, 2009; Pestka et al., 2007; Tarr et al., 2011; Vieyres et al., 
2010).  
 
5.2.6 OPTIMISATION OF PRODUCTION OF GBV-B PV 
 
5.2.6.1 INCREASE OF ENVELOPE PROTEIN EXPRESSION IN PRODUCER CELLS 
 
To increase the expression level of GBV-B envelope proteins, the E1E2 genes were sub-cloned 
into a eukaryotic expression vector pCAGGS that contains a different promoter (see Figure 7-
6), which has been previously successfully used for the expression of viral Env protein (Niwa 
202 | P a g e  
 
et al., 1991, Kuhl et al., 2011). GBV-B Env was amplified using the NSIIE1E2_F primer (Table 2-
2) which contains a NheI site instead of HindIII site, and the SP6 universal primer (Table 2-2). 
The fragment was then cloned into pCAGGS using NheI and XhoI (a restriction site 
downstream of ClaI in the vector pcDNA3). Sanger sequencing confirmed the correct identity 
of the E1E2 fragment in this plasmid. Transfection of 293T cells was then performed with 
pCAGGS-GBV-B E1E2 using the transfection reagent XtremeGeneHP. Cell lysate was 







FIGURE 5-7: WESTERN BLOT SHOWING THE INCREASED EXPRESSION LEVEL OF GBV-B ENVELOPE PROTEINS IN TRANSFECTED CELL LYSATE 
 
LANE 1: UNTRANSFECTED CELLS, AND LANE 2: GBV-B E1E2 TRANSFECTED CELLS. GLYCOSYLATED GBV-B E2 SIZE APPROXIMATELY 44KDA 
WHILST GLYCOSYLATED E1E2 SIZE IS 75KDA.  
 
PV production was repeated with the three-plasmid transfection using the following 
plasmids: pCMV8.91 (HIV gag and pol), pCSFLW (firefly luciferase reporter gene) and the 
relevant viral envelope proteins (HCV and GBV-B). Plasmids were transfected into 293T cells 
in a 1:1:1.5 ratio using the XtremeGeneHP transfection reagent. PV were then concentrated 
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by centrifugation and run in a western blot. Although GBV-B E1E2 expression had increased, 
PV production remained unsuccessful (data not shown).  
 
5.2.6.2   USE OF ALTERNATIVE REPORTER GENE AND DETECTION METHOD 
 
 
To further optimise the PV production the reporter gene GFP was substituted for the more 
sensitive firefly luciferase gene (luc) using the restriction enzymes EcoRI and NotI. 
Bioluminescent reporter products, including luciferase, are known to be more sensitive and 
have a broader dynamic range than reporter genes based on fluorescence, such as GFP (Paley 
and Prescher, 2014). An alternative protocol was used to produce GBV-B PV, based on 
published work on HCV PV, as described in Chapter 2.4.6 (Tarr et al., 2007; Urbanowicz et al., 
2015). Lentiviral PV were created from a first generation packaging plasmid which contains 
the HIV genome with the firefly luciferase gene inserted instead of the nef gene. This plasmid 
contains wild type LTRs, with intact HIV U3 promoters, and therefore replicates as normal 
wild-type virus would. In comparison, self-inactivating vectors, due to the deletion of a region 
in the U3 promoter at the 3’LTR, can only undergo one round of replication. In addition to 
wild-type LTRs which yield higher titres of PV, frameshifts ensure that the virus produced 
does not express the HIV envelope.  
HEK293T cells were transfected using PEI with the first-generation packaging plasmid, 
pNL4.3luc+Env-, which contains HIV-1 gag-pol and the luc gene in the place of the HIV 
envelope. Different amount of plasmid pCAGGS expressing GBV-B envelope proteins were 
added to the transfection mix. As controls, HCV PV were produced as above (as positive 
control) alongside PV lacking the envelope through the omission of the envelope-containing 
plasmid (ΔEnv PV, as negative control). HCV envelope proteins were provided through a 
plasmid containing the synthetic construct isolate UKN1A20.8 envelope glycoprotein gene 
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(kindly donated by Alex Tarr, University of Nottingham, GenBank number: ABV82434.1) as 
these HCV envelope proteins have been well documented to efficiently incorporate into 
lentiviral-based particles (Tarr et al., 2013, 2011).   
Supernatant from transfected cells was collected, filtered using a 0.45µm filter and serial 
dilutions were used to infect the human hepatocellular carcinoma cell line Huh7, in the 
presence of polybrene (Figure 5-8, see Chapter 2.4.12). Infected cells were detected by 
measuring the level of luciferase production using the Bright-Glo Luciferase Assay System. 
Lentiviral GBV-B PV, made with either 400ng or 80ng of the plasmid containing GBV-B 
envelope proteins generated a signal higher than the background (PV delta Env) but only the 
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FIGURE 5-8: INFECTION OF HUH7 CELLS WITH LENTIVIRAL-BASED PV 
 
LENTIVIRAL-BASED PV BEARING EITHER HCV, GBV-B OR NO ENVELOPE (ΔENV) WERE GENERATED THROUGH CO-TRANSFECTION OF 293T 
CELLS.  PV WERE PRODUCED USING 2µG OF HCV E1E2- EXPRESSING PLASMID OR DIFFERENT AMOUNTS OF PCAGGS-GBVB E1E2 (16NG, 
80NG, 400NG OR 2 µG). SERIAL DILUTION OF THE SUPERNATANT COLLECTED AT 72 HOURS WERE USED TO INFECT HUH7 CELLS.  INFECTION 
WAS MEASURED THROUGH THE DETECTION OF BIOLUMINESCENCE AND REPORTED AS RELATIVE LUMINESCENCE UNIT PER ML (RLU/ML). 
RESULTS ARE MEAN VALUES OF TRIPLICATES READINGS AND THE LUMINESCENCE VALUES ARE SHOWN BELOW. 
 
PV based on a lentiviral core are highly suitable for use in a GBV-B neutralisation assay as 
they are able to infect non-dividing cells, such as hepatocytes, and are typically produced at 
high titres. However, the luminescence readout (RLU/ml) obtained with GBV-B PV were lower 
than for the HCV PV.  Some primary isolates of HCV envelope proteins from patients are 
known to only incorporate onto retroviral-based PV (Alex Tarr, personal communication), 
therefore pseudotyping of GBV-B Env on to retroviral particles was tested in the attempt to 
increase the titre of GBV-B PV. The retroviral-based PV were created using the three plasmid 
co-transfection system and PEI. The producer cell line, 293T, were seeded in a 10cm-dish and 
1 5 25 125
HCV PV 14713 2143 477 0
GBV-B 2000ng PV 2003 0 830 0
GBV-B 400ng PV 10160 1360 0 0
GBV-B 80ng PV 11323 23 0 0
GBV-B 16ng PV 1303 4787 0 263















HCV PV GBV-B 2000ng PV GBV-B 400ng PV
GBV-B 80ng PV GBV-B 16ng PV Delta PV
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transfected with 1µg of a plasmid containing Moloney MLV (MoMLV) gag-pol (pCMV), 1 µg of 
retroviral vector containing firefly luciferase flanked by MLV LTRs (pCFCR_luc) and different 
amounts of pCAGG-GBVB E1E2: 80ng, 400ng or 2µg. As a negative control, ΔEnv PV were 
produced through the omission of the Env plasmid. Supernatant from transfected cells was 
collected after 72 hours, filtered and serial dilutions were used to infect Huh7 cells in the 
presence of polybrene. After 3 days, the production of firefly luciferase was measured as 
before.  When compared to lentiviral GBV-B PV production, infection of Huh7 cells using the 
retroviral GBV-B PV was less efficient (Fig 5-9). Only PV made with 80ng of the pCAGGS-GBV-
BE1E2 plasmid gave a good signal above ΔEnv PV background luminescence. 
 
 
FIGURE 5-9: INFECTION OF HUH7 CELLS WITH RETROVIRAL-BASED PV 
 
RETROVIRAL-BASED PV BEARING EITHER GBV-B OR NO ENVELOPE (ΔENV) WERE GENERATED THROUGH CO-TRANSFECTION OF 293T CELLS 
AND TITRATED BY ADDING SERIAL DILUTION TO HUH7 CELLS. GBV-B PV WAS PRODUCED USING DIFFERENT AMOUNT OF PCAGGS-GBVB 
E1E2: 80NG, 400NG OR 2µG. THE RESULTS REPRESENT THE AVERAGE OF THREE REPLICATES AND THE LUMINESCENCE VALUES ARE SHOWN 
BELOW. 
1 5 25
GBV-B 2000ng PV 383 76 120
GBV-B 400ng PV 0 0 0
GBV-B 80ng PV 1537 70 0
















GBV-B 2000ng PV GBV-B 400ng PV GBV-B 80ng PV Δ PV
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5.2.6.3 DETECTION OF THE ENVELOPE PROTEIN ON PV SURFACE BY IMMUNOSTAINING  
 
 
Western blots were performed to confirm the presence of the correct viral envelope proteins 
on the surface of the HCV and GBV-B PV. Lentiviral-based HCV, GBV-B (made with 400ng of 
pCAGGS-GBV-B_E1E2) and ΔEnv PV were concentrated 63-fold by overnight centrifugation 
using a slow spin (5,500rpm for 4 hours in a Biofuge Pico bench-top centrifuge with the 7500 
3328 microlitre rotor at 4°C, see Chapter 2.4.9). PV proteins were then separated on an SDS-
PAGE, transferred to a nitrocellulose membrane and then blotted with an anti- HIV-1 p24 
antibody. All the samples contained lentiviral cores present in the supernatant (Figure 5-10A).   
This membrane was stripped and blotted with AP33, an anti-HCV E2 antibody. Although there 
was some non-specific binding, a band was visible only in the sample containing the HCV PV. 
HCV E2 is 64KDa (as estimated by DNA Dynamo software), however it is heavily glycosylated 
and the band seen in the blot is likely to be the E1E2 dimer (Figure 5-10B).  This result 
strongly suggested the incorporation of HCV E2 on the surface of the PV.  
The blot was then stained with an anti-HA to detect GBV-B E2, however there was no signal 
(not shown). Therefore, supernatant containing PV was further concentrated to a final factor 
of 2000 times through further centrifugation of previously concentrated PV. The 
concentrated PV samples were then processed as above and immunoblotted with an anti-HA 
antibody (Figure 5-10C) or an anti-GBV-B E2 polyclonal rabbit sera (Marnata et al., 2015) 
(Figure 5-10D).  In both cases, a band representing glycosylated E2 was detected only in the 
sample containing GBV-B PV, suggesting that GBV-B Env is incorporated onto the lentiviral 
particles.   




FIGURE 5-10: INCORPORATION OF HCV AND GBV-B ENV PROTEINS ON THE LENTIVIRAL PV 
 
PV PRODUCED WITHOUT ENV (LANE 1), WITH GBV-B E1E2 (LANE 2) OR HCV E1E2 (LANE 3) WERE CONCENTRATED 63-FOLD AND 
ANALYSED BY WESTERN BLOT USING AN ANTI-P24 ANTIBODY (A) OR AP33 AGAINST HCV E2 ANTIBODY (B).  
THE SAME SAMPLES WERE FURTHER CONCENTRATED UP TO 2000 TIMES AND ANALYSED BY WESTERN BLOT WITH AN ANTI-HA ANTIBODY (C) 
OR A RABBIT ANTI-GBV-B E2 POLYCLONAL SERA (D). 
 
 
The infectivity of retroviral-based GBV-B PV was much lower than the infectivity seen with 
lentiviral-based GBV-B PV. To investigate whether this could be due to a less efficient GBV-B 
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envelope incorporation into the retroviral particle the same analysis by western blot as above 
was performed on the retroviral-based HCV, GBV-B (made with 80ng of pCAGGS-GBV-B E1E2) 
and ΔEnv PV. Similar to the results obtained with the lentiviral PV, 63-fold concentrated PV 
were detected using a polyclonal sera targeting MLV p30 in all the samples (Figure 5-11A). 
The membrane was then stripped and re-probed with the HCV E2-specific AP33 antibody for 
the detection of HCV E2 on PV particles. An HCV-specific band was visible indicating 
incorporation of the HCV Env on the retroviral-based PV (Figure 5-11B). GBV-B PV 
concentrated 2000-fold were tested using an anti-GBV-B E2 polyclonal rabbit sera, but no 
specific band was detected in sample containing GBV-B PV (Figure 5-11C). This result suggests 
that a lower number of infectious, envelope-bearing particles were obtained with the 
retroviral-based system in comparison with the lentiviral system, which could be due to an 
inefficient incorporation of the Env onto the particles surface.  




FIGURE 5-11: INCORPORATION OF HCV AND GBV-B ENV PROTEINS ONTO RETROVIRAL-BASED PV 
 
PV PRODUCED WITHOUT ENV (1) WITH GBV-B E1E2 (2) OR HCV E1E2 (3) WERE CONCENTRATED 63-FOLD AND ANALYSED BY WESTERN 
BLOT USING A RABBIT ANTI-MLV P30 SERA (A) OR AP33 ANTIBODY AGAINST HCV E2 (B).  THE SAME SAMPLES CONCENTRATED 2000-FOLD 
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5.2.7 OPTIMISATION OF THE PV INFECTION ASSAY 
 
HCV and GBV-B lentiviral-based and retroviral-based PV were successfully produced through 
the co-transfection of 293T cells with a two-plasmid or three-plasmid system, respectively, 
and PEI. The infectivity of these particles were determined through the use of an infection 
assay based on Huh7 cells, however, the infectivity was relatively low and therefore requires 
optimisation. The incorporation of GBV-B Env could only be confirmed for lentiviral GBV-B PV 
so these PV were used preferentially. 
 
5.2.7.1 THE STABILITY OF PV CANNOT BE IMPROVED THROUGH THE MODIFICATION OF THE PV 
PRODUCTION PROTOCOL 
 
It has been previously observed that PV stability is affected by storage temperature (Ghani et 
al., 2009; Strang et al., 2005; Wright et al., 2009). For example, Wright and colleagues saw a 
sharper decrease in the titre of lentiviral PV bearing the rabies virus envelope if PV were 
stored at room temperature in comparison to -20°C (Wright et al., 2009). The stability of 
retroviral PV bearing retroviral envelope proteins, such as VSV-G, has also been described to 
be poor at 37°C in other similar studies (Ghani et al., 2009; Strang et al., 2005). Indeed, the 
infectivity of HCVcc, the JFH-1 isolate of HCV able to replicate in cell culture, is completely 
lost by 48 hours if stored at 37°C in culture medium (Song et al., 2010). Using the protocol 
from Chapter 5.2.5, PV are collected at 72 hours post transfection. However, PV can be 
collected 48 hours post transfection. It is therefore possible that some HCV or GBV-B PV are 
being degraded before collection. To investigate this hypothesis, HCV and ΔEnv PV were 
collected from transfected 293T cells at both 48 and 72 hours post transfection. HCV PV were 
used as these produce higher levels on infectivity than GBV-B PV. PV were then filtered, 
diluted five-fold and these dilutions were then used to infect Huh7 cells in the presence of 
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polybrene. After 72 hours, the production of luciferase was measured using Bright Glo 
reagent (Figure 5-12). 
 
   
FIGURE 5-12: THE INFECTIVITY OF HCV AND ΔENV PV PRODUCED AT 48 AND 72 HOURS AFTER TRANSFECTION OF 293T CELLS 
 
LENTIVIRAL-BASED PV BEARING EITHER HCV OR NO ENVELOPE (ΔENV) WERE GENERATED THROUGH CO-TRANSFECTION OF 293T CELLS AND 
COLLECTED AT BOTH 48 HOURS AND 72 HOURS POST TRANSFECTION. THIS SUPERNATANT WAS FILTERED, TITRATED BY SERIAL DILUTION AND 
ADDED TO HUH7 CELLS. THE RESULTS REPRESENT THE AVERAGE OF THREE REPLICATES AND THE LUMINESCENCE VALUES ARE SHOWN BELOW. 
 
 
5.2.7.2 LENTIVIRAL-BASED AND RETROVIRAL-BASED GBV-B PV PARTICLES CAN BE 
CONCENTRATED BY ULTRACENTRIFUGATION 
 
To enhance the infectivity of PV (represented by the production of the luciferase reporter 
gene), supernatant from transfected 293T cells was concentrated by a factor of 50 by 
ultracentrifugation through a sucrose cushion (see Chapter 2.4.9). This concentrated 
supernatant was then serially diluted and used to infect Huh7 cells, using the established 
1 5 25 125
HCV PV 48h 15247 1217 393 403
HCV PV 72h 24433 7697 533 383
∆ PV 48h 690 1237 113 200













HCV PV 48h HCV PV 72h ∆ PV 48h ∆ PV 72h
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protocol. This was shown to successfully increase the level of HCV PV infection of Huh7 cells 
by approximately 10-fold (Figure 5-13A). 
 
After the successful optimisation of HCV PV infectivity of Huh7 cells, these modifications were 
applied to the protocol for lentiviral and retroviral-based GBV-B PV infection of Huh7 cells. 
This showed that GBV-B PV could be concentrated, however the final infectivity of GBV-B PV 
remained lower than HCV PV (Figure 5-13B). Additionally, the production of luciferase from 












FIGURE 5-13: INFECTIOUS HCV AND GBV-B CAN BE CONCENTRATED BY ULTRACENTRIFUGATION 
 
LENTIVIRAL-BASED PV BEARING EITHER THE HCV (A) OR GBV-B ENVELOPE (B) OR RETROVIRAL-BASED PV BEARING THE GBV-B ENVELOPE 
(B) WERE GENERATED THROUGH CO-TRANSFECTION OF 293T CELLS. THE SUPERNATANT WAS COLLECTED, FILTERED AND CONCENTRATED BY 
ULTRACENTRIFUGATION THROUGH A SUCROSE CUSHION. CONCENTRATED PV WERE THEN TITRATED BY SERIAL DILUTION AND ADDED TO HUH7 
CELLS. THE RESULTS REPRESENT THE AVERAGE OF THREE REPLICATES AND THE LUMINESCENCE VALUES ARE SHOWN BELOW. 
 
 
1 5 25 125 625 3125
Lenti HCV PV unconcentrated 20403 6697 337 0 0 0












Lenti HCV PV unconcentrated Lenti HCV PV concentrated
1 5 25 125 625 3125
Lenti GBV-B PV
unconcentrated
573 28 65 28 1670 0
Lenti GBV-B PV concentrated 11365 583 0 0 0 0
Retro GBV-B PV
unconcentrated
1550 433 163 0 0 0












Lenti GBV-B PV unconcentrated Lenti GBV-B PV concentrated
Retro GBV-B PV unconcentrated Retro GBV-B PV concentrated
A 
B 
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5.2.7.3 INVESTIGATION OF DIFFERENT TARGET CELLS TO ENHANCE GBV-B INFECTIVITY 
 
 
Huh7 cells were chosen as the target cells for the infectivity assay to gauge the infectivity of 
GBV-B PV as they have been extensively used to determine the infectivity of HCV PV. To 
enhance the infectivity seen, different target cells were investigated for their permissiveness 
for GBV-B PV infection. Primary tamarin fibroblasts, African green monkey cells (Vero), feline 
kidney cells (CrFK), fetal rhesus monkey kidney cells (FRhK-4) and human hepatocarcinoma 
(Huh7.5) cells were all tested. These cell lines were tested for the following reasons:  
• tamarin fibroblasts as HCV has been previously shown to infect a human fibroblast 
cell line (Zibert et al., 1995); 
• FRhK-4 and Vero cells as they are of Old World monkey origin and therefore more 
closely related to the natural host range of GBV-B (New World monkeys) than human 
cells lines; 
• CrFK as they are known to be permissive for a number of viruses including 
retroviruses, coronaviruses and herpesviruses (Baldinotti et al., 1994; Ikeda et al., 
1997; Klumperman et al., 1994); 
• Huh7.5 cells as these have shown a greater susceptibility to HCV infection than Huh7 
cells (Bartenschlager and Pietschmann, 2005); 
Serial dilutions of both concentrated and unconcentrated GBV-B PV were used to infect cells 
in the presence of polybrene. After 72 hours, luciferase production was measured (Table 7-2); 
a summary of cell line permissibility for GBV-B PV is shown in Table 5-1. Whilst lentiviral GBV-
B PV are preferable for the development of the GBV-B PV neutralisation assay due to the 
higher titre of virus produced and higher infectivity, retroviral GBV-B PV was used in the 
infection assays with primate cells. This is due to the presence of restriction factors in both 
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Old World monkeys and New world monkeys that either block or limit lentiviral infection 
(Song et al., 2005).   
Target cells of Old World monkey origin were shown to not support GBV-B PV transduction 
whilst the feline CrFK and human Huh7.5 cells were shown to support efficient GBV-B PV 
infection. Despite the high level of permissiveness seen with CrFK cells, GBV-B PV infection of 
these cells was not stable and PV entry into this cell line was unlikely to be due to receptor-
mediated endocytosis. For this reason, Huh7.5 cells were chosen as the most appropriate 
target cell for the GBV-B PV neutralisation assay. 
 
 LENTIVIRAL-BASED GBV-B PV RETROVIRAL-BASED GBV-B PV 
TAMARIN FIBROBLAST Not tested Not permissive 
FRHK-4 Not tested Not permissive 
VERO Not tested Not permissive 
CRFK Highly permissive  Low level permissibility 
HUH7.5 Highly permissive Not tested 
 
TABLE 5-1: CRFK AND HUH7.5 CELLS SUPPORT EFFICIENT GBV-B PV INFECTION 
 
ALL CELL LINES INVESTIGATED WERE INFECTED WITH SERIAL DILUTIONS OF EITHER LENTIVIRAL-BASED OR RETROVIRAL-BASED PV PRODUCED 
THROUGH THE CO-TRANSFECTIONS OF 293T CELLS WITH THE TWO OR THREE PLASMID SYSTEM AND PEI. HUH7.5 WERE INFECTED WITH ONLY 
LENTIVIRAL PV DUE TO TIME RESTRICTIONS AS IT WAS PRESUMED THAT LENTIVIRAL PV HAVE HIGHER LEVELS OF INFECTIVITY. 
LUMINESCENCE VALUES FOR EACH CELL LINE TESTED ARE SHOWN IN THE APPENDIX (TABLE 7-2), WHILST A SUMMARY OF PERMISSIBILITY 
(DETERMINED BY THE RESULTS SEEN IN TABLE 7-2) FOR EACH EXPERIMENT IS SHOWN ABOVE. 
 
5.2.7.4 REMOVAL OF THE GBV-B E2 C-TERMINAL HA TAG ENHANCES GBV-B PV INFECTIVITY IN A 
MODIFIED INFECTION ASSAY PROTOCOL 
 
 
In the case of HCV PV, a C-terminal HA tag was shown to reduce the infectivity by 65% (Op De 
Beeck et al., 2004)(Beeck et al., 2004). The HA tag was therefore deleted from the C-terminus 
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of GBV-B E2 by PCR. Additionally, the use of centrifugal inoculation, or spinoculation, has 
been shown to enhance viral infection in previous studies (O’Doherty et al., 2000; Yan et al., 
2015).  Due to time restrictions, these optimisations were performed at the same time.  
To remove the HA tag from the C-terminus of GBV-B E2, GBV-B E1E2 genes were re-amplified 
by PCR with modified primers, using pCAGGS_GBV-BE1E2_HA as the template. For this 
reaction, the forward primer NSIIE1E2_F was designed that contained an NsiI restriction 
enzmye site and the reverse primer NHEIE1E2NOTGA_R containing the C-terminal amino 
acids of GBV-B E2, a stop codon and a NheI restriction enzmye site. This PCR product 
produced a specific band at the correct size by gel electrophoresis, which was then subcloned 
into the pCAGGS vector using the restriction enzymes NsiI and NheI. Sanger sequencing 
confirmed this cloning was successful.  
Lentiviral GBV-B PV were produced by co-transfection of 293T cells with the first generation 
packaging plasmid, pNL4.3Luc+Env-, and the plasmid containing GBV-B envelope proteins 
E1E2 without an HA tag (pCAGG_E1E2noHA). Supernatant from these cells, containing PV, 
was collected and concentrated by ultracentrfugation. A small amount of supernatant from 
transfected cells was not concentrated to act as a control. Lentiviral GBV-B PV were used to 
infect Huh7.5 cells in the presence of polybrene. After GBV-B PV were added to cells, the cells 
were spun at 2500rpm using a Hettich Rotanta 460R centrifuge and the 5624 plate rotor for 
30 minutes, as described in Chapter 2.4.12.  Spinoculation is well known to increase the 
infectivity of viruses by increasing the chance that the virus interacts with the host cell entry 
receptor on the surface of the target cell (O’Doherty et al., 2000). After three days, 
luminescence was measured using a luminometer. This infection assay shows that through 
the removal of the HA tag and the use of spinoculation, the permissiveness of Huh7.5 cells for 
GBV-B PV increased by around 70% (Figure 5-14). Consequently, these modifications will be 
adopted for the GBV-B neutralisation assay. 





FIGURE 5-14: THE PERMISSIVENESS OF HUH7.5 CELLS FOR GBV-B PV IS ENHANCED AFTER THE REMOVAL OF THE C-TERMINAL GBV-B E2 
HA TAG AND THE USE OF A SPINOCULATION-BASED PROTOCOL 
 
LENTIVIRAL-BASED PV BEARING EITHER THE GBV-B ENVELOPE LACKING THE C-TERMINAL E2 HA TAG WERE GENERATED THROUGH CO-
TRANSFECTION OF 293T CELLS. THE SUPERNATANT WAS COLLECTED, FILTERED AND CONCENTRATED BY ULTRACENTRIFUGATION. AS A 
CONTROL, A PROPORTION OF THE SUPERNATANT WAS NOT CONCENTRATED. PV-CONTAINING SUPERNATANT WAS THEN TITRATED BY SERIAL 
DILUTION, ADDED TO HUH7.5 CELLS AND THE CELL CULTURE PLATE CENTRIFUGED FOR 30 MINS AT A LOW SPEED (2500RPM). THE RESULTS 
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To better understand the immunological events surrounding GBV-B clearance as a model for 
acute HCV clearance, a GBV-B neutralisation assay was designed based on the use of GBV-B 
pseudotyped viral particles (PV). This would allow the testing of GBV-B-infected tamarin sera 
in this assay to detect any neutralising antibodies present. These neutralising antibodies are 
likely to play an important role in GBV-B clearance, as a strong association has been described 
between HCV neutralising antibodies and clearance of the virus (Cashman et al., 2014). 
PV are a highly useful tool for the study of viruses that are difficult to propagate in cell 
culture, such as GBV-B. These viruses consist of a viral core encapsulating a reporter gene 
flanked by LTRs. Due to the ability of retroviruses to incorporate foreign viral envelopes onto 
their viral cores, the envelope of a target virus can be expressed on these PV. The 
development of HCV PV has enabled the study of several different fields including HCV 
biology and the characterisation of the humoral immune response using patient sera. As 
such, GBV-B PV production, and the subsequent development of a GBV-B neutralisation 
assay, would be of high value. 
To produce GBV-B PV, the GBV-B envelope was first cloned and expressed in mammalian cells 
(Figure 5-1 and 5-2, respectively). Although GBV-B Env protein cloning and expression was 
relatively straight-forward, their incorporation onto PV particles proved to be difficult. PV 
bearing the VSV envelope protein were successfully produced and the VSV-G envelope 
protein was detected by immunoblotting; in comparison, the GBV-B PV particle could be 
detected but the GBV-B envelope on PV could not. This was most likely due to a lack of 
incorporation of the GBV-B envelope on PV, which was not unexpected as there is a 
significant difference between the life cycle of flaviviruses and retroviruses. Retroviruses bud 
through the plasma membrane, whilst flaviviruses bud through the ER (Morita and Sundquist, 
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2004; Welsch et al., 2007). As such, there is no opportunity for PV to gain GBV-B envelope 
proteins from the plasma membrane as they are predicted to contain ER retention signals 
(Cocquerel et al., 1999, 1998a).  
Despite these differences between retroviruses and flaviviruses, retroviral PV can incorporate 
HCV envelope proteins if these proteins are expressed at extremely high levels due to ‘leaky 
expression’ on the plasma membrane (Bartosch et al., 2003). Unfortunately, it was shown 
that GBV-B Env expression was suboptimal if transfected alongside other plasmids, such as 
those used for PV production (Figure 5-4). To address this issue, the STAR-HV cell line, based 
on STAR cells (Ikeda et al., 2003), was produced which generated PV with no envelope 
protein (Figure 5-5). STAR-HV cells could then be transfected with the plasmid containing the 
GBV-B envelope alone, thereby bypassing the issue of suboptimal expression. Unfortunately, 
PV bearing the GBV-B envelope were not produced using these cells (Figure 5-6). This could 
be due to the fact that these cells are already expressing other stably transfected proteins.  
Finally, an alternative PV production protocol was adopted, based on incorporating a 
different reporter gene into PV particles (Tarr et al., 2013, 2011; Urbanowicz et al., 2015). 
This led to the successful detection of both lentiviral-based and retroviral-based GBV-B PV, as 
both of these PV could successfully infect Huh7 cells, a cell type known to be permissive for 
HCV PV infection (Figure 5-8 and Figure 5-9).  
GBV-B Env incorporation onto PV particles was confirmed by immunoblotting PV with 
antibodies that could detect the C-terminal HA tag of GBV-B E2 and a polyclonal antibody 
recognising GBV-B E2 (Figure 5-10 and Figure 5-11). These Env proteins were not 
incorporated efficiently on PV and were subsequently only detected by immunoblotting after 
being concentrated 2000-fold. In contrast, HCV Env could be detected by western blot after a 
63-fold concentration suggesting that the HCV envelope is more easily incorporated onto PV, 
perhaps due to a greater degree of ‘leaky expression’ on the plasma membrane. 
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Furthermore, the GBV-B envelope could not be detected by western blot on retroviral 
particles, most likely due to a combination of poor incorporation of envelope proteins on to 
the particles and a lower titre of virus produced in comparison to lentiviral particles. As 
infection assays were performed prior to western blots, infectious retroviral particles bearing 
GBV-B envelopes can be produced but not detected by western blot. 
Despite this success, GBV-B PV infection was shown to be inefficient in comparison to HCV PV 
infection (Figure 5-8). Attempts to optimise the infection were therefore made using several 
approaches including the incorporation of two PV collection time points in the production 
protocol, the concentration of PV before use in infection assays, investigation of different 
target cells, removal of the HA tag from GBV-B E2 and the use of spinoculation. The 
incorporation of two PV collection time points was a relatively minor modification to ensure 
that PV were stored at the correct temperature to limit degradation, although it was seen 
that most HCV PV were produced between 48 and 72 hours post transfection (Figure 5-12). 
The effect of concentration, however, had a substantial effect, with lentiviral GBV-B PV being 
concentrated by a factor of approximately 20 and retroviral GBV-B PV by a factor of 3 (Figure 
5-13).   
Another modification to the infection protocol was a change in the target cell used (Table 5-
1). Huh7.5 cells were adopted as these appeared to give the highest level of luminescence 
read out and therefore infection. This is in line with the literature that states that these cells 
support a higher level of HCV infection, possibly due to the mutation in a protein that is 
involved in innate antiviral defences (Bartenschlager and Pietschmann, 2005).  Whilst the 
feline kidney cells used were permissive for GBV-B PV, these cells were not used as it is 
unlikely that PV entry was via the typical, as yet unidentified, GBV-B entry receptors. 
The final, and most effective, change to the infection protocol to increase the level of GBV-B 
PV infection in Huh7.5 cells, was the deletion of the HA tag at the C-terminus of GBV-B E2 and 
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the use of a spinoculation step during infection (Figure 5-14). Unfortunately, due to time 
restraints, these modifications were adopted together so it is not possible to identify which of 
these adjustments led to a 70% increase in infectivity of GBV-B PV or whether the 
combination was critical. It is likely that both had some impact as both are documented in the 
literature to have a significant effect (Bartosch et al., 2003; O’Doherty et al., 2000; Yan et al., 
2015).  
This infection assay can now be used as a basis of a GBV-B neutralisation assay to test 
archived tamarin sera to detect any possible neutralising antibodies, although biological 
repeats of the infection assay are first required. Additionally, these PV could be used in a 
range of other studies including identifying the GBV-B entry receptors and confirming the 
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CHAPTER 6 : DISCUSSION 
 
HCV is a major public health concern with around 500,000 deaths per year from HCV-related 
liver disease (Lozano et al., 2012). Despite this large disease burden, there is currently no 
available vaccine and the highly effective HCV treatments available have been significantly 
restricted by the NHS due to their high cost (Gornall et al., 2016). Even if this highly effective 
treatment were to reduce in cost, treatment does not protect against reinfection or provide a 
remedy for the HCV-associated liver disease (Freeman and Cox, 2016). Additionally, the 
largely asymptomatic nature of HCV infection means that many infected people do not 
realise they are infected and therefore would not know to seek treatment. In fact, Public 
Health England have estimated that only 5% of people with chronic viral hepatitis are aware 
of their positive status (Public Health England, 2016). To reduce the disease burden of this 
virus, the development of a prophylactic vaccine is necessary. 
The development of an HCV vaccine has been extremely challenging, partly due to the virus’ 
genetic variability (Naderi et al., 2014). Moreover, clearance of the virus is not thought to 
provide protection against reinfection, but rather protect against chronic disease (Osburn et 
al., 2010). Due to the subclinical nature of acute HCV infection, an animal model is necessary 
to investigate the immunological events that occur surrounding HCV clearance (Gerdts et al., 
2007). Understanding these events could then inform the design of a novel vaccine for HCV.  
Aside from humans, HCV is known to only infect chimpanzees, which, due to ethical 
constraints, limited availability and high study costs, are no longer used in the study of HCV 
(Vercauteren et al., 2015). Despite this, there are a number of experimental animal models 
available that involve either investigating specific parts of the viral life cycle/pathogenesis or 
the study of closely-related hepaciviruses (Billerbeck et al., 2013).  
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In this project, GBV-B infection of tamarins has been used as an animal model of acute HCV 
infection, as spontaneous clearance of GBV-B occurs in most cases (Stapleton et al., 2011). 
However, there is a limited amount of data available on GBV-B. This project therefore had 
two aims: 
1. To investigate the pathology of GBV-B to further validate GBV-B infection in tamarins 
as a useful animal model of acute HCV infection. 
2. To understand the immunological events that lead to viral clearance to potentially 
inform HCV vaccine design.  
Alongside hepatocytes, HCV is also known to infect other extrahepatic cells, such as 
lymphocytes and brain cells, resulting in extrahepatic manifestations (Ikeda et al., 1997; 
Weissenborn et al., 2009). It is therefore of interest to determine if GBV-B can also infect 
these cells, as extrahepatic manifestations have only been potentially demonstrated in 
transgenic mice models (Koike et al., 1997). In the case of GBV-B, a previous study showed 
that GBV-B RNA could be isolated from several different extrahepatic tissues, including 
lymphocytes, splenocytes and lymph nodes (Ishii et al., 2007). Immunohistochemistry with 
GBV-B specific antibodies could then be used to determine if viral proteins are also present in 
these cells along with other relevant cells, such as brain cells.  
Before immunohistochemistry could be performed, antibodies targeting specific GBV-B 
proteins had to be produced. The production of these antibodies was required as no GBV-B 
antibodies were commercially available. Initially, ribosome display was employed, as 
described in Chapter 2.2.17, as this in vitro display technology allows the rapid selection of 
highly-specific antibodies from a hugely diverse library of antibodies (Zahnd et al., 2007). This 
diversity is only limited by the number of ribosomes and unique antibody mRNA molecules 
within the system. Moreover, due to the amplification of the antibody library by PCR after 
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each round of screening, random mutations can be introduced into antibodies allowing the 
direct evolution of GBV-B-specific antibodies throughout the rounds of selection.  
In Chapter 3, the set-up required for ribosome display was described. GBV-B proteins, for use 
as target antigens for the screening of the antibody library, and the antibody library itself was 
produced. The GBV-B proteins core, NS3 and NS5BΔ23 were chosen as initial screening 
targets as these proteins had been successfully produced within other laboratories and 
therefore protein production protocols already existed (Pilot-Matias et al., 1996; Ranjith-
Kumar et al., 2003; Scarselli et al., 1997; Zhong et al., 2000). Additionally, antibodies targeting 
these proteins in vivo were described in the literature (Ishii et al., 2007; Iwasaki et al., 2011; 
Pilot-Matias et al., 1996; Sbardellati et al., 2001). GBV-B E2 was not included as a target 
antigen as recombinant, soluble GBV-B E2 has never been produced and therefore GBV-B E2-
specific antibodies have never been identified. 
Production of these GBV-B proteins in a prokaryotic system and purification using nickel 
affinity columns was relatively straightforward (see Chapter 2.3.4). Prokaryotic expression 
was chosen over eukaryotic expression as large amounts of protein are easy to produce in 
this system and, as stated above, the protocols already existed and did not require time-
consuming protocol optimisation.  Western blots with an anti-His tag antibody confirmed 
each protein was present in each preparation (Figure 3-3). Tamarin sera, from two different 
tamarins, was also applied to each of the three blot membranes, although only GBV-B core 
was recognised (Figure 3-3C). This could be due to a range of reasons including, but not 
limited to, GBV-B core antibodies being produced at a higher volume than NS3/NS5BΔ23 
antibodies (core is the nucleocapsid of the virus), the tamarins tested not producing 
antibodies targeting NS3 or NS5BΔ23 or that antibodies targeting core and antibodies 
targeting non-structural proteins are produced at different times during infection.  
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The plasmids containing GBV-B protein sequences were sent for large scale production and 
purification by the Protein Production facility at Queen Mary University. This was largely 
successful, although NS3 remained difficult to produce in large enough quantities despite 
using the identical, previously successful, protocols to the small-scale production and 
purification of NS3 (Figure 3-4). To solve this issue, different bacterial strains, different 
bacterial promoters or perhaps a different protocol (such as that described in Ishii et al., 
2007) could have been adopted, however, due to time restrictions, the NS3 protein was not 
used as an antibody screening target so this optimisation wasn’t required. Before use as a 
target antigen, NS5BΔ23 (as this was to be used as a screening antigen first) was sent for 
mass spectrometry analysis. This showed that NS5BΔ23 was indeed present in the protein 
preparation (Appendix, Table 7-1).  
After the successful production of GBV-B proteins in a prokaryotic system, the antibody 
library was generated for use in ribosome display. This antibody library was based on the 
heavy and light chain variable regions of the tamarin immunoglobulin genes which could be 
modified to produce scFvs (Figure 3-5). To permit the cloning of tamarin immunoglobulin 
genes, tamarin RNA was isolated from splenocytes from a tamarin that had recently cleared 
its acute GBV-B infection. In this way, successfully rearranged immunoglobulin genes can 
potentially be isolated and the VH and VL regions cloned. However, the cloning of the VH and 
VL regions was somewhat challenging as the tamarin genome has not currently been 
sequenced. As such, the only viable option was to design primers using marmoset 
immunoglobulin sequences as tamarins and marmosets are closely-related (Lanford et al., 
2003).   
Degenerate primers were designed to cover known heavy and light chain variable region 
sequences within the immunoglobulin genes (von Büdingen et al., 2002). For example, only 
kappa light chain variable sequences have been identified in marmoset immunoglobulin 
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genes and were therefore cloned. This may indicate that kappa chains are more abundantly 
used in the B cell receptor (BCRs) complex than lambda and are therefore more readily 
isolated. Indeed, it is well known that light chain usage varies between mammals, with 
human BCRs expressing 70% kappa light chains, cattle expressing 95% lambda light chains 
and rhesus macaques expressing 50% of each (Tizard, 2013). However, the lack of lambda 
chain isolation from marmosets may simply be due to the fact that kappa sequences were 
more readily cloned than lambda sequences. Due to the huge number of antibody sequences 
that were already available with only kappa light chain usage, this was deemed sufficient for 
this study’s purpose.  
All tamarin variable regions were cloned by PCR successfully (see Chapter 2.2.4) and the 
identity and diversity of these variable regions was confirmed using Sanger sequencing. To 
confirm the identity of tamarin variable regions, sequences were compared against their 
marmoset equivalent using the Basic Local Alignment Search Tool (BLAST, available at: 
https://blast.ncbi.nlm.nih.gov/Blast.cgi) as this is the first time that tamarin variable regions 
have ever been cloned. This analysis confirmed that the sequences were closely related to 
marmoset immunoglobulin sequences thereby corroborating the approach taken in this 
project. Diversity was also confirmed by isolating around 100 variable region sequences from 
different VH and VK families and comparing intrafamilial sequence variation using DNA 
Dynamo. All identified variable regions were unique. 
The remaining necessary elements (the T7 promoter sequence, the linker and the spacer) 
required for scFv library construction were added through a further five rounds of PCR (see 
Chapter 2.2.4). Five PCRs were required for the addition of three elements due to the length 
of each of the additional element sequences. The T7 promoter was chosen as scFv expression 
is required downstream in the process and the human constant region (CH1) was chosen as 
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the spacer for the identification of scFv after downstream expression. Sanger sequencing was 
performed at both the 3rd and 6th PCR stage to ensure the correct identify of scFv. 
Once the scFv library had been constructed and the GBV-B target antigens had been 
produced, ribosome display was performed. GBV-B NS5BΔ23 was used as the first target 
antigen as this is the viral polymerase. If NS5BΔ23 protein was therefore detected in 
extrahepatic tamarin tissues, this would suggest active replication of the virus in these 
tissues. Although scFv sequences were successfully isolated from screening of the scFv library 
against NS5BΔ23, only 5% of sequences corresponded to full length scFv.  Full length scFv 
were readily identified within the scFv library by Sanger sequencing before the screening 
against NS5BΔ23 so this suggested that either the tamarin that was used to create the scFv 
library had never made NS5BΔ23 antibodies or that the ribosome display protocol required 
further optimisation.  
Despite this, two scFv sequences were identified (one with a full-length linker and one with a 
truncated linker) and these scFv were expressed in prokaryotic cells (Figure 4-3, as described 
in Chapter 2.3.1). To aid with downstream scFv stability, solubility and identification, scFv 
were cloned into the p4D5_Fc vector that contains human CH2 and CH3 regions (Czajkowsky 
et al., 2012; Liu, 2003; Moutel et al., 2009). Although both scFv could be produced at high 
levels, neither scFv was NS5BΔ23-specific by ELISA (Figure 4-4). This may be due to the 
improper folding of NS5BΔ23 in prokaryotic cells (mass spectrometry only proved that the 
protein was present), improper folding of scFv in prokaryotic cells or that there was an issue 
with the selection stage of ribosome display.  
Although it is possible that there was an issue with the selection stage of ribosome display 
due to the isolation of only one full length scFv sequence, ribosome display was repeated 
with a different screening antigen- GBV-B core. Core was chosen as the screening antigen as 
core-specific antibodies have been more readily identified in vivo than NS5B-specific 
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antibodies (Bukh et al., 2008; Ishii et al., 2007; Iwasaki et al., 2011; Pilot-Matias et al., 1996; 
Sbardellati et al., 2001; Woollard et al., 2008). Furthermore, core antibodies had been 
identified by western blot in Chapter 3 (Figure 3-3C). 
After this screening, six full-length unique scFv sequences were isolated. Additionally, an out-
of-frame scFv was also isolated and used as a protein expression control. The most 
appropriate host for scFv expression was selected through the small-scale expression of one 
scFv in various prokaryotic hosts. Induction of scFvs proved to be difficult due to low 
expression levels (Figure 4-6).  Protocol optimisation was attempted, such as using different 
growth temperatures, IPTG concentrations, and culture mediums, but scFv induction 
remained low. This could be due to the expressed scFv being toxic to the bacterial cells, 
although this was not the case with NS5BΔ23 scFv (Wang et al., 2013).  Despite low induction 
levels, the expressed scFv could be identified by western blot using an anti-His antibody 
(Figure 4-6). 
Once expressed, these scFv were tested for their GBV-B core-binding capabilities by ELISA as 
described in Chapter 2.3.7 (Figure 4-7). Unfortunately, all scFv were non-specific for core, as 
they also bound to the plastic 96-well plate. This could have been due to improper folding of 
scFv in the bacterial cells so scFv were later expressed in a mammalian cell line (Figure 4-9). 
Unfortunately, the mammalian expressed scFv then lost all binding capabilities, as 
determined by ELISA, perhaps due to correct protein folding. It may be the case that these 
scFv, once folded properly, would only bind to their specific target, such as one of the 
ribosome display components. 
As it has been well documented that antigen-specific scFv are enriched in the scFv library 
with each round of screening against the target antigen (Hanes and Plückthun, 1997; 
Schaffitzel et al., 1999), ribosome display was repeated. Three rounds of screening were 
performed to increase the chance of isolating core-specific scFv. Of note, the recovery of the 
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scFv library after each round of screening was increasingly less efficient with each round of 
screening (Figure 4-10). This could be due to a difficulty in amplifying scFv sequences (as 
recovery is PCR-based) or it could have been that non-specific scFv were being lost with each 
round of screening and therefore the scFv library was reducing in size. Due to these 
difficulties, only four antibodies were isolated after three rounds of screening the scFv library 
against core, of which only two were full-length (Table 4-3). These full-length antibodies were 
also likely to be the same antibody as Sanger sequencing and IgBLAST analysis of the 
nucleotide sequence revealed that both scFv had the same VDJ gene segments and CDR3 
sequences. 
As seen with the previous scFv antibodies, prokaryotic expression of these scFv was 
challenging as protein induction levels were low. Expressed scFv were eventually isolated 
from BL21 cells and the binding properties of all four scFv were investigated by ELISA. In 
comparison to the scFv isolated after one round screening, scFv isolated after three rounds of 
screening all bound specifically to core (Figure 4-12A). These scFv may well prove to be 
relatively low affinity as they do not maintain their binding capabilities when diluted (Figure 
4-12B), although affinity maturation is a possibility using ribosome display. 
To investigate the issue with the scFv selection stage of the ribosome display protocol, the 
CDR3 sequences of the scFv libraries, before and after antigen panning, were deep 
sequenced, as described in Chapter 2.2.15.  Only the CDR3 regions were sequenced as it is 
thought that the majority of the diversity of antigen-specificity of antibodies is due to this 
sequence (Xu and Davis, 2000). Degenerate primers covering all possible scFv CDR3 
sequences were designed from previously sequenced tamarin variable regions from Chapter 
3.1.1 (Table 4-4). These primers were based on recognising conserved sequences before and 
after the CDR3 sequences, which were remarkably similar to their human counterparts (see 
Table 7-6). CDR3 sequences from both the heavy chain and light chain of tamarin variable 
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regions were amplified by PCR and deep sequenced. PCRs were performed in duplicate for 
increased reliability of results. 
To analyse CDR3 sequences within the scFv libraries, the Antibody Mining Toolbox was used 
(see Chapter 2.2.16, D’Angelo et al., 2013). CDR3 sequences were readily identified from all 
libraries. This sequencing showed that there was indeed an issue with the selection stage of 
ribosome display as there is no significant selection of specific scFv sequences and the 
libraries were not decreasing with complexity (Figure 4-14-4-16). This data suggests that the 
ribosome display protocol needs to optimised. For example, the use of different selection 
techniques (such as protein-coated magnetic beads), an increased spacer length for scFv, and 
the use of proof-reading polymerases during the elongation steps of scFv could all impact the 
selection stage of ribosome display and may impact the number of antigen-specific scFv 
isolated (Schaffitzel et al., 1999). 
Due to the difficulties encountered with ribosome display, monoclonal antibodies (mAbs) 
were also produced using the hybridoma method using a standard protocol previously 
established in the laboratory. This protocol was effective and several core-specific mAbs were 
produced with similar binding specificities as seen with the scFv isolated after three rounds of 
panning using ribosome display (Figure 4-12, 4-18). Although these mAbs were easier and 
quicker to produce, the ribosome display method offers an animal-free method for obtaining 
antibodies. Therefore, if successfully optimised, ribosome display would be a more 
appropriate method to adopt in the future for the production of antibodies. Due to time 
constraints, neither core-specific scFv or mAbs were evaluated in immunohistochemistry 
studies.  
The other aspect of this project was the investigation of immunological events surrounding 
GBV-B clearance. Although it is likely that a combined cellular and humoral immune response 
is responsible for successful viral clearance, it has been suggested in previous GBV-B studies 
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that a delayed humoral immune response, particularly the neutralising antibody response, 
can cause extended, or chronic, viraemia (Iwasaki et al., 2011; Martin et al., 2003).  As such, 
the humoral immune response to GBV-B was investigated. To facilitate this, a neutralisation 
assay was needed to determine if neutralising antibodies are present during GBV-B clearance.  
However, HCV, and therefore most likely GBV-B, does not replicate well in cell culture 
(Steinmann and Pietschmann, 2013). A neutralisation assay based on pseudotyped viral 
particles (PV) was therefore developed, as this bypasses the need for GBV-B replication in cell 
culture (Temperton et al., 2015). Additionally, this method has been used successfully to 
investigate the neutralising antibody response to HCV (Bartosch et al., 2003; Lavillette et al., 
2005; Meunier et al., 2005; Tarr et al., 2011).  For this, GBV-B E1 and E2 envelope proteins are 
expressed on a retroviral core that encapsulates a reporter gene. During infection, this 
reporter gene is incorporated into the host cell’s genome and expressed thereby providing a 
simple infectivity measurement (Temperton, Wright and Scott, 2015). 
To produce PV expressing GBV-B envelope proteins, the envelope proteins were first cloned 
by PCR (Figure 5-1, see Chapter 2.2.4). An HA tag was added at the C-terminus for 
identification purposes as no commercial GBV-B antibodies to E1 or E2 are currently 
available. These proteins were then expressed in a mammalian cell line, 293T, isolated and 
detected by western blot using an anti-HA antibody (Figure 5-2A). For further confirmation 
(as no E1E2 antibody is available), the envelope proteins were expressed again in the 293T 
cell line that had been treated with an N-glycosylation inhibitor. The proteins were then 
isolated and detected by western blot, which showed that both proteins were approximately 
the correct size (Figure 5-2B).  
PV production was then attempted through the transfection of 293T cells (as described in 
2.4.6). As a positive control, PV bearing VSV-G envelope protein were also produced as this 
can be easily generated at very high titres. Western blots were performed to detect the 
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relevant components of the PV: the envelope protein and the retroviral core. This showed 
that although PV bearing VSV-G were successfully produced, PV did not bear GBV-B E1E2 on 
their surface (Figure 5-3). This was originally thought to be due to a suboptimal expression 
level of the envelope proteins, most likely due to the difference between the life cycle of 
retroviruses and flaviviruses (such as GBV-B). In the case of retroviruses, the retrovirus buds 
through the plasma membrane and therefore the envelope proteins need to be in this 
location. However, flaviviruses bud internally from the ER. As such, GBV-B E1 and E2 proteins 
contain ER retention signals and would therefore not be at the plasma membrane (Cocquerel 
et al., 1998). It is thought that HCV PV are able to be produced if the expression level is high 
enough to allow leaky protein expression from the ER permitting a proportion of the 
envelope proteins to relocate to the plasma membrane (Bartosch et al., 2003; Drummer et 
al., 2003). 
To determine if GBV-B E1E2 was being suboptimally expressed during PV production, 293T 
cells were transfected with the GBV-B E1E2 plasmid in combination with varying amounts of 
an empty plasmid (representing PV production plasmids). This showed that E1E2 expression 
levels were significantly reduced when E1E2 was transfected with another plasmid, even if 
this plasmid was empty, although it is unclear why this would be the case (Figure 5-4).   
To circumvent this issue, a cell line that stably expressed lentiviral core proteins was 
obtained. These STAR cells, were transduced with lentiviral particles containing the gfp 
reporter gene (Figure 5-5, see Chapter 2.4.7). Two rounds of transduction were required to 
ensure approximately 100% (98.2%, Figure 5-5) of cells were GFP-positive. These cells were 
shown to be successfully producing PV, as evidenced by western blots of the STAR cell 
supernatant (Figure 5-6). These STAR cells could then be transfected with the GBV-B E1E2 
plasmid alone to enhance the level of protein expression. Disappointingly, this still resulted in 
PV not bearing E1E2 proteins. This may have been due to an issue with suboptimal expression 
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or that GBV-B envelope protein are more tightly retained in the ER. It is likely that E1E2 was 
still expressed at a suboptimal level as 293T E1E2-transfected cell lysate contained a low level 
of E1E2 (Figure 5-6D).  
Finally, through the adoption of a different PV protocol and the substitution of the gfp 
reporter gene for the luciferase reporter gene (see Chapter 2.4.6), PV expressing either HCV 
and GBV-B were successfully produced as determined by the infection of Huh7 cells (Figure 5-
8 and 5-9), a cell type known to support HCV PV infection (Bartosch et al., 2003). HCV PV 
appeared to have a higher infectivity, which could be due to a higher level of HCV envelope 
incorporation on to PV than GBV-B envelope proteins, a higher titre of HCV PV being 
produced or Huh7 cells having a low susceptibility to GBV-B infection at the same efficiency 
as HCV infection.  
Both lentiviral (HIV) and retroviral (MLV)- based PV were produced in this study as lentiviral 
PV are unable to infect cells of New World monkey origin due to pre-existing viral entry 
restriction factors (Song et al., 2005). Additionally, some viral envelope proteins incorporate 
efficiently onto retroviral-based PV, some onto lentiviral-based PV and some onto both 
particles (Personal communication, Dr Alexander Tarr, University of Nottingham). Retroviral 
PV expressing GBV-B envelope proteins were shown to have a much lower infectivity than 
their lentiviral counterparts (Figure 5-9). This was somewhat expected as lentiviruses are able 
to infect non-dividing cells, whilst gammaretroviruses cannot (Matreyek and Engelman, 
2013). 
In parallel to performing infection assays, western blots of concentrated HCV and GBV-B PV 
were performed to confirm that the envelope proteins were indeed incorporated onto the PV 
particle (Figure 5-10). To detect the relevant envelope proteins, PV had to be significantly 
concentrated (see Chapter 2.4.9). This is most likely due to an inefficient incorporation of the 
envelope protein onto the PV. Of note, HCV envelope proteins could be detected on PV after 
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63-fold concentration. In comparison, GBV-B PV had to be concentrated up to 2000-fold 
before any signal on the western blot could be detected. Additionally, whilst GBV-B envelope 
proteins could be detected on lentiviral-based PV, GBV-B envelope proteins could not be 
detected on retroviral-based PV (Figure 5-11). This is likely to be due to a lower titre of virus 
being produced in the case of retroviral PV, possibly in combination with a less efficient 
envelope incorporation onto retroviral PV. This would also explain the reduced infectivity 
seen with retroviral GBV-B PV.  
The successful HCV and GBV-B PV production protocol was then optimised again; successful 
modifications included the adoption of ultracentrifugation, the use of a modified target cell 
line, the removal of the E2 C-terminus HA tag and the use of spinoculation.  
Ultracentrifugation was successful for both lentiviral-based and retroviral-based PV. It 
increased the infectivity readout by a factor of greater than ten in the case of HCV PV. GBV-B 
PV infectivity still remained much lower than HCV PV infectivity; the lentiviral GBV-B PV 
infectivity readout was increased by around a factor of 20 in comparison to an increase of 
only three-fold for retroviral-based GBV-B PV (Figure 5-13). Of note, lentiviral GBV-B PV 
production was relatively unstable as the infectivity readout ranged between around 10,000 
RLU/ml to only 500 RLU/ml (Figure 5-8 and Figure 5-13). This suggests either inefficient PV 
production, inefficient incorporation of the envelope proteins on to the PV or that the cells 
are not particularly permissive for GBV-B infection.  
To determine the role of permissibility of target cells for the development of the GBV-B PV 
neutralisation assay, several different target cells were investigated. Cells of both New World 
and Old World monkey origin were tested as they may have been more permissive for GBV-B 
infection than human cell lines. No cells of monkey origin that were tested in this study 
proved highly permissive for GBV-B, although this may be due to the poorly infectious 
retroviral GBV-B PV. Interestingly, the cell lines Huh7.5 and CrFK seemed to be highly 
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permissive for lentiviral GBV-B PV. Huh7.5 cells were chosen as the target cell line as they are 
hepatocytes and are more likely to express the relevant entry receptors in comparison to the 
feline cell line.  
The final optimisation stages, the removal of the HA tag and the use of spinoculation during 
the infectivity assay, were adopted at the same time due to time restrictions but together 
increased the permissiveness of Huh7.5 cells for GBV-B PV by around 70% (Figure 5-14). The 
removal of the HA tag, in the case of HCV PV, was shown to increase their infectvity by 
around 65% (Op De Beeck et al., 2004). It has been suggested that the HA tag affects the 
function of the transmembrane domains of E1E2 during the fusion process, which would 
explain why infectivity was affected. Supporting this theory, when mutations were 
introduced into the the transmembrane domain of the VSV-G protein, viral fusion was severly 
affected (Cleverley and Lenard, 1998). It therefore may the case that by altering the C-
terminus of GBV-B E2, viral fusion is severely reduced. Additionally, the use of centrifugal 
inoculation, or spinoculation, has been shown to enhance viral infection in previous studies 
by increasing the chance encounters between the virus and the host (O’Doherty et al., 2000; 
Yan et al., 2015).   
Interestingly, in the middle of this study in September 2015, Marnata and colleagues 
published a study which involved producing GBV-B PV. As they used codon-optimised GBV-B 
envelope proteins (which enhances the translation of proteins in mammalian cells), these 
envelope proteins appeared to be incoporated more efficiently onto PV (Marnata et al., 
2015). It would therefore be of interest to include this protocol modification in future GBV-B 
PV production. Despite this, the GBV-B infection assay developed during this project could 
form the basis of any future GBV-B  neutralisation assay study. Unfortunately, due to time 
restrictions, tamarin sera was not assessed in this assay.   
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In summary, this project has led to both the production of GBV-B specific antibodies for use 
in the investigation of GBV-B pathology and the development of a GBV-B neutralisation assay. 
In the near future, these GBV-B core-specific antibodies could be used in immunochemistry 
studies to determine the tropism of the virus in comparison to HCV. As the conditions for 
ribosome display are now set up, other GBV-B proteins could also be used as ribosome 
display screening targets. These could be used in various studies, including the tracking of the 
viral lifecyle (which is still largely unknown for GBV-B) and vaccine development. Additionally, 
the production of tamarin antibody libraries at different stages of infection and either the 
monitoring of the diversity of the immunoglublin repertoire through deep sequencing or 
isolation of scFv antibodies through ribsome display could help to determine the differences 
between the antibody response to HCV and the antibody response to GBV-B.  
To aid in the investigation of the antibody response to GBV-B, a GBV-B neutralisation assay 
was also developed. This now simply requires the testing of tamarin sera to determine if 
neutralising antibodies to GBV-B exist. Human sera from HCV-infected individual could also 
be tested to determine if any cross-reactivity exists, which could potentially help inform 
vaccine design. The infection assay that forms the basis of the neutralisation could also be 
used to determine the entry receptors for GBV-B, for example through the use of antibodies 
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CHAPTER 7 : APPENDIX 
 









GBV-B PROTEIN PRODUCTION 
CORE_F GCG AGG GGA 
TCT GGG AG 
55 Forward primer for cloning GBV-B core 
(previously done in lab and therefore not cloned 
in this project) 
CORE_R GTC TGG GTC AGT 
GAC CCG C 
55 Reverse primer for cloning GBV-B core (previously 
done in lab and therefore not cloned in this 
project) 
NS3RBS_F TCC ATC TAG AAA 
GAA GGA GAT 
ATA CCA TGG CAC 






Forward primer for cloning 
GBV-B NS3 serine protease 
NS3NOTI_R TTG CGC GGC 
CGC TGT GTA CTG 
GGG ATG G 
55 NotI 
restriction site 
Reverse primer for cloning GBV-
B NS3 serine protease 
NS5BNCO1_F TCC ACC ATG GCT 
AGC ATG AGC 
TAC ACC TGG ACC 
60 NcoI 
restriction site 
Forward primer for cloning 
GBV-B NS5B 
NS5B-23_R GCA AGC GGC 
CGC CTT CTG CAA 
TCT TCT CTG 
60 NotI 
restriction site 
Reverse primer for cloning GBV-
B NS5B without its C-terminal 
23 amino acids 
HINDIIIE1E2_F TGG TAA GCT TGC 
CAC CAT GGG TTG 
GTT CGG TGT CCA 
CCT TTT TG 
67 HindIII 
restriction site 
Forward primer for cloning 
GBV-B E1E2 into pcDNA3 
E1E2CLAI_R AAC CAT CGA TCC 
GAG CCA TGG 
GCA CAA ACC 
65 ClaI restriction 
site 
Reverse primer for cloning GBV-
B E1E2 into pcDNA3. Mutates 
the last amino acid of E2 from 
Alanine to Arginine 
NSIIE1E2_F TGG TAT GCA TGC 
CAC CAT GGG TTG 
55 NsiI restriction 
site  
Forward primer for cloning 
GBV-B E1E2 without an HA tag 
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GTT CGG TGT CCA 
CCT TTT TG 
NHEIE1E2NOTG
A_R 
AAC CGC TAG CTC 
ACG CAG CCA 




Reverse primer for cloning GBV-
B E1E2 without the HA tag. 





 Reverse primer used for cloning 
GBV-B E1E2 into pCAGGS. 
SCFV LIBRARY CONSTRUCTION PRIMERS 
DT29VN TTT TTT TTT TTT 
TTT TTT TTT TTT 
TTT TTV N 
n/a  cDNA synthesis 
VH1/7_F GGT GGT GGT 
GGT TCT CAG GTG 
CAG CTG GTG 
CAG TCT GG 
54 Stage 1 scFv 
production 
Forward primer for cloning 
tamarin variable region of 
heavy chain (families 1 and 7). It 
includes 1x G4S. 
VH3/5_F GGT GGT GGT 
GGT TCT GAG 
GTG CAG CTG 
GTG SAG TCT GG 
54 Stage 1 scFv 
production 
Forward primer for cloning 
tamarin variable region of 
heavy chain (families 3 and 5). It 
includes 1x G4S. 
VH4_F GGT GGT GGT 
GGT TCT CAG GTG 
CAG CTG CAG 
GAG TCG GA 
56 Stage 1 scFv 
production 
Forward primer for cloning 
tamarin variable region of 
heavy chain (family 4). It 
includes 1x G4S. 
VH6_F GGT GGT GGT 
GGT TCT CAG GTG 
CAG CTG CAG 
GAG TCA GG 
54 Stage 1 scFv 
production 
Forward primer for cloning 
tamarin variable region of 
heavy chain (family 6). It 
includes 1x G4S. 
VH_R GGA ACG CGG 
CCG CGA CAT CTG 
GGT TCT TGG TGG 
AGG CTG A 





Reverse primer for cloning 
tamarin variable region of 
heavy chain. Includes part of 
spacer. 
VK1_R CGA ATT CCA CCA 
TGG CCC AGA 
TGA CCC AGT CTC 
C 
54 Stage 1 scFv 
production, 
EcoRI and NcoI 
restriction 
sites 
Forward primer for cloning 
tamarin variable region of 
kappa light chain (family 1). It 
includes Kozak sequence. 
VK2/4_R CGA ATT CCA CCA 
TGG CCG TGA 
54 Stage 1 scFv 
production, 
Forward primer for cloning 
tamarin variable region of 
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TGA CYC AGT CTC 
C 
EcoRI and NcoI 
restriction 
sites 
kappa light chain (families 2 and 
4). It includes Kozak sequence. 
VK3_R CGA ATT CCA CCA 
TGG CCG TGW 
TGA CRC AGT CTC 
C 
54 Stage 1 scFv 
production, 
EcoRI and NcoI 
restriction 
sites 
Forward primer for cloning 
tamarin variable region of 
kappa light chain (family 3). It 
includes Kozak sequence. 
VK5_R CGA ATT CCA CCA 
TGG CCA CAC TCA 
CGC AGT CTC C 
56 Stage 1 scFv 
production, 
EcoRI and NcoI 
restriction 
sites 
Forward primer for cloning 
tamarin variable region of 
kappa light chain (family 5). It 
includes Kozak sequence. 
VK_R GAA CCA CCA CCA 
CCG AAG ACA 
GAC GGC GCA 
GCC ACA GC 
54/56 Stage 1 scFv 
production 
Reverse primer for cloning 
tamarin variable region of 
kappa light chain. It includes 1x 
G4S. 
RHVHFLINK GTA ATA CGA CTC 
ACT ATA GGG 
CGA ATT CCA CCA 
TGG 
52 Stage 2, 3 and 
5 scFv 
production, 
EcoRI and NcoI 
restriction 
sites 
Forward primer adding part of 
the T7 promoter to the variable 
region of the light chain. 
BAMH1LINK GGA GCC GCC 
GCC GCC GGA 
TCC ACC ACC ACC 
AGA ACC ACC ACC 
ACC 




Reverse primer for elongating 
linker of the variable region of 
the light chain. 
RHVLFLINK GGC GGC GGC 
GGC TCC GGT 
GGT GGT GGT TCT 
52 Stage 2 scFv 
production 
Forward primer elongating 
linker of heavy chain variable 
region by adding a repeat of 
G4S. 
HUCH1_F CGT CGC GGC 
CGC GTT CCC CCT 
GGY RCC CT 




Forward primer for cloning 
constant region of heavy chain 
HUCH2_XHOI GTT CCT CGA 
GGG TRT CCT TGG 
GTT TTG GGG 
GGA A 





Reverse primer for cloning 
constant region of heavy chain 
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RDT7 CTA TAG AAG 
GGT AAT ACG ACT 
CAC TAT AG 
56 Stage 6 scFv 
production 
Forward primer completing T7 
promoter of scFv library 
RECMRNA_F GTA ATA CGA CTC 
ACT ATA GGG 
CGA ATT C 
56  Forward primer used in the 
recovery of scFv mRNA after 
ribosome display 
HURECMRNA_R AGG TGC TGG 
GCA CGG GGG 
CAT G 
56  Reverse primer used in the 
recovery of scFv mRNA after 
ribosome display 
SEQUENCING PRIMERS 
T7 PROMOTER TAA TAC GAC TCA 
CTA TAG GG 
50  Forward sequencing primer for   
SP6 UNIVERSAL ATT TAG GTG ACA 
CTA TAG 




GCT AGT TAT TGC 
TCA GCG G 
50  Reverse sequencing primer for 
p4D5 vector. 
PSF_F ATC GTT GCG TTA 
CAC ACA C 
50  Forward sequencing primer for 
pSF. 
PSF_R GCT GCC TTG TAA 
GTC ATT GGT C 
50  Reverse sequencing primer for 
pSF. 
PCAGGS_F TTC TCC ATC TCC 
AGC CTC GGG 
50  Forward primer for sequencing 
pCAGGS. 
PCAGGS_R CCC ATA TGT CCT 
TCC GAG TGA 
50  Reverse primer for sequencing 
pCAGGS. 
M13_F GTT TTC CCA GTC 
ACG AC 
50  Forward sequencing primer for 
pGEM T-Easy vector. 
M13_R AAC AGC TAT GAC 
CAT G 
50  Reverse sequencing primer for 
pGEM T-Easy vector. 
DEEP SEQUENCING PRIMERS 
VH1_F TCG TCG GCA 
GCG TCA GAT 
GTG TAT AAG 
AGA CAG ACG 
GCC GTV TAT TAC 




Forward deep sequencing 
primer for amplifying CDR3 
regions of tamarin heavy chain 
variable regions (1/3). 
VH2_F TCG TCG GCA 
GCG TCA GAT 
GTG TAT AAG 




Forward deep sequencing 
primer for amplifying CDR3 
regions of tamarin heavy chain 
variable regions (2/3). 
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GCC AKV TAT TAC 
TGT GCG AGR 
VH3_F TCG TCG GCA 
GCG TCA GAT 
GTG TAT AAG 
AGA CAG ACA 
GCC GTC TAT TAC 




Forward deep sequencing 
primer for amplifying CDR3 
regions of tamarin heavy chain 
variable regions (3/3). 
VH_R GTC TCG TGG GCT 
CGG AGA TGT 
GTA TAA GAG 
ACA GGA CAT 
CTG GGT TCT TGG 




Reverse deep sequencing 
primer for amplifying CDR3 
regions of tamarin heavy chain 
variable regions. 
VK1_F TCG TCG GCA 
GCG TCA GAT 
GTG TAT AAG 
AGA CAG GTT KCR 





Forward deep sequencing 
primers for amplifying CDR3 
regions of tamarin light chain 
variable regions (1/3). 
VK2_F TCG TCG GCA 
GCG TCA GAT 
GTG TAT AAG 
AGA CAG TTT GCC 





Forward deep sequencing 
primer for amplifying CDR3 
regions of tamarin light chain 
variable regions (2/3). 
VK3_F TCG TCG GCA 
GCG TCA GAT 
GTG TAT AAG 
AGA CAG TYT GCA 





Forward deep sequencing 
primer for amplifying CDR3 
regions of tamarin light chain 
variable regions (3/3). 
VK_R GTC TCG TGG GCT 
CGG AGA TGT 
GTA TAA GAG 
ACA GGA AGA 
CAG ACG GCG 




Reverse deep sequencing 
primer for amplifying CDR3 
regions of tamarin heavy chain 
variable regions. 
TABLE 7-1: LIST OF PRIMER SEQUENCES.  
RESTRICTION SITES ARE UNDERLINED. 
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GBV-B PROTEIN PRODUCTION PLASMIDS 
 
NAME  USE  GENE REFERENCE 
4D5_CORE_HIS GBV-B core 
production 
GBV-B core, See 3.2.1 
PET32B_NS3_HIS GBV-B NS3 
production 
GBV-B NS3 protease See 3.2.1 
P4D5_NS5BΔ23_HIS GBV-B NS5BΔ23 
production 
GBV-B NS5B, 
truncated (last 23 
amino acids deleted) 
See 3.2.1 
TABLE 7-2: LIST OF PLASMIDS USED TO PRODUCE RECOMBINANT GBV-B PROTEINS  
ANTIBIOTIC CONCENTRATION WAS 100 µG/ML FOR AMPICILLIN IN LB BROTH AND AGAR PLATE. 
 
SCFV PRODUCTION PLASMIDS 
 
NAME USE GENE REFERENCE 
PGEM T-EASY_CH1 Spacer in scFv 
library 
Human CH1 region n/a 
P4D5_8RFP_FC Positive control for 
scFv expression, 
backbone for scFv 
prokaryotic 
expression 
RFP flanked by a 





scFv production in 
prokaryotic cells 
scFv isolated after 
panning against 
NS5BΔ23, with 
human Fc receptor 
See 4.2.2 
P4D5_NS5BΔ23.SCFV_12_FC NS5BΔ23-specific 
scFv production in 
prokaryotic cells 
scFv isolated after 
panning against 
NS5BΔ23, with 
human Fc receptor 
See 4.2.2 
P4D5_CORE.SCFV_1_FC Core-specific scFv 
production in 
prokaryotic cells 
scFv isolated after 
panning against 
core, with human 
Fc receptor 
See 4.2.4 
P4D5_CORE.SCFV_2_FC Core-specific scFv 
production in 
prokaryotic cells 
scFv isolated after 
panning against 
core, with human 
Fc receptor 
See 4.2.4 
P4D5_CORE.SCFV_3_FC Core-specific scFv 
production in 
prokaryotic cells 
scFv isolated after 
panning against 
core, with human 
Fc receptor 
See 4.2.4 
P4D5_CORE.SCFV_4_FC Core-specific scFv 
production in 
prokaryotic cells 
scFv isolated after 
panning against 
core, with human 
Fc receptor 
See 4.2.4 
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scFv isolated after 
panning against 
core, with human 
Fc receptor. 
Truncated due to 
early stop codon 
See 4.2.4 
P4D5_CORE.SCFV_6_FC Core-specific scFv 
production in 
prokaryotic cells 
scFv isolated after 
panning against 
core, with human 
Fc receptor 
See 4.2.4 
P4D5_CORE.SCFV_7_FC Core-specific scFv 
production in 
prokaryotic cells 
scFv isolated after 
panning against 
core, with human 
Fc receptor 
See 4.2.4 









PSF_CORE.SCFV_1_FC Core-specific scFv 
production in 
eukaryotic cells 
scFv isolated after 
panning against 
core, with human 
Fc receptor 
See 4.2.5 
PSF_CORE.SCFV_2_FC Core-specific scFv 
production in 
eukaryotic cells 
scFv isolated after 
panning against 
core, with human 
Fc receptor 
See 4.2.5 
PSF_CORE.SCFV_3_FC Core-specific scFv 
production in 
eukaryotic cells 
scFv isolated after 
panning against 
core, with human 
Fc receptor 
See 4.2.5 
PSF_CORE.SCFV_4_FC Core-specific scFv 
production in 
eukaryotic cells 
scFv isolated after 
panning against 
core, with human 
Fc receptor 
See 4.2.5 
PSF_CORE.SCFV_6_FC Core-specific scFv 
production in 
eukaryotic cells 
scFv isolated after 
panning against 
core, with human 
Fc receptor 
See 4.2.5 
PSF_CORE.SCFV_7_FC Core-specific scFv 
production in 
eukaryotic cells 
scFv isolated after 
panning against 
core, with human 
Fc receptor 
See 4.2.5 
P4D5_CORE.SCFV_13_FC Core-specific scFv 
production in 
prokaryotic cells 
scFv isolated after 
3 rounds of 
panning against 
core, with human 
Fc receptor 
See 4.2.8 
P4D5_CORE.SCFV_27_FC Core-specific scFv 
production in 
prokaryotic cells 
scFv isolated after 
3 rounds of 
panning against 
See 4.2.8 
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core, with human 
Fc receptor 
P4D5_CORE.SCFV_59_FC Core-specific scFv 
production in 
prokaryotic cells 
scFv isolated after 
3 rounds of 
panning against 
core, with human 
Fc receptor 
See 4.2.8 
P4D5_CORE.SCFV_65_FC Core-specific scFv 
production in 
prokaryotic cells 
scFv isolated after 
3 rounds of 
panning against 




TABLE 7-3: LIST OF PLASMIDS USED TO EXPRESS SCFV PROTEINS ISOLATED FROM RIBOSOME DISPLAY 













Mattiuzzo et al., 2007 






TABLE 7-4: LIST OF PLASMIDS USED TO TRANSFECT MAMMALIAN CELL LINES 
ANTIBIOTIC CONCENTRATION WAS 100 µG/ML FOR AMPICILLIN IN LB BROTH AND AGAR PLATE. 
 
 
PSEUDOTYPE VIRUS PRODUCTION PLASMIDS 
 
NAME 
USE GENE REFERENCE 
PCMV8.91 First attempt at 
GBV-B PV 
production 
HIV-1 GagPol Zufferey et al., 1997 
PCSGW HIV-1 derived 
vector expressing 
GFP  
Bainbridge et al., 
2001, Demaison et 
al., 2002 
PCDNA3.1_E1E2_HA GBV-B E1E2 with C-
terminus HA tag 
See 5.2.1 
PMDG VSV-G Naldini et al., 1996 





Ikeda et al., 2003, 
Sanber et al., 2015 
PHCMV-7A Production of HCV 
PV in STAR-HV cells 
HCV E1E2 Bartosch et al., 2003 
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the firefly luciferase 
gene. Made 
previously in the 
lab by substituting 
GFP. 
Bainbridge et al., 
2001, Demaison et 
al., 2002 
PCMV INTRON Fourth, successful 
attempt at GBV-B 
PV production 
MoMLV GagPol Collins et al., 1995 




huPAR-2 gene with 
firefly luciferase 






Connor et al., 1995, 
NIRRRP catalog # 
3417 
PCAGGS_E1E2_HA GBV-B E1E2 with C-
terminus HA tag 
See 5.2.6.1 
PCDNA3.1D_HCVE1E2 Synthetic HCV E1E2 Johansson et al., 
2007 
PCAGGS_E1E2_NOHA Production of GBV-
B PV with no HA tag  
GBV-B E1E2 See 5.2.7.4 
 
TABLE 7-5: LIST OF PLASMIDS USED TO CREATED PV EXPRESSING EITHER VSV, HCV OR GBV-B ENVELOPE PROTEINS.  
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TABLE 7-6: ANALYSIS OF TAMARIN V REGION SEQUENCES  
TAMARIN SCFV SEQUENCES, CONTAINING VH AND VL SEQUENCES, WERE OBTAINED BY SANGER SEQUENCING. CDR3 REGIONS WERE 
IDENTIFIED USING IGBLAST SOFTWARE (DOWNLOADABLE) AND THE SEQUENCES IMMEDIATELY PRIOR TO THE CDR3 REGIONS WERE ALIGNED 
TO THEIR HUMAN COUNTERPARTS SHOWING SIGNIFICANT HOMOLOGY. 









FIGURE 7-1: PLASMID MAP OF PET22B+ 
THIS PLASMID CONTAINS A PELB LEADER SEQUENCE TO DIRECT THE RECOMBINANT PROTEIN TO THE BACTERIAL PERIPLASM, THEREBY ALLOWING 
PROTEIN SECRETION. THIS PLASMID IS DESIGNED FOR EXPRESSION OF RECOMBINANT PROTEINS IN BACTERIAL CELL LINES. 
 
 




FIGURE 7-2: PLASMID MAP OF PET32B+ 
THIS PLASMID CONTAINS SEVERAL TAGS FOR PROTEIN PRODUCTION, INCLUDING AN S TAG, A TRXA TAG AND TWO HIS TAGS. THIS PLASMID IS 
DESIGNED FOR EXPRESSION OF RECOMBINANT PROTEINS IN BACTERIAL CELL LINES. 
 
 




FIGURE 7-3: PLASMID MAP OF P4D5  
THIS PLASMID IS A DERIVATIVE OF PET32B THAT CONTAINS ONLY ONE TAG- A C-TERMINAL HIS TAG. THIS PLASMID WAS ALTERED BY MARKIV 
AND COLLEAGUES TO SIMPLIFY PROTEIN PURIFICATION, AS SOME TAGS ARE KNOWN TO BE HIGHLY HYDROPHOBIC (MARKIV ET AL., 2011). 
LATER, THE FC DOMAIN OF IGG WAS CLONED INTO THIS VECTOR FOR EXPRESSION OF SCFV ANTIBODIES. IT IS DESIGNED FOR EXPRESSION OF 
RECOMBINANT PROTEINS IN BACTERIAL CELL LINES. 
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FIGURE 7-4: PLASMID MAP OF PSF 
THIS PLASMID IS DESIGNED FOR EXPRESSION OF RECOMBINANT PROTEINS IN MAMMALIAN CELL LINES. IT CONTAINS A SECRETORY SIGNAL 
PEPTIDE TO ALLOW PROTEINS TO BE EXPORTED FROM THE CYTOSOL. DURING THE COURSE OF THIS PROJECT, THE FC DOMAIN WAS ALSO 
CLONED INTO THIS VECTOR TO ALLOW DOWNSTREAM EXPRESSION OF FUNCTIONAL SCFV. 
 




FIGURE 7-5: PLASMID MAP OF PCDNA3.1 
THIS PLASMID IS DESIGNED FOR EXPRESSION OF RECOMBINANT PROTEINS IN MAMMALIAN CELL LINES. THIS PLASMID IS A DERIVATIVE OF 
PCDNA3 (WHICH IS NO LONGER COMMERCIALLY AVAILABLE); IT HAS AN ALTERED MULTIPLE CLONING SITE AND LACKS AN SP6 PROMOTER 
BINDING SITE. 




FIGURE 7-6: PLASMID MAP OF PCAGGS 
THIS PLASMID IS DESIGNED FOR EXPRESSION OF RECOMBINANT PROTEINS IN MAMMALIAN CELL LINES. IT HAS A CMV ENHANCER, THE STRONG 
CHICKEN ß-ACTIN PROMOTER FOLLOWED BY A CHICKEN ß-ACTIN INTRON SEQUENCE WHICH DRIVES EXPRESSION OF RECOMBINANT PROTEIN 
















Area Score Coverage No. of 
peptides 
GBV-B polyprotein Q69422 2.563E10 782.90 9.50 21 
Chaperone protein DnaK 
(E.coli O139:H28) 
A7ZHA4 6.086E8 174.49 40.60 17 
Cysteine desulfurase IscS 
(E.coli O139:H28) 




A7ZS61 7.834E8 164.84 27.57 15 
Elongation factor Tu 1 
(E.coli O139:H28) 
A7ZSL4 1.374E9 105.34 40.10 12 
 
TABLE 7-7: MASS SPECTROMETRY DATA FOR THE RECOMBINANT NS5BΔ23 PREPARATION 
THE NS5BΔ23 PREPARATION ISOLATED FROM E.COLI WERE FIRST DIGESTED BY TRYPSIN AND LATER ANALYSED USING MASS SPECTROMETRY BY 
JUN WHEELER AT NIBSC. THE SEQUENCES OBTAINED FROM THIS MACHINE WERE THEN RUN AGAINST THE PUBMED GENBANK DATABASE. 
THE TOP FIVE RESULTS FROM THIS ANALYSIS ARE SHOWN IN THE TABLE ABOVE, WHICH SHOWS THE MOST ABUNDANT SEQUENCES IN THIS 















ALL CELL LINES INVESTIGATED WERE INFECTED WITH SERIAL DILUTIONS OF EITHER LENTIVIRAL-BASED OR RETROVIRAL-BASED PV PRODUCED 
THROUGH THE CO-TRANSFECTIONS OF 293T CELLS WITH THE TWO OR THREE PLASMID SYSTEM AND PEI. UNCONCENTRATED AND 
CONCENTRATED SAMPLES OF BOTH LENTIVIRAL-BASED AND RETROVIRAL-BASED GBV-B PV WERE USED FOR EACH INFECTION AS I HAVE 
SHOWN THAT UNCONCENTRATED GBV-B PV HAVE LOW INFECTIVITY. THE LUMINESCENCE FROM THE PRODUCTION OF THE REPORTER GENE, 
LUCIFERASE, INCORPORATED INTO TARGET CELL GENOMES THROUGH SUCCESSFUL INFECTION WAS DETECTED FOR EACH CELL LINE. HUH7.5 
WERE INFECTED WITH ONLY LENTIVIRAL PV DUE TO TIME RESTRICTIONS AS IT WAS PRESUMED THAT LENTIVIRAL PV HAVE HIGHER LEVELS OF 

























Not tested 0 0 
FRHK-4 Not tested 23 2023 
VERO Not tested 127 2892 
CRFK 1853 1198 8070 35833 
HUH7.5 4800 26400 Not tested 
TABLE 7-8: PERMISSIBILITY OF DIFFERENT CELL LINES WITH GBV-B PV 
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